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Abstract 
Vincristine is used especially for the treatment of a variety of paediatric cancers including 
leukaemias and brain tumours. Unfortunately, up to 90% of vincristine-treated patients develop 
peripheral neuropathy characterized by sensory, motoric and autonomic symptoms. The sensory 
symptoms include pain, in particular hypersensitivity to light touch, as well as loss of sensory 
discrimination to detect vibration and touch. The symptoms of vincristine-induced neuropathy are 
only poorly controlled by currently available analgesics and therefore often necessitate dose 
reductions or even cessation of treatment. The aim of this thesis was to identify new therapeutic 
targets for the treatment of vincristine-induced peripheral neuropathy (VIPN) by combining 
behavioural experiments, histology, transcriptomics and pharmacology and extending the 
knowledge to oxaliplatin and cisplatin induced neuropathy management.  
In chapter one I present a general literature review that addresses the mode of action, genomics, 
clinical presentation, pathophysiology and treatment of chemotherapy induced peripheral 
neuropathy (CIPN) caused by the most commonly used anticancer-agent groups; vinca alkaloids, 
platinum derivates and taxanes. In chapter two I present the development and characterisation of 
a novel mouse model of VIPN based on local intraplantar injections of vincristine that allowed me 
to reproduce several symptoms of VIPN and allowed me to compare, in chapter three, differential 
gene expression profiles in DRG following vincristine, oxaliplatin or cisplatin administration. The 
transcriptomic analysis revealed predominant effects on genes associated with the immune system 
after treatment with vincristine, while oxaliplatin treatment affected mainly neuronal genes. 
Treatment with cisplatin resulted in a mixed gene expression signature. Specifically, vincristine 
induced a striking upregulation of inflammatory genes in DRGs involved in regulation and 
activation of macrophages and interleukin one receptor signalling. In chapter four, I demonstrate 
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that vincristine-induced peripheral neuropathy is driven by activation of the NLRP3 
inflammasome and subsequent release of interleukin-1ß, with mechanical allodynia and gait 
disturbances significantly reduced in knockout mice lacking canonical NLRP3 signalling pathway 
components or after treatment with the NLRP3 inhibitor MCC950. Moreover, treatment with the 
interleukin-1 receptor antagonist anakinra prevented the development of vincristine-induced 
neuropathy without adversely affecting chemotherapy efficacy or tumour progression in patient-
derived medulloblastoma xenograph models. These results detail for the first time the molecular 
neuro-inflammatory mechanisms leading to vincristine-induced mechanical allodynia and gait 
disturbances and suggest that repurposing the biological disease modifying anti-rheumatic 
anakinra may be an effective and safe treatment strategy for vincristine-induced peripheral 
neuropathy. 
In summary, data presented in this thesis provide invaluable insights in the mechanism of 
vincristine induced peripheral neuropathy and provide preliminary data for future basic research 
and clinical studies. 
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1. CHAPTER 1: Literature Review 
1.1. Foreword 
This chapter addresses the epidemiology, clinical presentation, genetics and pathophysiology of 
chemotherapy induced peripheral neuropathy. It was published as an invited review in Frontiers 
in Molecular Neuroscience in 2017 [1] and it is a highly cited publication with over 100 citations 
to date. To fit with the style and narrative of this thesis, it has been amended from the published 
article. Hana Starobova performed literature research, wrote the manuscript and designed all 
figures. Irina Vetter contributed to editing of the manuscript and figures. 
  
1.2. Introduction 
Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of many 
chemotherapeutic agents and a major cause of ongoing pain in cancer survivors [2]. There are six 
main substance groups that cause damage to peripheral sensory and motor neurons, resulting in 
development of CIPN: the platinum-based antineoplastics (particularly oxaliplatin and cisplatin), 
the vinca alkaloids (particularly vincristine and vinblastine), the epothilones (ixabepilone), the 
taxanes (paclitaxel, docetaxel), the proteasome inhibitors (bortezomid) and immunomodulatory 
drugs (thalidomide). The high success rate of these drugs in cancer treatment has led to a steady 
increase in the survival rates of patients. Consequently, the number of cancer survivors suffering 
from neuropathic pain conditions is rising as well. Overall, approximately 68% of patients 
receiving chemotherapy develop CIPN within the first month of treatment [3], the development of 
which is related to both, single as well as cumulative drug doses. Additionally, various conditions 
like pre-existing nerve damage, for example in diabetic patients, can be linked to an increased risk 
of developing CIPN.  
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Although the mechanisms of action and molecular target(s) of these chemotherapeutic agents are 
diverse and include both DNA and microtubular targets to arrest cell division and induce cell death, 
the pathobiology of chemotherapy-induced neuropathy, irrespective of the causative agent, shares 
some important similarities. Notably, CIPN is characterized by predominantly sensory axonal 
peripheral neuropathy [4] that typically develops in a “stocking and glove” type distribution, with 
longer axons affected first [5]. The histopathological changes associated with CIPN commonly 
involve large myelinated fibres, although bortezomib-induced neuropathy also involves small 
fibres [6-8]. These changes to the morphological and molecular physiology of peripheral nerves 
result in the development of sensory and motoric symptoms such as hypersensitivity to mechanical 
stimuli or distal weakness due to mechanisms which are not entirely understood.  
The symptoms of CIPN can be severe; management with common analgesic approaches are often 
unsatisfactory; and despite increasing insights into the underlying pathophysiological mechanisms, 
the development of CIPN is currently not preventable. Thus, the increasing incidence of CIPN is 
a highly relevant and growing clinical issue that leads to dose reduction, changes to less effective 
chemotherapeutic agents or even cessation of the therapy resulting in suboptimal cancer treatment 
[9]. This review focusses on the commonly used antineoplastic substances oxaliplatin, cisplatin, 
vincristine, docetaxel and paclitaxel which interfere with the cancer cell cycle, leading to cell death 
and tumour degradation, and cause severe acute and chronic peripheral neuropathies.  
1.3. Cancer Chemotherapy: Drug Mechanism of Action and Metabolites 
The mechanism of action of chemotherapeutic agents that lead to potent effects on tumour cell 
proliferation and cell death are well-studied and relatively well understood (Fig. 1). However, it is 
not entirely clear whether these (mostly) desirable effects on rapidly proliferating cells are also 
responsible for causing undesirable effects on non-proliferating sensory neurons, or whether 
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additional pharmacological effects contribute to the development of CIPN. While many 
chemotherapeutic agents can cause peripheral neuropathy, this is not a universal feature of all such 
compounds, suggesting that at least some additional mechanisms likely contribute. For example, 
carboplatin affects predominantly the hematopoietic system, while cisplatin and oxaliplatin both 
cause CIPN, albeit with different symptomatology. Similarly, while all vinca alkaloids can cause 
CIPN, this side effect is most common with vincristine, and less common with vinblastine, 
vinflunine, and vinorelbine [10]. These effects cannot be solely explained by different drug 
potencies, metabolites and pharmacokinetic properties. Nonetheless, the pathophysiology of CIPN 
is likely multi-factorial and contribution of at least some specific anti-cancer mechanisms, 
discussed below, is probable. 
1.3.1. Oxaliplatin and cisplatin 
The platinum-based chemotherapeutic agents oxaliplatin and cisplatin, both of which are listed on 
the World Health Organization's List of Essential Medicines, are used for the treatment of various 
solid tumours. Oxaliplatin is used in combination with folinic acid and 5-fluorouracil as a part of 
the FOLFOX regimen for first-line and adjuvant colorectal cancer therapy, while cisplatin is one 
of the most effective treatments for solid tumours including small cell lung cancer, testicular, 
ovarian, brain and bladder cancer. The intracellular concentration of platinum-based 
antineoplastics is maintained via several active transporters, including the copper transporter 
CTR1 which mediates drug uptake [11] as well as copper-transporting ATPases that mediate 
efflux, such as ATP7A and ATP7B [12]. 
Like other platinum-based compounds, oxaliplatin and cisplatin interfere with tumour cell 
proliferation via the formation of deoxyribonucleic acid (DNA)-platinum adducts. Cisplatin is 
converted to a strong electrophile after hydrolysis of its two chloride atoms, which are displaced 
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by two molecules of water once the platinum complex enters the cell. Activated cisplatin then 
crosslinks two purine bases (adenine/guanine) of DNA by reacting with nitrogens at position seven 
of the purine rings, thus interfering with cell division and transcription of messenger ribonucleic 
acid (mRNA) [13]. Similarly, the mono- and di-aquated oxaliplatin creates DNA intra-strand 
crosslinks by binding two guanine bases or a guanine-adenine pair of GC-rich regions of DNA 
[14]. Additionally, oxaliplatin causes inter-strand crosslinks and DNA-protein crosslinks which 
may contribute to the mode of action of oxaliplatin [15]. These DNA mono- and bi-adducts in turn 
inhibit DNA replication and transcription, a fatal effect on cells in the S-phase of the cell cycle 
(when chromosomes are replicated) [16]. Oxaliplatin also inhibits DNA transcription/mRNA 
production by interacting with transcription factors, inhibition of RNA polymerases and by 
creating nucleosomal DNA adducts leading to cell death [17]. In addition, activation of the 
immune system may be involved in the anticancer effects of oxaliplatin, with production of 
interferon γ by T-cells and resultant immunogenic cell death via TLR4 activation observed in both 
murine and human colon cancer cells [18]. Likewise, cisplatin causes additional non-genomic 
effects including the production of reactive oxygen species resulting in altered mitochondrial 
function and activation of both intrinsic and extrinsic apoptosis pathways. Cisplatin also affects 
calcium signalling pathways and the function of several protein kinase families, including the 
MAPK (mitogen activated protein kinases), JNK (c-Jun N-terminal kinase o), PKC (protein kinase 
C) and AKT (serine/threonine kinases) leading to cell death [13].  
 
A unique feature of oxaliplatin is its rapid non-enzymatic transformation to the reactive dichloro 
1,2-diaminocyclohexyl-platinum complex and oxalate, which occurs via replacement of the 
oxalate moiety with chloride ions in the blood plasma. Indeed, the generation of the oxalate 
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metabolite is one of the few features distinguishing oxaliplatin from cisplatin, and has been 
proposed as one mechanism accounting for the differences in clinical presentation - most notably 
the presence of cold-induced neuropathy after treatment with oxaliplatin, but not cisplatin. 
However, a contribution of oxalate to oxaliplatin-induced cold pain has not been shown 
consistently [19], and it is plausible that additional metabolites – including platinum complexes 
that bind to cellular proteins – may contribute to the development of CIPN.  
1.3.2. Vincristine 
Vincristine is one of the most important antineoplastic substances used for chemotherapy of 
several childhood and adult tumours, and is – administered by intravenous infusion – a component 
of several different chemotherapy regimens (e.g. MOPP, COPP and BEACOPP regimen for 
therapy of Hodgkin's disease).  While the mechanisms of vincristine transport into the cell are still 
unclear, a carrier-mediated transport mechanism characterized by Michaelis-Menten kinetics, 
temperature dependence and competitive inhibition was demonstrated in different murine 
leukaemia cells [20]. The adenosine triphosphate (ATP) binding cassette (ABC) transporter 
family, ABCB1, ABCC1, ABCC2 and ABCC3 contribute to vincristine efflux from the cell 
cytosol and to the development of cancer cell resistance to the therapy [21]. Additionally, a 
relationship between cholesterol and phospholipid levels and vincristine uptake into murine 
leukaemia cells has been demonstrated, showing that increased levels of cholesterol and 
phospholipids in the cell membrane accounts for lower vincristine accumulation [22].  
Vincristine binds to the β-subunit of tubulin and inhibits microtubules formation. The microtubules 
are cytoskeletal proteins that are involved in several important cell functions, for instance the 
regulation of cell shape, mitosis, chromosome segregation, cell division and retrograde as well as 
anterograde cellular transport. The proper function of microtubules depends on a balance between 
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permanent aggregation and disaggregation of the α- and β-tubulin subunits. Therefore, the 
disruption of microtubule aggregation by bound vincristine can lead to mitotic arrest and cell death 
[23]. The structure of the catharnine ring of the vinca alkaloids seems to be important for binding 
to axonal and cytoskeletal microtubules. Vinorelbine, composed of an eight-membered catharnine 
ring, shows a preference in binding to mitotic spindles over axonal microtubules, resulting in 
decreased neurotoxicity compared to vincristine, which is composed of a nine-membered 
catharnine ring [24].  
1.3.3. Paclitaxel and docetaxel 
Paclitaxel and docetaxel belong to the family of taxanes; chemotherapeutic agents used in the 
treatment of breast, prostate, lung, pancreatic, gynaecological and other solid tumours that act by 
inhibiting disassembly of tubulin from the microtubule polymer. However, despite a similar 
mechanism of action, subtle differences in their molecular pharmacology, pharmacokinetics and 
pharmacodynamics result in distinct clinical effects. Docetaxel binds to tubulin with greater 
affinity than paclitaxel, and causes cell cycle arrest in the S rather than G2-M phase junction as is 
the case for paclitaxel [25]. Both compounds do not cross the blood-brain-barrier (BBB), although 
paclitaxel is accumulated in DRG neurons – which lie outside the BBB – via largely unknown 
mechanisms [26-29]. Both paclitaxel and docetaxel are extensively metabolized, via cytochrome 
P 2C8 and 3A4, respectively, albeit pharmacological activity of these metabolites is modest at best 
and their contribution to the development of CIPN is unknown. 
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Figure 1. Mechanism of action of vincristine, paclitaxel, oxaliplatin and cisplatin 
Anti-tumour mechanism of action of vincristine, paclitaxel, oxaliplatin and cisplatin leading to cell 
arrest and cell death. (A) Vincristine prevents microtubule aggregation, whereas paclitaxel 
prevents microtubule disaggregation, an effect leading to cancer cell division arrest and cell death. 
(B) Oxaliplatin and cisplatin bind to nuclear DNA (deoxyribonucleic acid) of cancer cells, causing 
disruption of DNA replication and RNA (ribonucleic acid) transcription and subsequent arrest of 
cancer cell division. The DNA adducts activate apoptotic pathways that induce cell death and 
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tumour degradation. (C) All four anti-tumour agents alter the function of mitochondria, followed 
by disruption of respiratory chain function and increased production of reactive oxygen species 
(ROS). Additionally, oxaliplatin and cisplatin cause damage to cancer cell mitochondria by 
binding to mitochondrial DNA, altering mDNA replication and transcription. (D) All four agents 
cause activation of immune cells, an effect likely contributing to tumour cell degradation. Only a 
few representative immune cell-types are shown [1].  
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1.4. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology and Clinical Presentation 
Chemotherapy-induced neuropathy is a common, dose-dependent side effect of many 
antineoplastics that not only leads to dose reduction or discontinuation of treatment, but also 
severely reduces the quality of life of patients [10, 30]. While the incidence of CIPN is compound-
specific [3], it also depends on patient co-morbidities and can, presumably, increase with 
concomitant treatment with other neurotoxic drugs [31], although this effect has not been 
systematically investigated. Invariably, the percentage of patients suffering from CIPN as well as 
the severity of the condition increases with the (cumulative) dose [3, 32]. Accordingly, the 
incidence of CIPN approaches nearly 100% for some agents at higher doses [3], although 
differences in the definition, evaluation and reporting of peripheral neuronal deficits can lead to 
large variability in the reported occurrence. Notably, many studies rely on detailed clinician-
administered grading scales or patient-reported outcomes using a range of questionnaires 
developed to evaluate the development of CIPN, while more objective assessments such as nerve 
conduction studies, nerve excitability studies, or quantitative sensory testing are used more rarely 
[33]. Importantly, CIPN is viewed by many clinicians as an unavoidable side effect of cancer 
chemotherapy, and one that is acceptable in light of the often greatly extended life-span offered by 
these chemotherapeutic agents [34]. In contrast, patients often view CIPN as a particularly 
troublesome side effect of cancer treatment that interferes significantly with their quality of life 
[35]. 
 
Clinically, CIPN presents as deficits in sensory, motor and autonomic function which develop in 
a compound-specific manner [33]. Sensory symptoms usually develop first in the feet and hands 
– reflective of the axon length, with longer neurites affected first – and manifest as paresthesias 
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and dysesthesias. In addition, painful sensations including non-evoked burning, shooting or 
electric shock-like pain as well as mechanical or thermal allodynia or hyperalgesia frequently 
occur [36-39]. In severe cases, these symptoms can progress to loss of sensory perception, which 
can be disabling [40]. Motor symptoms include distal weakness, gait and balance disturbances and 
impaired fine movements. While rarer than sensory symptoms, motor impairment can progress to 
paralysis and cause significant functional disruption [41, 42]. In contrast, autonomic symptoms 
occur less frequently and may involve orthostatic hypotension, constipation and altered sexual or 
urinary function [42]. With the exception of paclitaxel and oxaliplatin, which cause an acute 
neuropathy that emerges either during or shortly after infusion [43, 44], the onset of CIPN is 
usually delayed and appears to depend on the total cumulative dose [45]. Some chemotherapeutics 
cause ‘coasting’ of symptoms, the progressive worsening of neuropathy after cessation of 
treatment, and in severe cases CIPN can develop into an irreversible sensory neuron deficit [46, 
47].  
1.4.1. Cisplatin 
Cisplatin causes a wide range of side effects including ototoxicity (hearing loss and tinnitus), 
nephrotoxicity, myelotoxicity and neuropathy. One of the most dose-limiting of these is peripheral 
neuropathy, which occurs in a dose- and time-dependent manner [48]. The onset of cisplatin-
induced neuropathy is variable, with some patients reporting the first appearance of symptoms 
after the first dose, and others after 12 cycles of therapy [49, 50]. Generally, cisplatin-induced 
neuropathy develops after cumulative doses above 350 mg/m2, with approximately 92% of patients 
developing neurotoxic symptoms – characterized by tingling, numbness and mechanical and 
thermal hyperalgesia – at cumulative doses of 500 to 600 mg/m2 cisplatin [51-53]. Cisplatin-
induced CIPN affects mostly the lower and upper limbs and includes mixed sensory and motor 
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effects, including loss of vibration sense and taste, paresthesia, weakness, and tremor [54, 55]. 
Motor nerve conduction velocity measurements in patients with decreased vibration sensitivity, 
loss of ankle jerks and paresthesias showed loss of sural nerve responses [52], with emergence of 
reduced sensory nerve action potentials and loss of large myelinated fibres at higher cisplatin doses 
[53]. The symptoms of cisplatin-induced neuropathy may persist for several months and can 
progressively worsen over time, a phenomenon called “coasting” [56]. With higher cumulative 
doses and longer times of exposure to cisplatin, the severity of CIPN increases, as does the 
likelihood of development of a chronic, irreversible neuropathy [49, 57]. Chronic cisplatin-induced 
neuropathy – the development of which appears to be independent of pre-treatment, vibration 
perception threshold, age, sex, tumour type or co-treatment with other chemotherapeutics – has 
been reported in approximately 5-20% of patients at 12 months [33, 58-61]. 
Several mechanisms contributing to cisplatin-induced neurotoxicity have been suggested (Fig. 2), 
including the loss of peripheral sensory neurons, changes in cell signalling cascades, changes to 
calcium homeostasis and signalling, oxidative stress, mitochondrial dysfunction and induction of 
apoptosis as a result of DNA platination [62].  
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Figure 2. Putative mechanisms involved in the development of cisplatin- and oxaliplatin-induced 
peripheral neuropathy. 
Overview of possible effects of oxaliplatin and cisplatin on the immune system, microglia and 
peripheral leading to neuronal inflammation and altered neuronal excitability. TNFα: Tumour 
necrosis factor alpha; DNA: deoxyribonucleic acid; ROS: Reactive oxygen species; NaV: Voltage-
gated sodium channel; KV: Voltage-gated potassium channel; TRP: Transient receptor potential 
channel; CaV: Voltage-gated calcium channel. 
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1.4.2. Oxaliplatin 
Treatment with oxaliplatin induces various side effects including myelotoxicity and peripheral 
neuropathy, albeit it lacks the ototoxic and nephrotoxic effects commonly observed after treatment 
with cisplatin. The neurotoxic effects of oxaliplatin include the development of an acute, transient 
neuropathy that occurs in almost 90% of patients within hours of infusion and is characterized by 
dysesthesias and paresthesias of the hands, feet and the perioral region. These symptoms are often 
induced by exposure to cool temperatures and are a key feature of oxaliplatin-induced cold 
allodynia [63]. In addition, motor symptoms including tetanic spasms, fasciculations and 
prolonged muscular contractions commonly occur [64]. Acute oxaliplatin-induced neuropathy 
generally subsides between treatment cycles [65], although continued exposure to oxaliplatin can 
lead to the development of a severe chronic neuropathy. The incidence of chronic peripheral 
neuropathy following oxaliplatin treatment has been estimated as approximately 70%, with 
development of the condition usually occurring at cumulative doses exceeding 540 mg/m2 [63, 
66]. Clinically, the symptoms of chronic oxaliplatin-induced neuropathy closely resemble those of 
the acute condition and include temperature-insensitive paresthesias, hypoesthesias and 
dysesthesias of the hands and feet. Additionally, changes in proprioception, which may affect 
normal daily activities requiring fine motor coordination, reportedly occur at cumulative doses 
exceeding 780 mg/m2 [64, 66].  
Oxaliplatin-induced central neuropathy is rare and is characterized by Lhermitte’s sign (an electric 
sensation experienced with flexing of the neck), proprioception deficiencies and urinary retention 
[66]. Risk factors for the development of both acute and chronic neuropathy include the cumulative 
dose, low body weight, a body-surface area >2.0, young age, persistent neuropathy in a past cycle, 
and variations in genes such as glutathione-S-transferase genes P1 [GSTP1] and glutathione-S-
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transferase genes M1 [GSTM1], as discussed below [64, 67]. Furthermore, oxaliplatin induced 
neuropathy may be exacerbated by surgery [68].  
 
The mechanisms contributing to development of oxaliplatin-induced CIPN (Fig. 2) include 
alteration in axonal excitability due to ion channel dysfunction, dysregulation of calcium 
homeostasis and altered function of transient receptor potential channels. Additionally, oxidative 
stress leading to neuronal and glial cell dysfunction and cell death induced by caspases, mitogen-
activated protein kinases and protein kinase C may contribute to development of oxaliplatin-
induced CIPN [69]. 
1.4.3. Vincristine 
Despite widespread use of vincristine for the treatment of paediatric cancers including acute 
lymphoblastic leukaemia, sarcoma, medulloblastoma and neuroblastoma as well as a range of 
tumours in adults, the epidemiology of vincristine-induced peripheral neuropathy (VIPN) is 
relatively poorly defined. While the reported incidence rates vary considerably – depending on the 
severity of symptoms, diagnostic criteria and concomitant use of other neurotoxic agents – most 
patients receiving vincristine develop some degree of sensory peripheral neuropathy at a 
cumulative dose of > 4 mg/m2 [3, 70-73].  
Symptoms of neuropathy can be present soon after initiation of vincristine therapy but usually 
develop within several weeks, and generally worsen with increasing cumulative doses of the drug. 
In addition, genetic factors can enhance the susceptibility to develop vincristine-induced 
neuropathy. An increased severity of VIPN was also observed in older compared with younger 
children, suggesting that age can be a risk factor for development of VIPN [71]. 
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VIPN can be divided into sensory, motoric and autonomic components, with tendon reflexes, 
vibration sensitivity and strength most affected in the first year of treatment [71]. Vincristine-
induced sensory neuropathy is characterized by numbness, tingling and neuropathic pain in the 
upper and lower extremities. In addition, patients receiving vincristine experience loss of sensory 
discrimination, specifically an inability to detect light touch, pinprick sensations or vibration, and 
an inability to differentiate between hot and cold temperatures [74]. Vincristine-induced motor 
neuropathy is characterized by weakness in the upper and lower extremities and the development 
of wrist- or foot-drop due to impaired dorsiflexion that arises from damage to peripheral nerves. 
This is accompanied by gait abnormalities, cramps, and loss of or reduction in deep tendon reflexes 
which can be severe [75]. Typical symptoms of autonomic neuropathy are constipation, urinary 
retention, and orthostatic hypotension. As would be expected, these symptoms can significantly 
reduce the quality of life of these patients [76]. 
The mechanisms contributing to development of VIPN include disruption of calcium homeostasis, 
activation of the immune system and subsequent neuroinflammation, membrane remodelling of 
peripheral neurons and loss of large myelinated fibres (Fig. 3) [69, 77, 78]. 
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Figure 3. Possible mechanisms involved in the development of vincristine-induced peripheral 
neuropathy. 
Overview of possible effects of vincristine on the immune system, peripheral tissues and sensory 
neurons leading to neuronal inflammation and altered excitability of peripheral neurons which may 
be considered as the main mechanisms contributing to the development of vincristine-induced 
CIPN. CXCL12: C-X-C Motif Chemokine Ligand 12; CX3CR: C-X-3-C motif chemokine 
receptor; TNF α: Tumour necrosis factor alpha; ILs: Interleukins; CXCR4: C-X-C motif 
chemokine receptor 4; ROS: Reactive oxygen species; NaV: Voltage-gated sodium channel; KV: 
Voltage-gated potassium channel; TRP: Transient receptor potential channel; CaV: Voltage-gated 
calcium channel. 
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1.4.4. Taxanes (paclitaxel, docetaxel) 
CIPN is also a dose-limiting adverse effect of treatment with taxanes, particularly paclitaxel, and 
occurs in a dose- and treatment duration-dependent manner. The threshold dose for development 
of taxane-induced peripheral neuropathy lies close to standard doses used in a range of 
chemotherapy regimens at approximately 300 mg/m2 for paclitaxel and 100 mg/m2 for docetaxel 
[33, 79, 80]. Accordingly, this symptom is very common, occurring in as many as 90% of patients, 
although it usually remains relatively mild until cumulative paclitaxel doses exceed 1400 mg/m2 
[81-83]. Overall, while paclitaxel is slightly less potent than docetaxel, it is more commonly 
associated with the development of CIPN [84, 85]. Consistent with CIPN being a direct 
consequence of the pharmacological effects of the taxanes on sensory neurons, higher single as 
well as higher cumulative doses are associated with both a greater risk for development of this side 
effect, as well as increased severity of symptoms [83, 86, 87]. In addition, concomitant treatment 
with other neurotoxic chemotherapeutic agents, or pre-existing neuropathies, may additionally 
increase the risk of developing CIPN [88]. While symptoms usually develop within several weeks 
of treatment initiation, paclitaxel and docetaxel can also induce an acute painful neuropathy – 
peaking approximately 3 days after infusion – that is characterized by pain, numbness and tingling, 
and which can be a predictor for the development of chronic neuropathy [44, 89-92].  
Symptoms of taxane-induced neuropathy are consistent with a predominantly sensory neuropathy, 
although motor effects (particularly distal weakness, muscle cramps and muscle aches) and 
autonomic dysfunction (including arrhythmias and orthostatic hypotension) can occur with higher 
doses. Specifically, numbness, tingling, mechanical allodynia and neuropathic pain developing 
symmetrically in the digits and extending to the extremities usually predominate; cold allodynia, 
loss of pinprick sensation as well as altered reflexes can also occur [32, 93, 94]. 
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Mechanisms that contribute to paclitaxel-induced neuropathy include immune-mediated 
processes, loss of peripheral fibres, demyelination and axon degeneration, altered retrograde and 
anterograde transport as well as mitochondrial dysfunction (Fig. 4). 
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Figure 4. Putative mechanisms involved in the development of paclitaxel-induced peripheral 
neuropathy. 
Overview of possible effects of paclitaxel on the immune system, microglia and peripheral neurons 
leading to neuronal inflammation and altered excitability of peripheral neurons. TLR4: Toll-Like 
Receptor 4; TNFα: Tumour necrosis factor alpha; ROS: Reactive oxygen species; NaV: Voltage-
gated sodium channel; KV: Voltage-gated potassium channel; TRP: Transient receptor potential 
channel; CaV: Voltage-gated calcium channel. 
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1.5. The Genetics of Chemotherapy-Induced Peripheral Neuropathy 
In recent years, several studies have identified genetic risk factors associated with the development 
of CIPN in cancer patients. Many of these are pharmacogenomic in nature, affecting either the 
absorption, distribution, metabolism or excretion of these chemotherapeutic agents. For instance, 
polymorphisms in glutathione transferases, cytochrome P450 enzymes and ATP binding cassette 
transporters may be involved in the development of varying types of CIPN as they affect the uptake 
and disposition of various cytotoxic drugs [95, 96]. 
Specifically, the polymorphism Ile105Val of the GSTP1 gene, encoding glutathione transferase 
P1, has been associated with a decreased risk of developing severe oxaliplatin-related cumulative 
neuropathy. This mutation is thought to increase the activity of glutathione transferase P1, an 
enzyme that catalyses the conjugation of hydrophobic and electrophilic compounds with 
glutathione, thus reducing the toxicity level of the bound substances. Indeed, in vitro experiments 
in Escherichia coli carrying different GSTP1 mutations demonstrated altered cytotoxicity, 
suggesting that GSTP1 polymorphisms could be predictors for the development of cumulative 
neuropathy [97, 98]. Similarly, polymorphisms in GSTM1, the gene encoding the enzyme 
Glutathione S-Transferase Mu 1, have been associated with a lower incidence of cisplatin-induced 
neuropathy [99], while polymorphism of the CYP450 3A enzyme system can necessitate 
vincristine dose adjustments to prevent neurotoxicity [75].  
 
An important contributing factor to the development of CIPN is thought to be the cellular uptake 
and accumulation of platinum-derivatives in sensory neurons [100-102]. Specifically, the copper 
transporter 1 (CTR1), members of the organic cationic transporter family (OCTf), and copper-
transporting ATPases have been proposed as key transporters maintaining the intracellular 
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concentration of platinum derivatives via active uptake and efflux processes [102-105]. Several of 
these transporters are also expressed on the plasma membrane of DRG cells, where they 
presumably contribute to the development of CIPN. While the human CTR1 plays a particularly 
important role in both resistance to platinum drugs and uptake in sensory neurons in vivo and in 
vitro [11, 100, 101], residual oxaliplatin accumulation in murine embryonic fibroblast from Ctr-/- 
animals suggests the existence of additional transport mechanisms leading to accumulation of 
platinum-based compounds [103]. These likely include the organic cationic transporters belonging 
to the solute carrier family. In particular, OCT1 (SLC22A1) and OCT2 (SLC22A2) and the cation 
and carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5) have been suggested to 
be involved in the cellular uptake of platinum drugs [106]. OCT2 in particular contributes 
significantly to accumulation of oxaliplatin, and genetic or pharmacological knockout of OCT2 
prevented the development of cold and mechanical hypersensitivity following treatment with 
oxaliplatin, suggesting that the OCT2 transporter plays a crucial role in oxaliplatin-induced 
cytotoxicity [104].  
 
Notably, a polymorphism in the ABCC2 gene has also been suggested to lead to higher oxaliplatin 
concentration in neurons, and was associated with oxaliplatin induced neuropathy [107]. Two 
additional SNPs in the same gene, rs3740066 GG and rs12826 GG, have been associated with an 
increased risk to develop neuropathy following vincristine treatment, presumably due to increased 
accumulation of vincristine in neuronal cell bodies leading to increased neurotoxicity [108]. In 
contrast, ABCB1, CYP1B1 and CYP2C8 gene mutations were associated with paclitaxel-induced 
neuropathy [109]. 
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In addition to genetic factors affecting the pharmacokinetics of chemotherapeutic agents, several 
polymorphisms relating to pharmacodynamic effects have been causally implicated in the 
development of CIPN. These include genetic risk factors that alter sensitivity to cytotoxic effects, 
cellular repair mechanisms and excitability of sensory neurons. For example, polymorphisms that 
alter the expression of the DNA excision repair protein ERCC-1 (excision repair cross-
complementing group 1) have been suggested to be involved in cisplatin- and oxaliplatin-induced 
cytotoxicity, though no clinical study to date has shown an association with CIPN [110]. Genetic 
variants of alanine glyoxylate aminotransferase (AGXT), an enzyme involved in oxalate 
metabolism, have been correlated with the severity of oxaliplatin-induced CIPN [111]. Similarly, 
a polymorphism in the ITGB3 gene – encoding for Integrin B3 – was not correlated with the 
development of oxaliplatin-induced CIPN, although it appeared to be related to the severity of this 
symptom [112]. This effect may be mediated via the differential activation of the mitogen activated 
protein kinases MAPK3 and MAPK1 that are induced by these ITGB3 variants, and which may 
contribute to development of CIPN [113]. Altered development of acute oxaliplatin-induced 
peripheral neuropathy was also reported in patients with single nucleotide polymorphisms (SNPs) 
in SCNA genes encoding the voltage-gated sodium channels, which are essential for the initiation 
and propagation of action potential in neurons. Specifically, polymorphisms in the NaV1.4 
(SCN4A-rs2302237) and NaV1.8 genes (SCN10A-rs1263292) have been associated with 
increased incidence of acute oxaliplatin-induced neuropathy [63], while patients carrying a 
polymorphism (rs6746030) in the SCN9A gene encoding for NaV1.7 seem to develop less severe 
neuropathy then patients carrying other SCN9A gene variants [114].  
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Genetic variants associated with the development and severity of taxane-induced neuropathy 
include low-frequency variants in the ephrin receptor genes EPHA6, EPHA5 and EPHA8 [115, 
116], the Charcot-Marie-Tooth disease gene ARHGEF10 [117], the glycogen synthase kinase-3β 
(GSK3β) gene [118], the DNA repair pathway genes XPC [119], the congenital peripheral 
neuropathy gene FGD4 [87], the β-tubulin IIa gene (TUBB2A) [120] and VAC14, a gene coding 
for a component of a trimolecular complex that tightly regulates the level of phosphatidylinositol 
3,5-bisphosphate [121]. 
 
A SNP in the centrosome protein encoded by CEP72 gene has been associated with development 
of vincristine-induced neuropathy in the later phases of therapy. This protein is important for 
microtubule formation and appears to increase the sensitivity of neuronal cells to vincristine 
damage [122]. Additionally, several other SNPs, including in CAMKK1 (Calcium/Calmodulin 
Dependent Protein Kinase 1, involved in regulation of apoptosis) , CYP2C8 (Cytochrome P450 
Form 1, involved in hepatic drug clearance) and CYP2C9 (Cytochrome P450 PB-1, involved in 
hepatic drug clearance), NFATC2 (Nuclear Factor of Activated T-Cells 2), ID3 (Inhibitor Of 
Differentiation 3) and SLC10A2 (apical sodium-dependent bile acid transporter) have been 
suggested to be involved in vincristine-induced neuropathy [95].   
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1.6. Pathological Mechanisms Contributing to CIPN 
The pathological mechanisms underlying the development of CIPN have been studied extensively 
and likely involve direct effects on the viability of sensory neurons, as well as cell-type specific 
consequences that occur downstream of on-target pharmacological activity of these cytotoxic 
drugs. In addition, off-target effects and additional mechanisms may also be involved, although 
the relative causative contribution remains unclear. Overall, despite diverse pharmacological 
mechanisms, a number of common pathologies have been proposed including oxidative stress, 
altered calcium homeostasis, axon degeneration, membrane remodelling and inflammatory 
processes (Figs. 2-4). 
1.6.1. Oxidative stress and apoptotic pathways 
Mitochondria are small organelles involved in many important cellular processes including energy 
production, storage of intracellular calcium and calcium signalling, apoptosis, regulation of 
membrane potential and cell metabolism. The main function of mitochondria is to produce 
adenosine triphosphate (ATP) via aerobic respiration. In healthy tissues, mitochondria produce 
small amounts of reactive oxygen species (ROS) such as peroxide, superoxide, hydroxyl radicals 
and singlet oxygen as by-products of oxygen metabolism. These radicals carry out important 
functions in cell signalling[123].  
Most chemotherapeutic agents cause damage to mitochondria leading to increased production of 
ROS and thus to increased oxidative stress [124-127]. The pathological increase in ROS 
production in turn can cause damage to intracellular biomolecules such as enzymes, proteins and 
lipid molecules [128-130], which in turn leads to demyelination and disruption of the cytoskeleton 
of peripheral nerves as well as sensitization of signal transduction processes [131, 132]. 
Furthermore, ROS can cause the activation of apoptotic pathways [133] and increase production 
61 
 
of pro-inflammatory mediators [134]. These processes can cause further damage to mitochondria, 
amplifying the production of ROS and pathological processes of oxidative stress [9].  
Oxaliplatin and cisplatin bind to mitochondrial DNA (mDNA) and form mDNA adducts which 
cannot be repaired since mitochondria do not express DNA repair systems. These Pt-mDNA 
adducts impair mitochondrial DNA replication and transcription, leading to altered protein 
synthesis and functional errors of the respiratory chain [135]. Similarly, vincristine causes 
dysregulation and structural modification of neuronal mitochondria, leading to activation of 
apoptotic pathways, alteration in neuronal excitability and dysfunction of glial cells. In contrast to 
platinum-induced mitochondrial dysfunction, the effects of vincristine on mitochondria likely 
involves altered mitochondrial Ca2+ signalling [69, 135]. This hypothesis is supported by the 
observation that potentiation of vincristine-induced cytotoxicity occurs in the presence of 
verapamil, a calcium channel blocker [136].  
Like vincristine, paclitaxel does not directly affect mitochondrial DNA, but nonetheless induces 
swollen and vacuolated mitochondria in both myelinated and unmyelinated sensory axons in the 
saphenous nerve [137]. These changes in turn are accompanied by increased ROS production in 
sensory neurons within the spinal cord, although the mechanisms leading to altered mitochondrial 
function are relatively poorly understood [9, 138-140]. 
1.6.2. Calcium homeostasis 
Calcium (Ca2+) is a key regulatory ion in many cellular and physiological processes. Its free 
intracellular concentration, which is usually maintained at nanomolar levels, is tightly regulated 
by various transport and sequestration mechanisms, including extracellular influx and release from 
internal stores, as well as efflux via plasma membrane pumps and uptake into the endoplasmic 
reticulum and mitochondria [141]. Changes in the intracellular Ca2+ concentration influence 
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membrane excitability, neurotransmitter release and gene expression of neuronal and glial cells 
[69]. Accordingly, dysregulation of Ca2+ homeostasis and Ca2+ signalling has been suggested to 
contribute to the development of oxaliplatin-, cisplatin-, vincristine- and paclitaxel-induced CIPN. 
 
The oxaliplatin metabolite oxalate is a well-known Ca2+ chelator that has been proposed to 
contribute to the development of oxaliplatin-induced CIPN. Indeed, local injection of oxalate into 
the footpad of mice induces spontaneous nocifensive behaviour as well as mechanical allodynia, 
albeit the dose required to observe this effect is considerably higher than the dose of oxaliplatin 
required to induce neuropathic pain [19]. In addition, the phenotype of nocifensive behaviours 
induced by oxalate differs significantly from oxaliplatin-induced neuropathy, which is 
characterized by cold allodynia and a lack of spontaneous nocifensive behaviour [19]. Oxalate-
induced pain likely arises as a consequence of chelation of extracellular Ca2+ ions, which in turn 
leads to an increase in sodium (Na+) conductance and a decrease of threshold potential and 
membrane resistance [19]. In contrast, an increase in extracellular Ca2+ concentration increases the 
probability of Na+ channel closure and results in decreased excitability of peripheral neurons [142]. 
Accordingly, the administration of Ca2+/Mg2+ (magnesium) prior to oxaliplatin infusion has been 
evaluated in several clinical trials as a strategy to prevent development of CIPN, although a 
consistent clinical benefit is unfortunately not apparent [143].  
 
In contrast, although effects on intracellular Ca2+ levels have been reported in sensory neurons, 
renal tubular cells and cancer cells, the contribution of Ca2+ to cisplatin-induced neuropathy is 
relatively poorly understood. In sensory neurons, cisplatin increased the expression of the N-type 
voltage-gated Ca2+ channels (CaV2.2), and it differentially affects the function of specific CaV 
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channel subtypes [144, 145]. However, the contribution of these effects to the clinical presentation 
of cisplatin-induced neuropathy remains unclear. 
 
Contributions of Ca2+ signalling to the pathology of CIPN have also been reported for paclitaxel, 
which causes rapid mitochondrial depolarization and Ca2+ release in both neuronal and non-
neuronal cells, possibly via activation of the mitochondrial permeability transition pore (mPTP) 
[146, 147]. In addition, lower concentrations of paclitaxel induce Ca2+ oscillations downstream of 
neuronal calcium sensor 1 (NCS-1), a protein that regulates G protein-coupled receptor 
phosphorylation in a calcium-dependent manner [148]. 
1.6.3. Axon degeneration 
Several studies in humans and animals have demonstrated axon degeneration after long-term 
administration of chemotherapeutic agents, including the loss of large myelinated, small 
unmyelinated (more rarely), and intra-epidermal nerve fibres (IENF) which may be connected to 
the development of sensory-motoric peripheral neuropathy [37, 78, 149-153]. Intra-epidermal 
nerve fibres are unmyelinated or thinly myelinated nociceptors located in the epidermis and are 
necessary for the sensation of pain arising from the periphery. Additionally, loss of myelin and 
changes to the axonal cytoskeleton likely alters the structure and function of peripheral nerves, 
which in turn may contribute to development of altered perception. However, while correlation of 
nerve fibre loss with the degree of neuropathy has been attempted in several conditions, and 
functional deficits arising from axon degeneration appear intuitive, the contribution of 
demyelination and peripheral nerve degeneration to the pathobiology of CIPN is not entirely clear.  
Clinical and electrophysiological studies have shown that oxaliplatin causes moderate sensory-
motor axon degeneration and loss of intra-epidermal nerve fibres [154]. Similarly, electron 
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microscopy of peripheral nerves from cisplatin-treated patients revealed axonal degeneration of 
large myelinated fibres as well as secondary myelin breakdown associated with loss of ankle jerks 
and decreased vibration sensitivity [155]. In mice, cisplatin damaged myelinated fibres of the 
sciatic nerve, diminished the action potential amplitude and reduced the nerve conduction velocity 
of the caudal sensory nerve [78]. Degeneration of distal sensory axons, secondary demyelination 
and nerve fibre loss have also been reported in vincristine- and paclitaxel-induced neuropathy [37, 
78, 156, 157].  
 
The molecular mechanisms leading to these observed changes in axonal function and structure 
remain unclear. Chemotherapeutics causing CIPN likely have direct toxic effects on axons – 
evidenced by a lack of effect on axon integrity when applied to neuronal cell bodies under 
compartmentalized culturing conditions [158] – although indirect effects due to altered gene 
expression cannot be ruled out. Altered microtubule function can also impair the anterograde and 
the retrograde axonal transport of synaptic vesicles loaded with lipids, proteins and ion channels. 
This in turn causes a length-dependent degeneration of axonal distal segments (Wallerian 
degeneration) and axonal membrane remodelling of peripheral nerves. However, these effects 
cannot adequately explain axon degeneration induced by cisplatin and oxaliplatin, which target 
cellular DNA. In addition, the different vinca alkaloids used in chemotherapy display variable 
efficacies and side effects but equally block tubulin polymerization, suggesting that additional 
mechanisms contribute to the direct damage of peripheral nerves [159].  
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1.6.4. Changes in neuronal excitability  
In addition to axonal degeneration, chemotherapeutic agents also cause changes to peripheral nerve 
excitability that contribute to the development of sensory peripheral neuropathy. These are likely 
caused by altered expression and function of a range of ion channels – including voltage-gated 
sodium (NaV), voltage-gated potassium (KV) and transient receptor potential (TRP) channels. 
 
Changes in sensory nerve excitability in patients treated with oxaliplatin, including a significant 
increase in the duration of the relative refractory period, have been attributed to effects on NaV 
channels [160]. Altered NaV channel function was also observed in rodent peripheral axons as well 
as DRG neurons, where oxaliplatin causes an increase in Na+ current, inhibition of maximal 
amplitude and the emergence of enhanced resurgent and persistent current amplitudes [161, 162]. 
Specifically, the NaV channel isoform NaV1.6 appears to be involved in the development of 
oxaliplatin-induced cold allodynia, with cooling-induced bursts of action potential firing abolished 
in neurons from Scn8a (med/med) mice lacking functional NaV1.6 [162]. Furthermore, acute 
oxaliplatin-induced cold pain behaviours were abolished by treatment with μ-conotoxin GIIIA, a 
selective NaV1.6 inhibitor, as was cisplatin-induced mechanical allodynia, albeit cisplatin does not 
directly affect the gating properties of NaV1.6 [19, 163].  
 
Effects on neuronal potassium (K+) channels – of which four major groups (voltage-gated K+ 
channels (KV), Ca
2+-activated K+ channels (KCa), two-pore K
+ channels (K2P) and inwardly-
rectifying K+ channels (Kir) are expressed in peripheral nerves – further exacerbate altered 
neuronal excitability in CIPN. Specifically, decreased expression of several K+ channels, including 
the K2P channels TREK1 and TRAAK, were found after oxaliplatin and paclitaxel treatment in 
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rodent DRG neurons [164, 165]. In addition, broadening of the repolarization phase, repetitive 
firing and after-hyperpolarization, consistent with effects on KV channels, were induced by 
treatment with oxaliplatin in the isolated sciatic nerve of the adult rat [166].  
 
In addition to acute effects on sensory neuron excitability, exposure to oxaliplatin and cisplatin 
has also been reported to alter expression of several thermo- and mechano-sensitive TRP channels, 
including TRPV1, TRPA1 and TRPM8 [164, 167-172]. The reported behavioural contributions of 
these channels to CIPN, however, remain seemingly at odds, with studies attributing functional 
effects to all, some, or none of these transducer ion channels. Whether these discrepancies arise 
from insufficient subtype selectivity of compounds with activity at TRP channels, compensatory 
expression changes in knockout animals or difference between animal models, remains to be 
determined. Paclitaxel- and vincristine-induced neuropathy has also been attributed to activation 
of TRPA1 and TRPV4 likely via the generation of reactive oxygen species [173-175], albeit 
disruption of TRP channel function due to altered association with microtubules may be an 
additional contributing mechanism [176]. 
1.6.5. Activation of the immune system and inflammation 
Chemotherapy agents are well known to cause profound effects on the immune system, most 
notably a transient immunosuppression due to inhibition of myeloproliferation. However, 
activation of the immune system by chemotherapeutics has increasingly received attention as an 
effect that is thought to support the destruction of tumour cells [177, 178], but which may also lead 
to neuroinflammation and thus contribute to the development CIPN. Specifically, effects of 
chemotherapeutics on the innate [179-181] and adaptive immune system [182-184], as well as 
effects on peripheral and central neuronal accessory cells – including satellite glial cells [185-187], 
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Schwann cells [188], astrocytes [189, 190] and microglia [191, 192] – have been observed, 
although most of these studies were carried out using rodent models [193] and it is not clear to 
which extend those findings can be translated in the clinical practice.  
 
Consistent with a contribution of the immune system to CIPN, oxaliplatin- and paclitaxel-induced 
mechanical hyperalgesia and epidermal nerve fibre loss was prevented by the tetracycline 
minocycline, an antibiotic known to inhibit macrophages/monocytes and microglia [154, 194-
196]. Both chemotherapeutic agents also lead to increased levels of proinflammatory cytokines 
(IL-6, IL-8, IL-1β, TNF-α), which can lead to sensitization of nociceptors [44, 90, 138, 190, 197-
206]. In addition, oxaliplatin increases the levels of circulating CD4+ and CD8+ lymphocytes in 
mice and down-regulates regulatory T (T-reg) cells [204].  
 
Vincristine induces the expression of integrins (immune markers) on the surface of endothelial 
cells, which allows macrophages expressing the CX3CR receptor to adhere to the endothelium and 
to migrate into nervous tissue. Activation of monocyte-macrophages by the chemokine CX3CL1 
also lead to production of ROS and subsequent activation of TRPA1 [175]. Additionally, 
vincristine and paclitaxel enhanced the binding of the STAT3 (Signal Transducer and Activator of 
Transcription 3) to the CXCL12 gene promotor [207] causing up-regulation of C-X-C Motif 
Chemokine Ligand 12 in DRG. CXCL12 is a member of the integrin family and acts as a ligand 
of the CXCR4 (CD184, C-X-C chemokine receptor type 4) and as an attractant for T-lymphocytes 
and monocytes. The activation of CXCR4 receptors in turn leads to an increase in intracellular 
Ca2+ and chemotaxis of immune cells to the site of inflammation [208]. Consequently, activation 
of the immune system, recruitment of immune cells and neuroinflammation should be considered 
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as a putative mechanism contributing to the development of vincristine-induced neuropathy 
specifically and CIPN more broadly. 
1.7. Prevention Therapies and Treatments 
The development of CIPN is likely multifactorial and involves several mechanisms as discussed 
above, although it is currently unclear which effect(s) initiate the pathological cascade leading to 
neuronal dysfunction. Despite clear similarities in both the pathological mechanisms and clinical 
symptomatology of CIPN, the pathophysiology of CIPN nonetheless is thought to be compound-
specific, with mechanism-specific prevention or treatment being the overarching clinical aim. In 
addition to providing targeted neuroprotection and relief from symptoms, any putative treatment 
for CIPN also must not interfere with the anti-tumour effects of the causative chemotherapeutic 
agent. Unfortunately, while the efficacy of a range of approaches preventing the development of 
CIPN including neuroprotectants and neutraceuticals (Table 1) have been evaluated in clinical 
trials, consistent beneficial effects have not as yet been shown for any single agent. Accordingly, 
current treatment strategies are predominantly based on modification of the chemotherapy 
regimen, including alteration of the dose, treatment cycles, timing, dosage form and duration, as 
well as symptomatic management using a range of pharmacological approaches (Table 2). These 
include treatments targeting the neuropathic component in CIPN, including anticonvulsants 
(gabapentin, carbamazepine, oxcarbazepine, lamotrigine, topiramate) and antidepressants 
(amitriptyline, nortriptyline, venlafaxine, duloxetine). However, as is the case for many types of 
pain, these agents do not provide a satisfactory level of relief for many patients, with further 
research required to identify additional preventative or curative approaches.  
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Table 1. List of clinically used nutraceutical agents for prevention of the development of CIPN.  
The outcome of each study is marked with + : positive effect on CIPN, - : no effect on CIPN, ± : 
potential positive effect on CIPN, × : negative effect on CIPN or anti-tumour therapy 
Nutraceutical agents 
Nutraceutical 
agent 
Class Chemotherapy 
agent 
outcome 
Vitamin E vitamins cisplatin + Decreased incidence and severity of 
peripheral neurotoxicity [209] 
+ Reduced risk of developing 
neurotoxicity [210] 
+ Neuroprotective effect [211] 
oxaliplatin - No significant decrease in the incidence 
of acute CIPN [212] 
paclitaxel + Neuroprotective effect [211] 
Glutamine α-amino acid cisplatin ± Possible reduction of severity of CIPN 
symptoms [213] 
vincristine + Improvement in sensory function and 
self-reported overall quality of life [214]. 
oxaliplatin ± Possible reduction of severity of CIPN 
symptoms [213] 
+ Reduction in incidence and severity of 
CIPN [215] 
paclitaxel ± Possible reduction in the severity of 
CIPN [216] 
+ Significant reduction of weakness, loss 
of vibratory sensation and toe numbness 
[217] 
Alpha-lipoic 
acid 
antioxidant cisplatin - Ineffective at preventing neurotoxicity 
[218] 
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oxaliplatin - Ineffective at preventing neurotoxicity 
[218] 
+ Reduced severity of CIPN [219] 
Glutathione antioxidant cisplatin + Prevention of neuropathy [220] 
± Possible neuroprotection [221] 
± Possible decrease of severity of CIPN 
[222] 
oxaliplatin × Increased resistance to platinum agents 
[223] 
+ Possible prevention of CIPN [224] 
Calcium/ 
magnesium 
ions oxaliplatin × Decreased anti-tumour efficacy of 
FOLFOX regimen in combination with 
Ca2+/ Mg2+ infusions [225, 226] 
± Possible reduction in incidence and 
intensity of acute CIPN symptoms [227] 
N-acetyl 
cysteine 
antidot oxaliplatin ± Possible reduction in incidence of 
CIPN [228] 
Acetyl-L-
carnitine 
amino acid taxanes × Worsening of CIPN [229] 
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Table 2. Summary of clinical studies investigating the efficacy of pharmacological agents for 
symptomatical treatment of CIPN.  
The outcome of each study is marked with + : positive effect on CIPN, - : no effect on CIPN, ± : 
potential positive effect on CIPN, × : negative effect on CIPN or anti-tumour therapy 
Pharmacological agents 
Pharmacological 
agent 
Class Chemotherapy 
agent 
Study outcome 
Amifostine  Cyto-
protective 
adjuvant 
cisplatin + Reduction of neurotoxicity 
[230-232] 
+ Reduction in ototoxicity [233, 
234] 
± Possible reduction of 
neurotoxicity [235] 
oxaliplatin + Decrease of severity of CIPN 
[236] 
paclitaxel - Ineffective in preventing or 
reducing neurotoxicity [237-240] 
+ Reduction of neurotoxicity [232, 
235, 241, 242] 
Carbamazepine 
Oxcarbazepine 
Anticonvulsant oxaliplatin + Prevention of CIPN [243, 244] 
- No prevention of CIPN [245, 
246] 
Calcium channel 
blocker 
- oxaliplatin + Inhibits the development of 
acute peripheral neuropathy [247] 
Gabapentin Anticonvulsant vinca alkaloids, 
platinum 
derivates, 
taxanes 
- No prevention of CIPN [248] 
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Lamotrigine Anticonvulsant Paclitaxel, 
docetaxel, 
carboplatin, 
cisplatin, 
oxaliplatin, 
vincristine and 
vinblastine 
- Not effective for relieving 
neuropathic symptoms [249] 
Etanercept Tumour 
necrosis factor 
(TNF) blocker 
cisplatin ± Transient analgesia  and delay in 
development of cisplatin induced 
mechanical allodynia [250, 251] 
Pregabalin Anticonvulsant oxaliplatin + Significant reduction of the 
severity of sensory 
neuropathy[252] 
Amitriptyline 
 
Tricyclic 
antidepressants 
vinca alkaloids, 
platinum 
derivatives or 
taxanes 
- No improvement of sensory 
neuropathic symptoms [253] 
Nortriptyline Tricyclic 
antidepressants 
cisplatin - No effect on paresthesia or pain 
[254] 
Venlafaxine Selective 
serotonin and 
norepinephrine 
reuptake 
inhibitor 
(SNRI) 
paclitaxel + Reduction of paresthesia [255] 
oxaliplatin + Pain relief and a significant 
autonomy improvement [256] 
+ Paresthesia improvement[257] 
Duloxetine Selective 
serotonin and 
norepinephrine 
reuptake 
inhibitor 
(SNRI) 
vinca alkaloids, 
platinum 
derivatives or 
taxanes 
+ Reduction in pain [258] 
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Topiramate Anticonvulsant oxaliplatin + Pain relief and a significant 
autonomy improvement [256] 
 
1.8. Summary and Conclusions 
CIPN is a common side effect of cancer chemotherapy that adversely affects the quality of life of 
patients. Although the individual biological effects of these chemicals on cancer cells are relatively 
well known and studied extensively, the precise mode of action on peripheral nerves is not always 
clear. The development of CIPN is likely multifactorial and involves effects on neuronal and/or 
mitochondrial DNA and gene expression, axonal transport, ion channel expression and function, 
as well as neuroimmune mechanisms. While rodent models – particularly those avoiding 
confounding physiological effects of high systemic chemotherapy doses – have provided valuable 
insight, validation of the mechanisms of CIPN in patients has been difficult not least because of 
the extensive co-morbidities usually present in this patient group. Nonetheless, significant 
advances in our understanding of the pathophysiological mechanisms of CIPN have been made, 
which will hopefully lead to improved clinical management of this devastating side effect in future.  
My hypothesis is, that the molecular mechanisms of CIPN are compound-specific and can be 
delineated using molecular and pharmacological approaches applied to murine models with 
following aims:  
Aim 1: Development of a novel animal model of VIPN and establishment of animal models of 
cisplatin and oxaliplatin induced peripheral neuropathy 
Aim 2: Transcriptomic analysis of genes following administration of vincristine, oxaliplatin and 
cisplatin in mouse DRG using established models of neuropathy and identification of novel targets 
for the treatment of CIPN  
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Aim 3: Molecular investigation of the identified targets and pharmacological intervention for 
CIPN with possible translation into the clinical practice.  
In the following chapter, I addressed aim one and established a novel animal model of VIPN to 
begin to investigate some of these mechanisms in detail. 
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2. CHAPTER 2: Development and characterization of a novel animal model of 
vincristine-induced peripheral neuropathy 
2.1. Foreword 
This chapter addresses the development of a novel mouse model of vincristine induced peripheral 
neuropathy based on local intraplantar injections of vincristine and the involvement of the innate 
immune system in development of vincristine induced peripheral neuropathy. It was published as 
a complete manuscript in Frontiers in Neuroscience in 2019 [259]. The manuscript was amended 
slightly to fit the style and flow of this thesis. Hana Starobova performed all behavioural 
experiments, tissue collection, sectioning and staining. Rachel Allavena performed the blinded 
morphological examination of tissue (Fig. 7 and Table 3). Hana Starobova wrote the manuscript 
and designed all figures.   
 
2.2. Introduction 
Animal models have yielded significant insights into the pathological mechanisms of CIPN and 
are an unreplaceable tool of pharmacological studies. However, no model can mirror the human 
conditions as these are usually in healthy animals and neither the dosing routes, doses, 
administration frequencies nor drug combinations perfectly mirror the circumstances in the clinic. 
Often these agents are administered to animals by systemic (i.p. or i.v.) injection and this may lead 
to ethically undesirable adverse events. For example, cisplatin models require monitoring of renal 
function [260]. In addition, general ill health of animals may interfere with assessment of sensory 
neuron-specific effects. For these reasons, some models have used intraplantar administration that 
reduces the administered drug dose to a minimum and reduces adverse effects [163]. However, 
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intraplantar injection may often cause only local effects and may exclude central sensitisation of 
nerves which often contributes to development of CIPN [261] .  
The assessment of the efficacy of novel treatments for vincristine-induced peripheral neuropathy 
(VIPN) in vivo necessitate the use of preferably murine models that reproduce the most common 
symptoms of VIPN, such as hyper- or hypoalgesia and gait disturbances. To date, animal models 
of vincristine-induced peripheral neuropathy are based on repeated intraperitoneal injections (i.p.) 
of vincristine and are highly restricted in the reproduction of neuropathy symptoms. For example, 
the repeated administration of 0.5 mg/kg vincristine (i.p.) elicits strong mechanical allodynia in 
C57BL6 mice [175, 259] and models based on i.p. injections of higher doses of vincristine (1 - 1.5 
mg/kg) elicit mechanical and heat hyperalgesia but induce adverse effects in treated animals such 
as severe weight loss. However, those models fail to reproduce motoric neuropathy and loss of 
sensory discrimination, restricting the use to only few symptoms of VIPN [262, 263]. 
In this chapter, I present the development and characterisation of an optimized mouse model of 
VIPN based on local intraplantar (i.pl.) injections of vincristine allowing us to isolate the effects 
of vincristine on the peripheral nerves and tissue and to mimic the side-effects described in 
Chapter 1, section 1.4.3.. I found that local vincristine injections cause dose and time dependent 
mechanical hypersensitivity that develops into mechanical hyposensitivity at high vincristine 
doses. In this optimized model, vincristine also caused dose-dependent changes in gait and strong 
infiltration of immune cells - in particular leucocytes to the site of injection and caused 
vacuolization of peripheral nerves and muscles. Additionally, I assessed the effects of minocycline 
treatment in the optimized mouse model of VIPN and in the conventional model based on 
intraperitoneal administration of vincristine. Minocycline prevented the development of 
mechanical hyperalgesia following intraplantar and intraperitoneal vincristine injection. 
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Additionally, mice lacking the Toll-like receptor 4 (Tlr4-/-) showed diminished mechanical 
hyperalgesia and paw swelling after vincristine injection. This chapter demonstrates that the novel 
animal model based on intraplantar injections of vincristine reproduces several symptoms of VIPN 
and it is a useful tool for future pharmacological studies. Moreover, I demonstrate that Tlr4 
signalling pathway partially drives the development of mechanical pain following vincristine 
administration in mice, highlighting the involvement of the innate immune system in development 
of VIPN. 
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2.3. Materials and methods 
2.3.1. Animals 
All behavioural experiments were performed with 8-10 week old adult wild type (C57BL/6J) mice 
or with Tlr4-/- mice of mixed sex, noting that no differences between sexes were observed in 
preliminary studies (Appendix 3, Fig. 20S). Animals were housed with rodent chow and water ad 
libitum in groups of three to five per cage under 12-hour light-dark cycles. All experiments were 
performed in accordance with the Animal Care and Protection Regulation Qld (2012), the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 8th edition 
(2013) and the International Association for the Study of Pain Guidelines for the Use of Animals 
in Research. Ethical approval was obtained from the University of Queensland animal ethics 
committee (certificate of approval: Appendix 4, section 10.1). All behavioural assessments were 
performed by a blinded observer, unaware of the treatment and genotype of each mouse, with 
animals randomized to treatment groups. 
2.3.2. Vincristine administration 
Vincristine sulphate (Sapphire Bioscience, Australia) was dissolved in sterile Dulbecco’s 
phosphate buffered saline (PBS, Appendix 2, section 8.1.) for intraperitoneal (i.p., 0.5 mg/kg, 
cumulative dose: 5mg/kg) injection or in sterile-filtrated 5% glucose solution (Appendix 2, section 
8.2.) for intraplantar (i.pl.; 1 pg (cumulative dose: 10 pg), 10 pg (cumulative dose: 100 pg), 100 
pg (cumulative dose: 1ng), 1 ng (cumulative dose: 10ng), 10 ng (cumulative dose: 100 ng), 100 ng 
(cumulative dose: 1 µg), 1 µg (cumulative dose: 10 µg) and 10 µg (cumulative dose: 100 µg)) 
injection. Vincristine or vehicle solution (5% glucose or PBS) was administered via intraperitoneal 
injection (10 µl/g, 30G needle with BD ultrafine insulin syringe) or via shallow subdermal 
79 
 
intraplantar injection into the right hind paw (10 µl, 30G needle with Hamilton glass syringe) under 
isoflurane anaesthesia (3%) using the injection schedule shown in Fig. 5.  
  
80 
 
 
 
Figure 5. Schedule of vincristine injections and behavioural measurements 
Vincristine (< 10 µg i.pl. or 0.5 mg/kg i.p.) or vehicle (5% glucose i.pl. or PBS i.p.) (open square, 
grey square) were administered for five consecutive days, with two days break, followed by 
another five consecutive injections. The highest vincristine dose (10 µg i.pl.) (black square) was 
administered for four consecutive days, followed by five days break and another two injections. 
Minocycline (25 mg/kg i.p.) (open triangle) was administered once daily, three days before 
vincristine administration and then with each vincristine injection. Arrows indicate the time points 
of behavioural assessments, which were always performed before the next vincristine injection 
with the exception of day 0, where behavioural assessment was performed 3 h after the first 
vincristine injection.  
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2.3.3. Drug treatment 
Minocycline, gabapentin (Sigma-Aldrich) and meloxicam (ABCAM Australia Pty Ltd) were 
dissolved in PBS. Minocycline (25 mg/kg) or PBS were administered by intraperitoneal injection 
(i.p., 10 µl/g, 30G needle with BD ultrafine insulin syringe) once daily, beginning three days prior 
to the first vincristine administration and then together with each vincristine (i.pl. or i.p.) injection 
using the injection schedule shown in Fig. 5. The dose of minocycline was based on effective 
doses reported in previous studies of chemotherapy-induced neuropathy [151, 154]. Meloxicam (5 
mg/kg) or gabapentin (100 mg/kg) were administered once by i.p. injection (10 µl/g, 30G needle 
with BD ultrafine insulin syringe) 24 hours after single vincristine injection (100 ng, i.pl., 10 µl, 
30G needle with Hamilton glass syringe) and behavioural assessment was performed 30 minutes 
after meloxicam and gabapentin administration. 
2.3.4. Mechanical threshold measurements 
Changes in mechanical paw withdrawal thresholds were assessed using an electronic von Frey 
apparatus (MouseMet, Topcat Metrology Ltd, United Kingdom) [264]. Mice were placed in the 
MouseMet test enclosures and allowed to acclimatize for minimum of 30 minutes.  The hind paw 
withdrawal threshold (PWT) of the ipsilateral (right, for i.pl. and i.p. administration) was 
determined by measuring the force required to elicit paw withdrawal in response to increasing 
force applied via a flat-tipped filament. The end-point of the measurement was determined by 
lifting, shaking or licking of the measured hind paw by the animal. The average of three 
measurements per mouse was computed as one biological replicate.  
2.3.5. Thermal threshold measurements 
Thermal threshold measurements were conducted using a MouseMet Thermal (Topcat Metrology 
Ltd, United Kingdom) [265]. Mice were placed in the MouseMet test enclosures and allowed to 
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acclimatize for minimum of 30 minutes. The thermal probe was preheated to 37 °C before applying 
it to the plantar surface of the ipsilateral (right, for i.pl. and i.p. administration) hind paw. The end-
point of the measurement was determined by adverse pain behaviour of the animals (lifting, 
shaking or licking of the measured hind paw). The heat rate was set to 2.5°C/sec, with a cut off set 
at 55°C to prevent tissue damage and the temperature that elicited paw withdrawal was recorded. 
The average of three measurements per mouse constituted one replicate. 
2.3.6. Gait analysis 
Gait analysis was performed using the CatwalkXT (Noldus Information Technology, Netherlands) 
[266]. Mice were allowed to cross freely the glass platform and 3 runs constituted one replicate. 
The green intensity of the walkway was set at 0.10 and camera gain at 20.00. Only runs of 3 sec 
to 12 sec duration with speed variances below 80% were considered for analysis, which was 
performed using the CatwalkXT software. Data is shown as % of the contralateral (left, not 
injected) hind paw. 
2.3.7. Paw thickness 
The paw thickness of the ipsilateral and contralateral hind paw was assessed using digital Vernier 
callipers (Kincrome, Vic, Australia). Mice were anaesthetized using 2% isoflurane and the distal-
proximal axis at the metatarsal level of the hind paw was measured 30 min after each vincristine 
injection. An average of two measurements for each paw constituted one replicate. 
2.3.8. Hematoxylin and eosin (H&E) staining 
C57BL/6J or Tlr4-/- mice were injected with vincristine (i.pl., 10 µg, 100 ng or i.p., 0.5 mg/kg) or 
with vehicle (i.pl., 5% glucose or i.p., PBS) (as described in section 2.3.2.) using the injection 
schedule shown in Fig. 5. After 24 h or on day seven, the mice were anesthetized with 10 mg/kg 
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xylazine and 100 mg/kg ketamine i.p.. The beating heart was exposed and a blunt needle (18G, 
Terumo Agani) was inserted through the heart into the aorta and fixed with a metal clamp. The 
animals were transcardially perfused first with ice-cold PBS (1ml/g body weight) followed by ice-
cold 4% paraformaldehyde in PBS (1ml/g body weight, Appendix 2, section 8.3.) using a Welch® 
peristaltic pump (digital, AC input 230 V, Schuko plug, with speed of the pump set to 25 rpm) and 
3.2 mm silicone tubing. The injected hind paws were dissected cut transversally in half and post 
fixed for 16 h in 4% paraformaldehyde, pH 7.4 at 4 °C. The paws were washed three times with 
PBS and then incubated at 37 °C in decalcification solution (Appendix 2, section 8.4.), pH 7.4 for 
14 days followed by three times 15 min washes in PBS and 48 h incubation in 50% Organic 
Compound Tissue (OCT, Tissue –Tek, Appendix 2, section 8.5.) in PBS. Finally, the paws were 
frozen in OCT (Tissue-Tek). Tissue was cut with a Leica cryostat CM1950 (Leica Biosystems). 
The paws were cut into 5 µm thick sections and were stained with hematoxylin and eosin in a 
Leica ST5020 Autostainer (Leica Biosystems, Mt Waverly, Victoria, Australia). Pictures were 
obtained using the wide-field Zeiss AxioImage M2.m Microscope and Axiocam 506 camera. 
Three animals per group and 5 sections per animal were analysed by blinded veterinary pathologist 
unaware of the treatment and a representative picture for each group is shown. 
2.3.9. Data and statistical analyses 
Data and statistical analyses were performed using GraphPad Prism Version 7.00. Statistical 
significance was determined as * p- adjusted < 0.05 and was calculated using two-way ANOVA 
with Tukey's multiple comparisons test. All data are shown as mean ± standard error of the mean 
(SEM); n = 6 for all groups (3 females and 3 males), all experimental groups were compared to 
vehicle receiving group (control). The ED50 was calculated using the area under the curve of the 
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experimental values following the i.pl. administration of 1 pg, 10 pg, 100 pg, 1 ng, 10 ng, 100 ng, 
1 µg and 10 µg vincristine. 
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2.4. Results 
2.4.1. A novel mouse model replicates several symptoms of vincristine-induced 
peripheral neuropathy 
Mouse models based on systemic administration of vincristine induce symptoms of mechanical 
allodynia, but poorly replicate important symptoms of human neuropathy such as sensory loss or 
gait disturbances. I thus sought to isolate the dose-dependent actions of vincristine on peripheral 
sensory neurons, by establishing a mouse model of VIPN based on the local administration of 
vincristine (1 pg, 10 pg, 100 pg, 1 ng, 10 ng, 100 ng, 1 µg and 10 µg) via shallow subcutaneous 
(intraplantar, i.pl.) injections into the hind paw of C57BL/6J mice (Fig. 5). I compared the resulting 
phenotypes to that of a conventional mouse model of VIPN based on systemic intraperitoneal (i.p.) 
administration. Local administration of vincristine caused a dose- and time-dependent mechanical 
hypersensitivity that developed slowly at lower doses of vincristine (≤ 10 ng) and rapidly at higher 
doses (≥ 100 ng), with a calculated ED50 of 3.7 ng (Fig. 6A and Fig 7 and Appendix 3, Table 8S). 
Intraplantar injection of vehicle (5% glucose) did not affect mechanical thresholds. Interestingly, 
besides causing initial mechanical hypersensitivity, local administration of higher vincristine doses 
(10 µg and 1 µg i.pl.) also led to the development of a more slowly developing mechanical 
hypoalgesia, as evidenced by an increase in the mechanical paw withdrawal threshold above 
baseline (Fig. 6A and Fig. 7 and Appendix 3, Table 8S). This effect occurred with a calculated 
ED50 of 924.5 ng and is consistent with the clinical symptomatology, which includes hypoesthesias 
that typically develop at higher cumulative vincristine doses [267]. An apparent recovery from the 
hypoalgesia, evidenced by a return of the mechanical paw withdrawal thresholds toward baseline 
values (dotted line), was observed after 25 days (Fig. 6A and Fig 7 and Appendix 3, Table 8S).   
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For comparison, I additionally assessed a conventional mouse model based on multiple 
intraperitoneal (i.p.) injections of vincristine (0.5 mg/kg; Fig. 5). As previously reported, in this 
model a significant decrease of the mechanical threshold, beginning on day 2 and persisting for at 
least two weeks, was observed (Fig. 6A and Fig. 7 and Appendix 3, Table 8S). Although 
vincristine is not administered by subcutaneous injection clinically, this route achieves high local 
concentrations at peripheral nerve endings and has provided considerable insight into the 
pathophysiological mechanisms of other chemotherapy-induced neuropathies [19, 163]. 
Interestingly, unilateral intraplantar administration of vincristine, at the highest dose tested (i.pl., 
10 µg), also elicited a more slowly developing mechanical allodynia in the contralateral paw (Fig. 
6A and Fig. 8), consistent with s.c. administration of vincristine eliciting systemic effects similar 
to i.p. administration. Similar contralateral effects were also observed with 1 µg (i.pl.) vincristine, 
but not with 100 ng (i.pl.) or lower doses (data not shown). No changes of the thermal threshold, 
paw swelling or gait parameters of the contralateral hind paw were observed (data not shown). 
Vincristine-treated patients regularly develop a loss of sensory discrimination including 
difficulties to discriminate between hot and cold temperatures [74]. I therefore assessed if our 
model replicates this symptom and found that administration of vincristine indeed caused dose-
dependent thermal hypoalgesia that was only apparent at higher vincristine doses (10 µg and 1 µg 
i.pl.; Fig. 6B and Fig. 7 and Appendix 3, Table 9S), while administration of the lower dose (100 
ng i.pl.) caused a small increase in thermal threshold that was only significant at day 9. Only minor, 
non-significant decreases in heat thresholds were observed at vincristine doses < 10 ng (Fig. 7 and 
Appendix 3, Table 9S), and thus overall, vincristine caused thermal hypoalgesia with an ED50 of 
470 ng based on the area under the curve over baseline for each vincristine dose. The 
intraperitoneal administration of vincristine caused a small, non-significant decrease in thermal 
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threshold on day 7, 9 and 11 compared with vehicle (Fig. 6B and Fig. 7 and Appendix 3, Table 
9S).  
A striking dose-dependent inflammatory response, evidenced by local redness and swelling of the 
injected paw, was visible within 30 min after intraplantar injection of doses as low as 1 ng, but not 
after i.pl. injection of vehicle (5% glucose) (Fig. 6C and Fig. 7 and Appendix 3, Table 10S). The 
intraperitoneal injection of vincristine or PBS did not cause any changes of paw thickness at any 
measured time point (Fig. 6C and Appendix 3, Table 10S).  
Vincristine-induced motor neuropathy manifests in patients as a foot drop, gait abnormalities and 
cramps [75]. I thus performed gait analysis using the CatwalkXT platform (Noldus Information 
Technology, Netherlands). The weight bearing parameter (print area) of animals receiving the 
highest dose (i.pl., 10 µg) of vincristine showed significant (*; p <0.05) differences when 
compared to vehicle-treated (i.pl., 5% glucose) animals from day 4, with slow apparent recovery 
on day 25 (Fig. 6D and Appendix 3, Table 11S). A significant, though less pronounced, change 
of print area (day 7, 9, 11, 25) was observed with 1 µg vincristine (i.pl.), while neither 100 ng 
(i.pl.) nor glucose (i.pl.) caused significant gait changes. The intraperitoneal injection of vincristine 
or PBS did not cause any changes in weight bearing (Fig. 6D and Appendix 3, Table 11S).  
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Figure 6. Behavioural characterization of a novel mouse model of vincristine-induced peripheral 
neuropathy 
Single daily injection of vincristine (i.pl; 10 µl solution containing 10 µg or i.p.; 10 µl/g solution 
containing 0.5 mg/kg) or vehicle (i.pl; 10 µl 5% glucose or i.p.; 10 µl/g PBS) were administered 
using the schedule in Fig. 5. Dotted lines indicate baseline values. (A) Mechanical paw withdrawal 
threshold (PWT) following vincristine administration, measured using an electronic von Frey 
instrument (MouseMet, TopCat Metrology. (B) Thermal paw withdrawal threshold (PWT) 
following vincristine administration assessed using MouseMet Thermal (TopCat Metrology). (C) 
Paw thickness 30 min after injection was assessed using a digital Vernier caliper (Kincrome, Vic, 
Australia). (D) Ipsilateral paw print area expressed in percent of the contralateral paw following 
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vincristine administration was assessed using the CatwalkXT platform (Noldus Information 
Technology, Netherlands). Print area is the average of paw contact area with the glass platform (in 
cm2). Statistical significance was determined using two-way ANOVA with Tukey's multiple 
comparisons test; the experimental groups (vincristine i.pl. or i.p.) were compared to the respective 
vehicle control group (i.pl., 5% glucose or i.p., PBS). No significant differences between the sexes 
were detected. All data are shown as mean ± SEM; n = 6 for all groups (3 females and 3 males). 
(*P  <  0.05). 
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Figure 7. Behavioural characterization of a novel mouse model of vincristine induced peripheral 
neuropathy. 
Single daily injection of vincristine (i.pl; 10 µl solution containing 1 pg, 10 pg, 100 pg, 1 ng, 10 
ng, 100 ng, 1 µg or 10 µg) or vehicle (i.pl; 10 µl 5% glucose) were administered using the schedule 
in Fig. 5. Dotted lines indicate baseline values. (A) Mechanical paw withdrawal threshold (PWT) 
following vincristine administration, measured using an electronic von Frey instrument 
(MouseMet, TopCat Metrology) (black squares) (B) Thermal paw withdrawal threshold (PWT) 
following vincristine administration assessed using MouseMet Thermal (TopCat Metrology) 
(black squares). (C) Paw thickness, 30 min after injection, was assessed using a digital Vernier 
caliper (Kincrome, Vic, Australia) (black squares). Statistical significance was determined using 
two-way ANOVA with Tukey's multiple comparisons test; the experimental groups (vincristine 
i.pl.) were compared to the vehicle control group (i.pl., 5% glucose). No significant differences 
between the sexes were detected. All data are shown as mean ± SEM; n = 6 for all groups (3 
females and 3 males). (*p <0.05). 
  
92 
 
 
 
Figure 8. Local vincristine administration causes bilateral mechanical hyperalgesia with no sex 
differences. 
Single daily injection of vincristine (i.pl; 10 µl solution containing 10 µg were administered using 
the schedule in Fig. 5. Dotted lines indicate baseline values. Mechanical paw withdrawal threshold 
(PWT) of female and male C57BL6 following vincristine administration of the i.pl. injected 
(ipsilateral) and not injected (contralateral) hind paw, measured using an electronic von Frey 
instrument (MouseMet, TopCat Metrology). Statistical significance was determined using two-
way ANOVA with Tukey's multiple comparisons test. The values of the ipsilateral hind paw were 
compared to the values of the contralateral hind paw for each sex separately. No significant 
differences between the sexes were detected. All data are shown as mean ± SEM; n = 3 for all 
groups (3 females or 3 males). (*p <0.05).  
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2.4.2. Histopathological evaluation reveals local infiltration of leukocytes after 
vincristine treatment 
In light of the apparent inflammatory effects of vincristine, I next sought to examine the 
histopathological changes after vincristine administration using hematoxylin and eosin (H&E) 
staining. Controls receiving intraplantar 5% glucose injections had minimal morphologic changes. 
Low-dose of vincristine (i.pl., 100 ng) caused mild muscular and subcutaneous edema and a mild 
neutrophilic perivascular infiltrate at 24 h although the nerve, bone, skin and vasculature were 
morphologically normal (Fig. 9A, Table 3). These changes remained similar at 7 days with 
moderate subcutaneous and muscular edema, some subjective nerve vacuolation, a mild leukocytic 
infiltrate and minimal fibroblast reaction apparent. (Fig. 9B, Table 3).  
The most severe morphological changes in the paw tissue were noted in animals treated with the 
highest dose (i.pl., 10 µg) of vincristine (Fig. 9A and B and Table 3), consistent with the vesicant 
effects of vincristine observed after extravasation (Fig. 6C) [268]. At 24 h post-injection, I 
observed minimal histopathological changes, including mild muscular and subcutaneous edema, 
some minor nerve vacuolization in a focal area of peripheral nerve and a mild perivascular 
leukocytic infiltration (likely neutrophils) (Fig. 9A, Table 3). The morphology worsened at day 7 
to regionally extensive, full thickness epidermal necrosis with marked edema of the underlying 
soft tissues (dermal collagen, muscle and nerve bundles). The dermis contained a moderate 
infiltrate of leukocytes, including macrophages and neutrophils as well as rare lymphocytes. (Fig. 
6C). Furthermore, there was expansion of the peripheral nerve bundles in the paw pad by clear 
fluid (edema) and a finely feathered vacuolization of the myelin sheaths (Fig. 9B, Table 3) 
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The systemic delivery of vincristine caused, at 24 hours and 7 days, only minimal morphologic 
changes related to tissue processing (Table 3). Sciatic nerves and DRGs examination did not show 
any visible morphological changes at any dose (data not shown). 
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Figure 9. Local vincristine administration leads to infiltration of leukocytes. 
Representative pictures (H&E staining) showing histopathological changes of the epidermis, 
dermis, hypodermis and adjacent areas of the plantar glabrous skin of the injected hind paw after 
administration of vincristine (i.pl.,10 µg or 100 ng vincristine) or vehicle (i.pl., 5% glucose) after 
96 
 
24 h (A) or 7 days (B). Injections were performed as indicated in Fig. 5. Magnification 200 x; 
scale bar (100 μm). Blinded histopathological examination was performed with help of Rachel 
Allavena. Black arrow: leukocytes, open arrow: arteriolar necrosis, green arrow: edema, blue 
arrow: dermal necrosis, double arrow: nerve vacuolization. 
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Table 3. Evaluation of local or systemic vincristine histopathological changes. 
Evaluation of local or systemic vincristine (i.pl., 10 μg, 100 ng or i.p., 0.5 mg/kg) or vehicle (i.pl., 
5% glucose or i.p. PBS) histopathological changes in the injected hind paws by H&E staining. 
Blinded histopathological examination was performed with help of Rachel Allavena. –: absent, +: 
minor, ++: mild, +++: moderate, ++++: extensive. 
PBS: phosphate buffered saline; i.pl.: intraplantar injection; i.p.: intraperitoneal injection. 
  
Treatment Vehicle Vincristine 
5% 
Glucose 
i.pl. 
PBS i.p. 
100 ng 
i.pl. 
10 µg i.pl. 
0.5 mg/kg 
i.p. 
 
Time point 24h 7 D 24h 7 D 24h 7 D 24h 7 D 24h 7 D 
M
o
rp
h
o
lo
g
ic
al
 c
h
an
g
e 
Muscle edema ₋ ₊ ₊ ₊ ₊ ₊₊₊ ₊₊ ₊₊₊ ₊ ₊ 
Nerve edema ₋ ₋ ₋ ₋ ₋ ₋ ₋ ₊ ₋ ₋ 
Nerve 
vacuolization  
₋ ₋ ₋ ₋ ₋ ₊ ₊ ₊ ₋ ₋ 
Dermal edema ₋ ₋ ₋ ₋ ₊ ₊₊₊ ₊₊ ₊₊₊ ₊ ₊ 
Dermal necrosis ₋ ₋ ₋ ₋ ₋ ₋ ₋ ₊₊₊₊ ₋ ₋ 
Dermal infiltrate ₊ ₊ ₋ ₋ ₊ ₊₊ ₊ ₊₊₊ ₋ ₋ 
Fibroblast 
reactivity 
₋ ₊ ₋ ₋ ₋ ₊ ₋ ₊ ₋ ₋ 
Vascular 
degeneration 
₋ ₋ ₋ ₋ ₋ ₋ ₊ ₊₊₊₊ ₋ ₋ 
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2.4.3. Minocycline prevents vincristine-induced mechanical allodynia and hind paw 
inflammation. 
In light of the inflammatory changes induced by vincristine, I next sought to elucidate whether 
these processes contribute to the symptoms of VIPN. Neuro-immune mechanisms have previously 
been implicated in the development of paclitaxel-induced neuropathy, which was prevented by 
treatment with minocycline [151]. I thus sought to assess the effects of minocycline on the 
development of vincristine-induced mechanical allodynia and inflammation using both models of 
VIPN.  
Co-treatment with minocycline (i.p., 25 mg/kg) significantly diminished mechanical 
hypersensitivity from day 2 of local and from day 1 of systemic vincristine treatment (Fig. 10A 
and B). Similarly, paw swelling following i.pl. administration of vincristine (100 ng) was 
significantly decreased at 3 hours and on day 2 (Fig. 10C). There was no significant effect of 
minocycline treatment on changes in thermal threshold (data not shown). 
Minocycline has previously been suggested to exert its anti-inflammatory actions via modulation 
of TLR4 expression [269]. Thus, to further confirm whether Tlr4 signalling contributes to the 
development of mechanical hypersensitivity and paw swelling following local vincristine 
administration, I also assessed the development of VIPN in Tlr4-/- mice. Similar to treatment with 
minocycline, paw withdrawal thresholds were significantly increased (*; p <0.05) in Tlr4-/- mice 
on day two of local vincristine treatment (Fig. 10D) compared to wild type (C57BL/6J) animals. 
Similarly, paw swelling was significantly decreased (*; p <0.05) in Tlr4-/- mice at 3 hours and 4 
days of local vincristine treatment (Fig. 10E). In contrast, treatment with the anti-inflammatory 
meloxicam (5 mg/kg i.p.) had no effect on vincristine-induced neuropathy, while the analgesic 
gabapentin reversed pain behaviours at high dose (100 mg/kg i.p.) (Fig. 10F). These data support 
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a Tlr4-mediated inflammatory process after both local and systemic vincristine administration 
resulting in development of neuropathic pain. 
Consistent with the reduced paw swelling of animals treated with vincristine (i.pl., 100 ng) and 
co-treated with minocycline (i.p., 25 mg/kg) (Fig. 10C), a reduced perivascular infiltrate and 
reduced fibroblast reaction after 7 days of treatment when compared to control group receiving 
vincristine (i.pl. 100 ng) and PBS (Fig 11A and B). Additionally, minimal reduction in 
subcutaneous and muscular edema with absence of epidermal and vascular necrosis. Similarly, 
Tlr4-/- animals treated with vincristine (i.pl., 100 ng) for 7 days showed reduced leukocytic 
perivascular infiltrate with minimal subcutaneous edema (Fig. 11C) when compared to control 
group receiving vincristine (C57BL6/J, i.pl., 100 ng). Thermal threshold of Tlr4-/- and control 
group receiving vincristine remained unchanged (data not shown). 
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Figure 10. Minocycline prevents the development of vincristine-induced mechanical allodynia in 
multiple mouse models. 
(A-B) Minocycline (i.p., 25 mg/kg) prevented the development of mechanical hypersensitivity 
following local (i.pl., 100 ng; A)) and systemic (i.p., 0.5 mg/kg; B)) administration of vincristine 
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(PWT: paw withdrawal threshold). (C) Treatment with minocycline (i.p., 25 mg/kg) had a small 
but significant (*; p < 
0.05) effect on paw swelling following administration of vincristine (100 ng, i.pl.). (D) The 
vincristine-induced decrease in paw withdrawal threshold (i.pl., 100 ng) was significantly 
increased (*; p <0.05 compared with wild-type controls) in Tlr4-/- animals at day 2.  (E) 
Vincristine-induced paw swelling (i.pl., 100 ng) was significantly decreased (*; p <0.05 compared 
with wild-type controls) in Tlr4-/- animals at 3 h and day 4. Dotted line represents baseline values. 
Minocycline was administered as described in Fig. 5. Statistical significance was determined using 
two-way ANOVA with Tukey's multiple comparisons test. No significant differences between the 
sexes were detected. (F) Treatment with gabapentin (100 mg/kg i.p.) but not the anti-inflammatory 
meloxicam (5 mg/kg i.p.) reversed mechanical allodynia elicited by local administration of 
vincristine (100 ng, i.pl.) # p <0.05 compared with baseline; n.s.: p > 0.05 compared with vehicle. 
All data are shown as mean ± SEM; n = 6 for all groups (3 females and 3 males). (*p  <0.05 
compared with vehicle). 
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Figure 11. Minocycline prevents infiltration of leukocytes following local administration of 
vincristine. 
Representative pictures (H&E staining) showing histopathological changes of the epidermis, 
dermis, hypodermis and adjacent areas of the plantar glabrous skin of the injected hind paw after 
administration of vincristine (i.pl., 100 ng vincristine) and PBS (A) or co-treatment with 
minocycline (i.p., 25 mg/kg) (B) in C57BL/6J mice or Tlr4-/- mice (C) treated with vincristine only 
(i.pl., 100 ng) after 7 days. Injections were performed as indicated in Fig. 5. Magnification 200 x; 
scale bar (100 μm). Black arrow: leukocytes, green arrow: edema. 
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2.5. Discussion 
Vincristine is known to exert direct effects on sensory neurons, with axonal degeneration 
preceding pathological changes at the cell body [270]. Accordingly, to delineate the peripheral 
mechanisms of VIPN, I assessed the pathophysiological effects induced by local intraplantar 
injection of vincristine. This approach has already provided significant insight into the mechanisms 
underlying oxaliplatin- and cisplatin-induced neuropathy [19, 163], and I thus reasoned that a 
combination of behavioural experiments with histological examination after vincristine treatment 
would enable the identification of novel therapeutic targets for treatment of VIPN.  
Notably, in addition to mechanical hypersensitivity, which also occurs in conventional models of 
VIPN based on intraperitoneal injection of vincristine, local vincristine administration elicited 
several symptoms that are common in human patients, including hypoesthesia to both mechanical 
and heat stimuli as well as gait abnormalities and signs of inflammation. Similar to humans, the 
development of these symptoms was dependent on the cumulative dose of vincristine and was 
partially reversible. Thus, repetitive i.pl. administration of vincristine may be a more suitable 
model to assess the efficacy of novel therapies and management strategies aimed at improving 
positive as well as negative symptoms of VIPN. Importantly, the mechanisms leading to VIPN 
appear to be conserved across the different routes of administration, with both i.p and i.pl. 
administration leading to mechanical allodynia that is caused by an inflammatory neuropathy.  
The effective concentration achieved in tissue, specifically at peripheral nerve terminals, after 
systemic dosing is unknown. However, the observation that the contralateral paw develops 
mechanical allodynia after i.pl. injection of the highest doses suggests that the local administration 
of vincristine leads to systemic effect and the spectrum of symptoms observed in this model is 
simply a reflection of higher local concentrations, rather than mechanistic differences in 
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pathophysiology that would be expected following different administration routes. Additionally, 
the effects seen on the contralateral side may be due to central sensitization of neurons in the spinal 
cord leading to neuronal hyper-excitability affecting the contralateral paw [271] and by 
accumulation of vincristine in the blood, which may likely occur following repeated i.pl. 
injections.  
The intraperitoneal injection of vincristine did not cause any visible changes of paw thickness or 
any gait abnormalities, suggesting that the mechanisms of VIPN following different routes of 
administration may differ. However, allodynia, hypoesthesia and gait disturbances appear to 
represent a continuum of pharmacological effects that cannot be achieved through systemic dosing 
without serious adverse effects. Moreover, visible paw swelling and redness are signs of strong 
inflammation and extravasation, therefore, the lack of those sigs do not exclude contribution of 
inflammatory processes to the development of VIPN following systemic vincristine 
administration. Thus, although i.pl., s.c. and i.p. injections are not routes of administration used in 
patients and experimental models based on these nonetheless provide important insights into the 
pathophysiological mechanisms of chemotherapy-induced neuropathy.  
The leakage of the vesicant drug vincristine into the tissue, called extravasation, causes blistering, 
pain, local swelling and ulceration in severe cases [272] and is likely, next to the peripheral nerve 
damage, the result of repeated i.pl. injections of vincristine. Treatment options for extravasation 
of vincristine include flushing of the injection site as well as treatment with hyaluronidase, which 
is intended to facilitate dispersal of the drug [273]. Intriguingly, my results suggest that the 
mechanisms leading to the vesicant effects of vincristine after i.pl. administration may overlap 
with the mechanisms leading to VIPN as both include immune system activation and pain. 
Moreover, minocycline administration and deletion of the TLR4 receptor in vincristine treated 
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mice, partially protects the animals from mechanical allodynia and paw swelling, suggesting 
similar mechanism for both side effects of vincristine. However, the role of the vesicant effects 
caused by local vincristine administration in VIPN development is unclear and requires further 
examinations.  
Vincristine binds to β-tubulin [274] and disrupts the function of microtubules, which are not only 
important during mitosis but also a critical component of axons. Accordingly, it has been proposed 
that altered axonal transport causes the progressive sensory-motor neuropathy observed in 
vincristine-treated patients. However, not all vinca alkaloids cause the same degree of neuropathy, 
suggesting that alternate pathways may contribute to the pathophysiology of VIPN. Indeed, several 
studies have implicated inflammatory processes, including the infiltration of macrophages and 
monocytes to sciatic nerve and DRGs [175, 275] and release of the cytokines TNF and IL-6 [198] 
in the pathophysiology of VIPN.  
Consistent with these studies, I observed striking infiltration of immune cells, in particular 
leukocytes, 24 h after vincristine injection. The subjective histopathological examination of the 
H&E staining of tissue presented in table 3 was performed by trained veterinary pathologist, 
however, the findings should be considered carefully and further identification and quantification 
of the infiltrating immune cells will be performed in future studies. The precise mechanisms 
leading to activation of the innate immune system by vincristine remain unclear. One plausible 
explanation is that cytotoxic effects of vincristine lead to the release of cellular contents, such as 
ATP, which in turn causes activation of immune cells [276, 277]. Alternatively, vincristine may 
directly act on immune cells through yet unknown mechanisms. Indeed, the related vinca alkaloid 
vinorelbine induces production of several cytokines, including IL1-ß, IL-6 and IL-12, in cultured 
dendritic cells and augments stimulation of T-cells without causing overt cell death [278]. 
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Interestingly, I saw few histopathological neuronal changes apart from an expansion of the 
peripheral nerve bundle and finely feathered vacuolization of the myelin sheaths at the highest 
(i.pl., 10 µg) vincristine dose. In contrast, mechanical hyperalgesia and immune cell infiltration 
occurred at considerably lower doses and developed comparatively rapidly, suggesting that 
positive symptoms of VIPN arise from altered neuronal excitability, possibly due to the well-
known action of pro-inflammatory cytokines on sensory neurons [279, 280]. For example, 
exposure of DRG neurons to TNF in vitro and in vivo increases excitability and produces ectopic 
firing, while IL-1β acts directly on sensory neurons and enhances excitability of nociceptors 
through modulation of voltage-gated sodium currents [279]. Additionally, vincristine has been 
shown to induce release of IL-6 in peripheral macrophages [180] and TNF by microglia and 
astrocytes in the spinal cord of vincristine-treated mice [281]. Moreover, chemotherapy agents 
were shown to have profound inflammatory effects on keratinocytes possibly leading to release of 
inflammatory mediators [282]. An immune-driven pathology is further supported by the anti-
allodynic effects observed in Tlr4-/- animals, and after treatment with minocycline. 
Interestingly, neuro-immune mechanisms have previously been implicated in the development of 
paclitaxel-induced neuropathy and intra-epidermal nerve fibre loss, which was prevented by 
treatment with minocycline [151]. Minocycline is commonly used as a prototypical inhibitor of 
peripheral immune cells and microglia [283] and has been shown to inhibit the production of pro-
inflammatory molecules in monocytes and microglia [284, 285]. Consistent with the inflammatory 
signature revealed by histological examination after treatment with vincristine, minocycline 
significantly reduced paw swelling, mechanical hypersensitivity and minimized leukocytic 
perivascular infiltration. While the anti-inflammatory and anti-apoptotic targets of minocycline 
remain unknown, this antibiotic has been shown to modulate the activation of microglia and 
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immune cells as well as the release of cytokines, chemokines and nitric oxide [286-288]. In 
addition, minocycline decreased the expression levels of Tlr4 in microglia in a model of chronic 
constriction injury and several studies have reported that minocycline-induced effects are 
replicated by inhibition or knockdown of the Tlr4 gene [269, 289]. Involvement of Tlr4 signalling 
pathways was also implicated in the pathophysiology of vincristine-induced neuropathy based on 
transcriptomic studies assessing gene expression changes in DRG neurons (GEO ref. GSE125003) 
(Chapter 3). Consistent with these data, hind paw sensitivity, paw swelling and leukocytic 
perivascular infiltrate were also reversed in Tlr4-/- animals, suggesting that minocycline acts on a 
common signalling pathway. In contrast, the simple anti-inflammatory cyclo-oxygenase inhibitor 
meloxicam was ineffective at reversing vincristine-induced inflammation and neuropathic 
symptoms, confirming that specific neuro-inflammatory mechanisms, such as activation and 
infiltration of immune cell underpin the development of VIPN. 
In a previous study reporting lack of efficacy of minocycline using a rat model of VIPN, the drug 
was administered by the intrathecal route [290]. In light of the significant peripheral inflammation 
I observed, which was paralleled by development of neuropathic symptoms, these data suggest 
that peripheral inflammatory mechanisms are key drivers of VIPN. 
As minocycline is a readily available approved drug with a well-defined adverse event profile, it 
may be suitable to treat some of the symptoms of VIPN, including pain and swelling arising from 
local extravasation and could provide immediate benefit to patients. Our data suggests that a pre-
treatment of patients with systemic minocycline may bring some benefits to those patients. 
However, it is not clear whether minocycline pre-treatment influences the preventative outcome 
of those symptoms and the dose of minocycline and the exact dosing regimen including side effects 
should be examined in future studies. Minocycline is administered perorally and pre-treatment 
108 
 
could be comfortably performed by the patient before the beginning of the chemotherapy regimen. 
However, future studies will reveal how minocycline’s immunomodulatory effect [284, 285] 
influences the chemotherapy outcome, tumour regression and overall patient health. Moreover, 
further investigation into the contribution of the TLR4 to the development of mechanical 
hyperalgesia may provide an opportunity for the development of novel analgesics. 
 
2.6. Conclusion 
In summary, in this chapter I demonstrated that local injection of vincristine causes several 
symptoms of VIPN and swelling and redness of the injected paw as well as infiltration of immune 
cells to the site of injection. Consistent with the neuro-inflammatory signature, mechanical 
allodynia was decreased in mice lacking Tlr4, as well as in mice treated with minocycline. My 
data thus provide evidence that the innate immune system contributes to the development of VIPN 
and suggests that TLR4 partially contributes to development of vincristine-induced painful 
hyperesthesia. The novel animal model based on local intraplantar injections will be used in 
Chapter 3 for comparative gene expression analysis and identification of novel therapeutic targets 
for the treatment of CIPN using the RNAseq of whole transcriptome of mouse DRGs following 
vincristine, oxaliplatin or cisplatin treatment.   
109 
 
3. CHAPTER 3: Identification of novel targets for the treatment of vincristine-
induced peripheral neuropathy and comparison with cisplatin and oxaliplatin 
3.1. Foreword 
This chapter addresses the comparison of symptoms and of gene expression changes in peripheral 
sensory neurons following the treatment with vincristine, oxaliplatin and cisplatin in C57BL6/J 
mice and the identification of novel therapeutic targets for the treatment of vincristine induced 
neuropathy. It was published in the Journal of Pain in 2019 [291]. The manuscript was modified 
partially to fit the style and flow of this thesis. The Institute for Molecular Bioscience Sequencing 
Facility created the list of DEGs. Hana Starobova performed behavioural experiments, DRG 
collection, and the complete transcriptomic analysis of DEGs. Hana Starobova wrote the 
manuscript and designed all figures. Jen Deuis and Alexander Mueller assisted with the 
behavioural experiments (Fig. 12). 
 
3.2. Introduction 
Sensory symptoms of chemotherapy induced peripheral neuropathy (CIPN) – including 
hypoesthesia, paresthesia, burning sensation, neuralgia, myalgia and decreased vibration sense – 
occur in patients receiving vincristine, oxaliplatin or cisplatin. Interestingly, although cisplatin and 
oxaliplatin are closely related structurally, the symptoms induced by these agents suggest divergent 
pathophysiological mechanisms, as oxaliplatin elicits characteristic cooling-induced dysesthesias 
that are not typically induced by cisplatin. Vincristine and oxaliplatin but not cisplatin additionally 
induce hyperesthesia, jaw pain and arthralgia, while gait abnormalities or difficulty walking are 
characteristic of motoric dysfunction and develop after treatment with all three drugs. However, 
muscle weakness seems to develop specifically after treatment with vincristine or oxaliplatin 
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(Table 4). In addition, patients treated with vincristine develop frequent autonomic symptoms, 
including paralytic ileus, postural hypotension and urogenital dysfunction [292]. 
As outlined in Chapter 1, section 1.6 the pathophysiological mechanisms leading to CIPN 
induced by vincristine, oxaliplatin and cisplatin have been studied extensively and appear to 
involve altered calcium homeostasis of neurons, mitochondrial dysfunction and inflammatory 
processes (for review see [1]). Nevertheless, a comparative analysis of gene expression changes in 
DRG neurons induced by these agents is lacking.  
Despite significant advances in our understanding of pain mechanisms [293], the search for new 
CIPN targets is limited by the time-consuming process of many experimental procedures leading 
to often incremental progress in our understanding of pain perception and CIPN development. 
However, the approach of gene expression analysis during painful conditions, such as CIPN in 
humans and rodents using transcriptome-based techniques has greatly accelerated the 
identification of potential targets and mechanisms.  
The transcriptome is a snapshot in time, quantifying the expression of coding and non-coding 
RNAs in a cell under specific conditions [294]. The technique was first introduced in the early 
1990s, and since then, the accuracy and speed of transcriptomics has improved, while costs were 
greatly reduced. Importantly, analysis of differentially expressed genes of neuronal cells and their 
surrounding tissue, reflecting the genomic response in pathological painful conditions, has greatly 
extended the list of potential targets that can be investigated experimentally in the future. 
Additionally, in the past, transcriptomic analysis of neuronal tissue has greatly extended our 
understanding of pain mechanism and progression [295, 296]. These techniques allow an 
understanding of the genomic and molecular responses of cells to pathological conditions, 
including the response of neurons and immune cells to chronic painful stimuli [296]. The RNAseq 
111 
 
is the most widely used technique and is a sequence-based approach based on the use of high-
throughput next generation sequencing approaches. The isolated RNA pool is converted into a 
cDNA library with adaptors attached to one or two ends. These cDNAs are sequenced using next 
generation sequencing: high-throughput, deep sequencing to generate short reads (30-300 bp) from 
one end (single-end sequencing) or from both ends (paired-end sequencing). The sequence reads 
are then aligned to a reference genome to identify the transcribed genes [297]. This technique is 
able to detect a larger number of differentially expressed genes compared to other approaches 
[298] as it allows detection and quantification of genes expressed in low abundance and does not 
rely on a priori knowledge of gene sequences [297] [299].  
In this chapter I sought to compare the gene expression profile of DRGs after treatment with 
vincristine, oxaliplatin or cisplatin (all administered i.pl.) to gain insight into the mechanisms of 
CIPN development. Overall, vincristine-induced gene expression changes were consistent with 
predominantly inflammatory processes with striking overexpression of genes involved in 
regulation of macrophages and interleukin-1ß signalling, while treatment with oxaliplatin led to 
altered expression of genes associated with neuronal damage. Furthermore, cisplatin caused gene 
expression changes consistent with a mixed inflammatory and neuropathic phenotype.  
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Table 4. Peripheral neuropathy symptoms in humans. 
Peripheral neuropathy symptoms in humans. Paresthesia: An abnormal sensation that is not 
unpleasant. Dysesthesia: An abnormal unpleasant sensation. Hyperesthesia: Increased sensitivity 
to stimulation. Hypoesthesia: Decreased sensitivity to stimulation. Neuralgia: Pain in the 
distribution of a nerve or nerves. +: Effect observed in humans; - : Effects not or extremely rarely 
observed in humans. 
 
Symptom 
Vincristine Oxaliplatin Cisplatin 
E
ff
ec
t 
R
ef
. 
E
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ec
t 
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ef
. 
E
ff
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t 
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. 
Hypoesthesia / numbness + 
[300, 
301] 
+ [302] + [55] 
Hyperesthesia / 
hypersensitivity 
+ [267] 
+ (esp 
to cold) 
[302] -  
Paresthesia / dysesthesia + 
[300, 
301] 
+ (often 
cold-
related) 
[302, 
303] 
+ [55] 
Burning sensation + [74] + [304] + [305] 
Neuralgia / pain + [301] + [302] + [55] 
Jaw pain + [306] + [245] -  
Arthralgia (joint pain) or bone 
pain 
+ [306] + [307] -  
Myalgia (muscle pain) or 
muscle cramps 
+ [306] + [302] + [56] 
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Decreased vibration sense + [308] + [93] + [55] 
Hyporeflexia / areflexia + [301] + [93] + [55] 
Muscle weakness + 
[300, 
301] 
+ [307] -  
Gait abnormalities (difficulties 
walking) 
+ 
[306, 
308] 
+ [93] + [55] 
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3.3. Materials and methods 
3.3.1. Animal ethics 
Ethics approval for in vivo experiments was obtained from the University of Queensland Animal 
Ethics Committee (see Chapter 1, section 2.3.1. and certificates of approval: Appendix 4, section 
10.1. and 10.2.) 
3.3.2. Induction of chemotherapy-induced neuropathy  
8-10 week old C57BL/6J mice were injected via shallow intraplantar (i.pl.) injection with 
vincristine (Sapphire Bioscience), oxaliplatin (Sapphire Bioscience) or cis-Diammineplatinum(II) 
dichloride (cisplatin, Sigma Aldrich) or with 5% glucose (control group) into the hind paw under 
3% isoflurane anaesthesia as described in Chapter 1, section 2.3.2 and allowed to recover in their 
home cages. The injection schedules and the time of tissue collection were chosen based on 
previous studies and reports of vincristine, oxaliplatin and cisplatin induced neuropathy symptoms 
[19, 163, 175]. Vincristine (10 µg; i.pl.) was administered once a day for four days as described in 
Chapter 1, section 2.3.2 and DRGs were collected on day 7 (cumulative dose 40 µg). Oxaliplatin 
and cisplatin were injected once (40 µg; i.pl.) and tissue was collected after 72 hours. The 
collection timepoints were determined depending on the dose and time dependency of early 
mechanical allodynia development following intraplanar injection of the drug [19, 163, 259].  
 
3.3.3. Behavioural assessment 
Mechanical allodynia was assessed as described previously in Chapter 1, section 2.3.4. using an 
electronic von Frey apparatus (MouseMet, TopCat Metrology). Three readings, taken at least 5 
min apart, were averaged to obtain the PWT for each animal.  
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Heat allodynia was quantified using the Hargreaves test, in which animals were acclimatized to 
plexiglass enclosures positioned on a pre-warmed glass plate for 30 min. A radiant heat source 
(IITC Life Science Plantar Test), directed at the plantar surface of the hind paws, was used to elicit 
paw withdrawal, with the pre-determined cut-off set to 20 sec to avoid tissue damage. The endpoint 
of the measurement was determined by lift, licks or flinches of the affected hind paw. Three 
measurements, taken at least 10 min apart, were averaged to obtain the average withdrawal time 
for each animal.  
Cold allodynia was quantified by counting the number of paw lifts, licks and flinches over 5 min 
in animals allowed to freely move on a Peltier-cooled plate maintained at 10 °C. All behavioural 
quantifications were carried out by a blinded observer (Hana Starobova) who was unaware of the 
treatment animals had received. Data and statistical analyses were performed using GraphPad 
Prism Version 7.00. Statistical significance was determined as ∗p <0.05 and was calculated using 
ordinary one-way ANOVA. All data are shown as mean ± standard error of the mean (SEM); n = 
6 for all groups. 
3.3.4. Sample preparation for RNA-Seq analysis 
Mice were euthanized using carbon dioxide and the spinal cord with ribs was dissected. The 
ipsilateral lumbar DRGs at L3, L4 and L5 were identified by counting the DRGs from the last rib 
(T2) and after dissection immediately placed in ice cold RNAlater (Invitrogen) and kept at 4 °C. 
The tissue was cut in small pieces to allow the RNA extraction. Total RNA from DRGs was 
isolated using the RNeasy Mini Kit (Qiagen, Melbourne, Australia, including on-column DNase 
digestion) according to manufacturer instructions. To obtain sufficient amount of RNA, DRGs 
from four animals were collected and pooled to obtain one biological replicate. Three biological 
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control replicates and three vincristine, oxaliplatin or cisplatin treated replicates were used for 
RNA-Seq.  
3.3.5. RNA-Seq 
RNA-Seq, including bioinformatics analysis, were performed by the Institute for Molecular 
Bioscience Sequencing Facility (The University of Queensland, Brisbane, QLD, Australia). RNA-
Seq was performed on the Illumina NextSeq 500 platform using 75-nucleotide single-end runs. 
Libraries were constructed using TruSeq stranded total RNA library preparation and the reads were 
mapped to Ensembl Mus musculus mm10 genome (version GRCm38) using STAR aligner 
(version star/2.3.0 e) [309] and samtools [310]. The counts were generated using the HTSeq 
package [311] and the list of differential expressed genes was created using the R (version 3.2.2) 
package DESeq2 [312].  
3.3.6. Bioinformatics analysis 
The volcano plots were generated using the R package ggplot2. The list of genes was ranked by 
adjusted p-value (Padj) and only genes with Padj < 0.05 and total log2-fold change of > 1 were 
considered to be differentially expressed and used for further analysis. Cell type enrichment 
analysis was performed using the CTen tool [313]. The score was generated using one-sided, 
Fisher's Exact test for enrichment and it is shown as the -log10 of the Benjamini-Hochberg (BH) 
Padj. Scores > 20, to optimally minimize the false positive rate (FPR). Each list of differentially 
expressed genes (DEG) was analysed separately. Gene set enrichment analysis (GSEA) was 
conducted using GSEA Java desktop application and Molecular Signature Database (MSigDB) 
[314]. Overlaps between differentially expressed genes and C5 curated gene set (Biological 
process) were computed with FDR q value setting < 0.05 and top 20 or 60 gene set overlaps were 
shown. The functional protein association network analysis was performed using STRING 
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database [315] and only interactions with medium or high confidence were shown; proteins were 
clustered using the Markov Cluster Algorithm with inflation parameter of 1.8 [316]. The gene 
identifiers were converted into gene names using DAVID Bioinformatics Resources 6.8, 
NIAID/NIH the Gene Name Batch Viewer tool. Lists of differentially expressed genes or GO 
biological terms were compared using the Molbiotools, multiple list comparator 
(http://www.molbiotools.com/listcompare.html). Data is available at the Gene Expression 
Omnibus (GEO submission number: GSE125003). Analysis was performed by Hana Starobova. 
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3.4. Results 
3.4.1. Vincristine, oxaliplatin and cisplatin induce neuropathy symptoms in mice 
To confirm development of peripheral neuropathy after administration of vincristine, oxaliplatin 
and cisplatin, and to directly compare the behavioural phenotypes induced by these agents, I first 
assessed mechanical, heat and cold allodynia. As previously described, all three agents elicited 
robust mechanical allodynia (Fig. 12A), with paw withdrawal thresholds decreasing from 3.2 ± 
0.1 g (control group) to 1.0 ± 0.3 g (oxaliplatin, p <0.05), 1.1 ± 0.2 g (cisplatin, p <0.05) and 1.6 
± 0.1 g (vincristine, p <0.05) within 24 h of injection. In contrast, heat withdrawal thresholds were 
unchanged from control (10.2 ± 1.0 s) after treatment with oxaliplatin (9.0 ± 1.6 s); decreased after 
treatment with cisplatin (6.0 ± 0.2 s, p <0.05) and increased after treatment with vincristine (16.5 
± 0.9 s, p <0.05) (Fig. 12B). Only oxaliplatin (90.7 ± 6.1 flinches) caused cold allodynia, while 
no cold-induced responses were observed in either vehicle-treated animals (0 ± 0 flinches), 
cisplatin-treated animals (0 ± 0 flinches) or vincristine-treated animals (2.2 ± 1.0 flinches) (Fig. 
12C).  
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Figure 12. Behavioural comparison of CIPN symptoms induced by oxaliplatin, cisplatin and 
vincristine. 
Mechanical, heat and cold responses were assessed in C57BL/6 mice treated with oxaliplatin, 
cisplatin and vincristine. (A) Oxaliplatin, cisplatin and vincristine led to a significant reduction in 
mechanical paw withdrawal compared with vehicle-treated control. (B) Cisplatin caused heat 
hyperalgesia while vincristine caused heat hypoalgesia and oxaliplatin had no effect on heat 
withdrawal thresholds assessed using the Hargreaves test. (C) Only treatment with oxaliplatin 
caused hypersensitivity to cooling, reflected by an increased number of paw flinches at 10 °C. 
Behavioural assessment was performed with help of Jennifer R. Deuis and Alexander Mueller. 
Data are presented as mean ± S.E.M. from n=6 animals. * p <0.05 compared with control by One-
way ANOVA. 
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3.4.2. Comparison of vincristine-, oxaliplatin- and cisplatin-induced changes in gene 
expression 
In order to gain more insights into mechanism underlying the development of vincristine-, 
oxaliplatin- or cisplatin-induced peripheral neuropathy, and to compare the substance-specific 
effects on peripheral neurons, I performed a transcriptome of mouse lumbar DRGs (L3-L5) after 
administration of vincristine, oxaliplatin or cisplatin (GEO submission number: GSE125003).  
Treatment with vincristine caused a significant (Padj < 0.05) differential expression of 368 genes, 
323 of which were up-regulated, with only 45 down-regulated (Fig. 13A and B) (For full list of 
DEGs following vincristine administration see Appendix 3, Table 12S). Among the highly down-
regulated genes (log2fold change <-1) was Ms4a1, which encodes Membrane Spanning 4-
Domains A1, also called CD20 antigen; a B-lymphocyte antigen. Highly upregulated DEGs 
(log2fold change >1) included Nts (Neurotensin), Atf3 (Activating Transcription Factor 3), Sprr1a 
(Small Proline Rich Protein 1A), Ecel1 (Endothelin Converting Enzyme Like 1), Cckbr 
(Cholecystokinin B Receptor) and Star (Steroidogenic Acute Regulatory Protein), which have all 
been associated with altered pain perception, neuropathic pain and neuronal injury in previous 
studies [317-323]. The direct and secondary interactions between DEGs following vincristine 
administration are shown in Appendix 3, Fig. 14.  
In contrast, the administration of oxaliplatin caused predominantly downregulation of DEGs (For 
full list of DEGs following oxaliplatin administration see Appendix 3, Table 13S). Following 
oxaliplatin treatment, 60 DEGs were up-regulated and 235 DEGs were down-regulated (Fig. 13C 
and D). Among the down-regulated genes (log2fold change < - 1) were Snhg1 (small nucleolar 
RNA host gene 1), Meg3 (Maternally expressed gene 3), Malat1 (Metastasis-associated lung 
adenocarcinoma transcript 1), Mirg (miRNA containing gene) and Wasf1 (WAS protein family, 
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member 1). Interestingly, none of these down-regulated genes has been associated with altered 
pain responses to date. Among the up-regulated genes (log2fold change > 1) were Ptgds 
(Prostaglandin-H2 D-isomerase), Vtn (Vitronectin) and Cldn11 (Claudin 11) (Fig. 13C), of which 
only Prostaglandin-H2 D-isomerase has been linked to painful states [324]. The direct and 
secondary interactions between DEGs following oxaliplatin administration are shown in Appendix 
3, Fig 15. 
Similarly, following cisplatin treatment, 72 DEG were up-regulated and 184 DEG were down-
regulated (Fig. 13E and F) (For full list of DEGs following cisplatin administration see Appendix 
3, Table 14S). Among the down-regulated genes (log2fold change < - 1) were Pclo (Piccolo 
(presynaptic cytomatrix protein)), Zfhx2 (Zinc finger homeobox 2), Raph1 (Ras association 
(RalGDS/AF-6) and pleckstrin homology domains 1) and Syn1  (Synapsin I); some of which 
have been associated with altered pain perception and neuropathic pain in previous studies [325-
328]. The highly upregulated DEGs (log2fold change > 1) included Lcn2 (Lipocalin-2), Hba-a2 
(Hemoglobin alpha, adult chain 2) and Alas2 (Aminolevulinic acid synthase 2, erythroid), of which 
only Lipocalin-2 have been associated with altered pain behaviour [329]. The direct and secondary 
interactions between DEGs following cisplatin administration are shown in Appendix 3, Fig 16. 
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Figure 13. Analysis of differentially expressed genes in mouse lumbar dorsal root ganglia L3- L5 
following vincristine, oxaliplatin and cisplatin administration. 
Volcano plot of all DEGs following vincristine (A), oxaliplatin (B) and cisplatin (C) 
administration showing the most highly upregulated (log2fold change > 1) or downregulated 
(log2fold change < - 1) genes. Only genes with Padj < 0.05 and log2-foldchange greater than 1 or 
smaller than -1 were used for further analysis. Vincristine administration caused the up-regulation 
of 323 DEG and the down-regulation of 45 DEG (D); oxaliplatin administration caused the up-
regulation of 60 DEGs and the down-regulation of 235 DEGs (E) and cisplatin administration 
caused the up-regulation of 72 DEGs and the down-regulation of 184 DEGs (F). 
  
124 
 
 
  
Figure 14. Network analysis showing interactions between differentially expressed genes 
following vincristine treatment generated with STRING version 10. 
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Network analysis showing interactions between differentially expressed genes following 
vincristine treatment generated with STRING version 10. Diagram is presented in confidence 
view and only interactions with high confidence of evidence are shown. Proteins were clustered 
using the Markov Cluster Algorithm with inflation parameter of 1.8. Full line: direct interaction; 
dotted line: secondary interaction.  
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Figure 15. Network analysis showing interactions between differentially expressed genes 
following oxaliplatin treatment. 
Network analysis was generated with STRING version 10. Diagram is presented in confidence 
view and only interactions with high confidence of evidence are shown. Proteins were clustered 
using the Markov Cluster Algorithm with inflation parameter of 1.8. Full line: direct interaction; 
dotted line: secondary interaction. 
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Figure 16. Network analysis showing interactions between differentially expressed genes 
following cisplatin treatment. 
Network analysis was generated with STRING version 10. Diagram is presented in confidence 
view and only interactions with high confidence of evidence are shown. Proteins were clustered 
using the Markov Cluster Algorithm with inflation parameter of 1.8. Full line: direct interaction; 
dotted line: secondary interaction.  
128 
 
As DRGs are a heterogeneous tissue containing the cell bodies of peripheral nerves, epithelial 
cells, fibroblasts, glial cells and immune cells, DEGs discovered following treatment with 
vincristine, oxaliplatin and cisplatin cannot be unequivocally assigned to sensory neurons alone. 
Thus the cell type enrichment analysis by CTen, a web-based analytical platform using a highly 
expressed, cell specific (HECS) gene database to identify enriched cell types from transcriptomic 
data [313] was performed, to gain insights into cell-specific effects of vincristine, oxaliplatin or 
cisplatin.  
Cell type enrichment analysis showed that DEGs after vincristine administration significantly 
overlap with gene profiles of bone marrow and immune cells (Fig. 17A and Appendix 3, Table 
15S). Specifically, the highest scores were assigned to bone marrow (157.5), bone (147.0), 
granulocytes (84.1), macrophages (41.7), spleen (38.8) and microglia (27.5), suggesting that 
treatment with vincristine leads to gene expression changes consistent with neuro-inflammatory 
mechanisms. Surprisingly, DEGs caused by oxaliplatin administration overlapped with gene 
profiles of neuronal cells, as the highest scores were assigned to cerebral cortex (9.4), 
hypothalamus (8.2), cerebellum (8.1), amygdala (6.6), spinal cord (5.4) and dorsal root ganglia 
(4.5). However, oxaliplatin treatment resulted in altered expression of genes that were associated 
with neurons (Fig. 17B and Appendix 3, Table 15S). In contrast, DEGs associated with cisplatin 
treatment showed mixed cell profiles overlapping with those seen in both vincristine- and 
oxaliplatin-treated animals, with the highest scores assigned to bone marrow (13.6), bone (11.4), 
granulocytes ((10.5), cerebral cortex (9.4), dorsal root ganglia (9.2) and spinal cord (8.4) (Fig. 17C 
and Appendix 3, Table 15S).  
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Figure 17. Cell type specific effect of vincristine, oxaliplatin and cisplatin. 
Cell type enrichment analysis of differentially expressed genes in lumbal DRGs L3-5 following 
vincristine (A), oxaliplatin (B) and cisplatin (C) administration. Cell type enrichment analysis was 
performed using the CTen tool. The score is generated using one-sided, Fisher's Exact test for 
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enrichment and it is shown as the -log10 of the Benjamini-Hochberg (BH) adjusted P-values. 
Scores > 20 optimally minimize the false positive rate (FPR).  
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To further identify shared genes that may contribute to the pathology of chemotherapy-induced 
neuropathy irrespective of the causative agent, I compared DEGs identified after vincristine, 
oxaliplatin or cisplatin administration (Fig. 18A-G). Vincristine and cisplatin shared 27 DEGs 
(Fig. 18E), vincristine and oxaliplatin shared 7 DEGs (Fig. 18F); and oxaliplatin and cisplatin 
shared the highest amount of DEGs, in total 171 (Fig. 18D and Appendix 3, Table 16S). 
Interestingly, I identified 5 genes that were shared between vincristine, oxaliplatin and cisplatin: 
aminolevulinic acid synthase 2, erythroid (Alas2), hemoglobin, beta adult t chain (Hbb-bt), 
integrin beta 2-like (Itgb2l), lymphocyte antigen 6 complex, locus C2 (Ly6c2) and nuclear receptor 
subfamily 4, group A, member 3 (Nr4a3) (Fig. 18G and Appendix 3, Table 16S). Interestingly, 
none of the above-mentioned genes have been associated with pain pathology to date, and their 
functional roles in CIPN are unclear. 
To further explore the functional roles of DEGs after vincristine, oxaliplatin or cisplatin 
administration, I performed Gene Set Enrichment analysis using the GSEA tool [314]. For each 
drug, the number of genes overlapping with the curated C5 gene set (k) and the false discovery 
rate q-value as a measure of statistical significance are shown in Table 5 (only top 20 GO terms 
for each drug are shown). Additionally, I compared the 60 most significant GO terms to identify 
similarities shared between the three experimental groups (Fig. 18B and C). All three 
experimental groups shared 2 GO terms; regulation of transport and response to external stimulus. 
Vincristine and oxaliplatin shared 6 GO terms; regulation of cell death, regulation of cell 
proliferation, regulation of multicellular organismal development, regulation of transport, response 
to endogenous stimulus and response to external stimulus. Vincristine and cisplatin shared 13 GO 
terms; including defence response, immune system process, locomotion and response to external 
stimulus. Oxaliplatin and cisplatin shared 15 GO terms, including cell projection organization, 
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macromolecular complex assembly, neurogenesis and vesicle mediated transport (for full lists of 
shared GO terms see Table 6). 
Remarkably, 46% of DEGs after vincristine administration overlapped with immune system-
associated processes, 22.6% with regulation of cellular processes, 4.4% with cellular transport 
processes and none with neuronal processes or DNA and RNA processing (Fig. 18C). In contrast, 
25% of DEGs after oxaliplatin administration overlapped with DNA and RNA processing, 18% 
with regulation of cellular processes, 13% with cellular transport processes, 12% with neuronal 
processes and only 5% of immune system associated processes (Fig. 18C). Moreover, 20% of 
cisplatin induced DEGs overlap with regulation of cellular processes, 14% with immune system 
associated processes, 10% with cellular transport processes, 9% with neuronal processes and 8% 
with DNA and RNA processing (Fig. 18C).  
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Table 5. Gene set enrichment analysis of differentially expressed genes in mouse lumbar dorsal 
root ganglia L3-L5 following vincristine, oxaliplatin and cisplatin administration. 
GSEA overlap analysis of DEGs with C5 curated gene set (biological process). K show the number 
of DEGs in overlap and FDR q-value indicate the significance of each overlap with the GO term 
and only 20 most significant overlaps are shown. VC: vincristine, OX: oxaliplatin, CIS: cisplatin, 
GO: gene ontology, FDR: false discovery rate, red: lowest values, yellow: 50% values, green: 
highest values. GO terms are alphabetically sorted. 
GO term 
VC # 
Genes 
in 
Overlap 
(k) 
VC 
FDR q-
value 
 
OX # 
Genes 
in 
Overlap 
(k) 
OX 
FDR q-
value 
 
CIS # 
Genes 
in 
Overlap 
(k) 
CIS 
FDR 
q-
value 
GO_CELL_MOTILITY 34 
2.35E-
15 
0 0 0 0 
GO_CELLULAR_MACROMOLECUL
AR_ 
COMPLEX_ASSEMBLY 
0 0 0 0 18 
4.12E
-07 
GO_CELLULAR_RESPONSE_TO_OR
GANIC_ 
SUBSTANCE 
56 
4.53E-
20 
0 0 0 0 
GO_CENTRAL_NERVOUS_SYSTEM
_ 
DEVELOPMENT 
0 0 18 
9.11E-
06 
0 0 
GO_CHROMATIN_ASSEMBLY_OR_ 
DISASSEMBLY 
0 0 0 0 12 
6.45E
-09 
GO_CYTOSKELETON_ORGANIZAT
ION 
0 0 0 0 22 
4.46E
-09 
GO_DEFENSE_RESPONSE 65 
3.47E-
37 
0 0 28 
2.14E
-10 
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GO_DEFENSE_RESPONSE_TO_OTH
ER_ 
ORGANISM 
0 0 0 0 18 
3.19E
-09 
GO_DNA_CONFORMATION_CHAN
GE 
0 0 0 0 12 
4.27E
-07 
GO_DNA_PACKAGING 0 0 0 0 11 
1.78E
-07 
GO_FAT_CELL_DIFFERENTIATION 0 0 7 
7.07E-
05 
0 0 
GO_HOMEOSTATIC_PROCESS 42 
2.87E-
15 
0 0 0 0 
GO_IMMUNE_RESPONSE 64 
6.68E-
39 
0 0 0 0 
GO_IMMUNE_SYSTEM_DEVELOP
MENT 
31 
4.52E-
17 
0 0 0 0 
GO_IMMUNE_SYSTEM_PROCESS 103 
1.61E-
61 
0 0 38 
8.98E
-12 
GO_INFLAMMATORY_RESPONSE 33 
3.6E-
22 
0 0 0 0 
GO_INNATE_IMMUNE_RESPONSE 35 
3.75E-
20 
0 0 0 0 
GO_LEUKOCYTE_MIGRATION 25 
1.25E-
19 
0 0 0 0 
GO_LOCOMOTION 46 
2.69E-
21 
0 0 0 0 
GO_MACROMOLECULAR_COMPLE
X_ 
ASSEMBLY 
0 0 0 0 26 
6.49E
-08 
GO_MOVEMENT_OF_CELL_OR_ 
SUBCELLULAR_COMPONENT 
51 
3.82E-
23 
0 0 29 
1.54E
-10 
GO_MRNA_METABOLIC_PROCESS 0 0 16 
2.98E-
06 
0 0 
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GO_MRNA_PROCESSING 0 0 15 
2.90E-
07 
0 0 
GO_NEGATIVE_REGULATION_OF_
CELL_ 
DEATH 
0 0 17 
4.15E-
05 
0 0 
GO_NEGATIVE_REGULATION_OF_
GENE_ 
EXPRESSION 
0 0 22 
6.81E-
05 
0 0 
GO_NEUROGENESIS 0 0 22 
2.77E-
05 
26 
6.49E
-08 
GO_POSITIVE_REGULATION_OF_ 
BIOSYNTHETIC_PROCESS 
0 0 29 
2.90E-
07 
0 0 
GO_POSITIVE_REGULATION_OF_G
ENE_ 
EXPRESSION 
0 0 29 
1.88E-
07 
29 
6.49E
-08 
GO_POSITIVE_REGULATION_OF_ 
IMMUNE_SYSTEM_PROCESS 
44 
1.15E-
23 
0 0 0 0 
GO_POSITIVE_REGULATION_OF_
MULTICELLULAR_ORGANISMAL_
PROCESS 
49 
5.67E-
20 
0 0 0 0 
GO_POSITIVE_REGULATION_OF_ 
RESPONSE_TO_STIMULUS 
58 
1.22E-
20 
0 0 0 0 
GO_POSITIVE_REGULATION_OF_ 
TRANSCRIPTION_FROM_RNA_ 
POLYMERASE_II_PROMOTER 
0 0 22 
2.21E-
07 
0 0 
GO_PROTEIN_COMPLEX_BIOGENE
SIS 
0 0 0 0 23 
1.21E
-07 
GO_PROTEIN_COMPLEX_SUBUNIT
_ 
ORGANIZATION 
0 0 0 0 31 
2.14E
-10 
GO_PROTEIN_DNA_COMPLEX_SU
BUNIT_ 
ORGANIZATION 
0 0 0 0 12 
8.26E
-08 
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GO_REGULATION_OF_ANATOMIC
AL_ 
STRUCTURE_MORPHOGENESIS 
0 0 19 
1.75E-
05 
0 0 
GO_REGULATION_OF_CELL_DEAT
H 
0 0 25 
1.44E-
06 
0 0 
GO_REGULATION_OF_CELLULAR_ 
LOCALIZATION 
0 0 0 0 24 
2.03E
-07 
GO_REGULATION_OF_IMMUNE_ 
RESPONSE 
38 
1.77E-
18 
0 0 0 0 
GO_REGULATION_OF_IMMUNE_ 
SYSTEM_PROCESS 
56 
1.66E-
25 
0 0 0 0 
GO_REGULATION_OF_TRANSCRIP
TION_ 
FROM_RNA_POLYMERASE_II_ 
PROMOTER 
0 0 35 
7.54E-
11 
0 0 
GO_REGULATION_OF_TRANSPOR
T 
0 0 30 
1.81E-
07 
36 
8.98E
-12 
GO_REGULATION_OF_VESICLE_ 
MEDIATED_TRANSPORT 
0 0 16 
1.81E-
07 
15 
2.82E
-07 
GO_RESPONSE_TO_BIOTIC_STIMU
LUS 
0 0 0 0 21 
6.49E
-08 
GO_RESPONSE_TO_CYTOKINE 32 
1.56E-
15 
0 0 0 0 
GO_RESPONSE_TO_ENDOGENOUS
_ 
STIMULUS 
0 0 24 
3.68E-
06 
0 0 
GO_RESPONSE_TO_EXTERNAL_ 
STIMULUS 
64 
1.97E-
26 
0 0 34 
1.91E
-10 
GO_RNA_PROCESSING 0 0 18 
5.09E-
06 
0 0 
GO_RNA_SPLICING 0 0 13 
2.67E-
06 
0 0 
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GO_RNA_SPLICING_VIA_ 
TRANSESTERIFICATION_REACTIO
NS 
0 0 10 
4.84E-
05 
0 0 
GO_TAXIS 28 
1.01E-
16 
0 0 0 0 
GO_TRANSCRIPTION_FROM_RNA_ 
POLYMERASE_II_PROMOTER 
0 0 17 
4.10E-
06 
0 0 
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Figure 18. Comparison of differentially expressed genes shared between vincristine, oxaliplatin 
or cisplatin. 
Venn diagrams of (A) differentially expressed genes (Padj <0.05; log2foldchange ±1) or (B) 
identified GO biological terms shared between vincristine, oxaliplatin or cisplatin. GO terms were 
identified using the gene set enrichment analysis of DEGs with C5 curated gene set (biological 
process) and were computed with FDR q value setting < 0.05 and top 60 gene set overlaps were 
shown. (C) The five most significant gene set enrichment signatures of the DEGs after vincristine, 
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oxaliplatin or cisplatin administration show predominant inflammatory processes after vincristine 
treatment, while DEGs following oxaliplatin and cisplatin administration overlap predominantly 
with DNA and RNA processing. Network analysis, generated with STRING version 10, showing 
interactions between differentially expressed genes shared between (D) oxaliplatin and cisplatin, 
(E) vincristine and cisplatin, (F) vincristine and oxaliplatin and (G) vincristine, oxaliplatin and 
cisplatin. Diagrams are presented in confidence view and only interactions with at least medium 
or high confidence of evidence are shown. Proteins were clustered using the Markov Cluster 
Algorithm with inflation parameter of 1.8.  
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Table 6. Comparison of differentially expressed genes shared between vincristine, oxaliplatin or 
cisplatin. 
GO terms shared between vincristine and/or oxaliplatin and/or cisplatin. GO terms were identified 
using the gene set enrichment analysis of DEGs with C5 curated gene set (biological process) and 
were computed with FDR q value setting < 0.05 and top 60 gene set overlaps were shown. 
Vincristine & Oxaliplatin & Cisplatin 
GO term 
GO_REGULATION_OF_TRANSPORT 
GO_RESPONSE_TO_EXTERNAL_STIMULUS 
  
Vincristine & Oxaliplatin 
GO term 
GO_REGULATION_OF_CELL_DEATH 
GO_REGULATION_OF_CELL_PROLIFERATION 
GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 
GO_REGULATION_OF_TRANSPORT 
GO_RESPONSE_TO_ENDOGENOUS_STIMULUS 
GO_RESPONSE_TO_EXTERNAL_STIMULUS 
  
Vincristine & Cisplatin 
GO term 
GO_DEFENSE_RESPONSE 
GO_DEFENSE_RESPONSE_TO_OTHER_ORGANISM 
GO_IMMUNE_SYSTEM_PROCESS 
GO_LOCOMOTION 
GO_MOVEMENT_OF_CELL_OR_SUBCELLULAR_COMPONENT 
GO_POSITIVE_REGULATION_OF_CELL_COMMUNICATION 
GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 
GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 
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GO_REGULATION_OF_SECRETION 
GO_REGULATION_OF_TRANSPORT 
GO_RESPONSE_TO_BACTERIUM 
GO_RESPONSE_TO_BIOTIC_STIMULUS 
GO_RESPONSE_TO_EXTERNAL_STIMULUS 
  
Oxaliplatin & Cisplatin 
GO term 
GO_CELL_PROJECTION_ORGANIZATION 
GO_MACROMOLECULAR_COMPLEX_ASSEMBLY 
GO_NEUROGENESIS 
GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 
GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION 
GO_POSITIVE_REGULATION_OF_TRANSPORT 
GO_PROTEIN_COMPLEX_BIOGENESIS 
GO_PROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 
GO_REGULATION_OF_CELLULAR_LOCALIZATION 
GO_REGULATION_OF_CLATHRIN_MEDIATED_ENDOCYTOSIS 
GO_REGULATION_OF_ORGANELLE_ORGANIZATION 
GO_REGULATION_OF_TRANSPORT 
GO_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT 
GO_RESPONSE_TO_EXTERNAL_STIMULUS 
GO_VESICLE_MEDIATED_TRANSPORT 
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3.4.3. Vincristine causes dysregulation of genes associated with innate-immune 
response and interleukin one signalling 
In Chapter 2 I show that development of vincristine induced mechanical allodynia is partially 
driven by the toll-like receptor 4 (Tlr4), an important regulatory component of the innate immune 
system. To gain further insight into the neuro-inflammatory mechanism of vincristine induced 
peripheral neuropathy, I have further analysed differentially expressed genes following vincristine 
administration associated with immune system using the network analysis method with STRING.  
Interestingly, DEG following vincristine administration that were associated with the immune 
system included several genes involved in interleukin signalling such as the interleukin-1 receptor, 
type I; interleukin-1 receptor, type II; interleukin-1 receptor antagonist; interleukin-1 receptor-
associated kinase 3; suppressor of cytokine signalling-3; interleukin-18 receptor accessory protein; 
P38 mitogen-activated protein kinase and interleukin-17 receptor A (Fig. 19 and Table 7). 
Moreover, I have identified dysregulated genes associated with pattern-recognition-receptor 
signalling, such 2'-5'-oligoadenylate synthetase; protein kinase C; jun proto-oncogene; myeloid 
differentiation primary response gene (88); toll-like receptor 2; caspase recruitment domain 
family, member 9; phospholipase C; NACHT, LRR and PYD domains-containing protein 12 and 
caspase 3. Additionally, I have found genes associated with cell attraction via chemokines, 
apoptosis, tumour-necrosis factor signalling, colony stimulating factors, integrins and transcription 
of genes (Fig. 19 and Table 7). 
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Figure 19. Differentially expressed genes associated with immune system following vincristine 
administration include genes involved in interleukin-one signalling. 
Network analysis was generated with STRING version 10, showing only interactions between 
genes associated with immune system. Diagrams are presented in confidence view and only 
interactions with at least medium or high confidence of evidence are shown. Proteins were 
clustered using the Markov Cluster Algorithm with inflation parameter of 1.8.  
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Table 7. List of differentially expressed genes associated with the immune system following 
vincristine administration used for STRING network analysis. Green: up-regulated genes, orange: 
down-regulated genes, Padj: adjusted P value, log2FoldChange: logarithms of fold change. 
Symbol Description 
Log2Fold 
Change 
Padj 
IL1R1 interleukin 1 receptor, type I 0.6 1.E-02 
IL1R2 interleukin 1 receptor, type II 1.6 2.E-02 
CSF2RA colony stimulating factor 2 receptor, alpha, low-affinity 0.9 7.E-03 
CD19 CD19 molecule -3.1 2.E-13 
PRKCQ protein kinase C, theta -0.8 3.E-02 
ITGB2 integrin, beta 2  2.0 1.E-06 
ITGAL integrin, alpha L (antigen CD11A (p180),  1.1 8.E-03 
LCP2 lymphocyte cytosolic protein 2  1.0 5.E-02 
IL1RN interleukin 1 receptor antagonist 1.8 4.E-04 
TNFRSF14 tumour necrosis factor receptor superfamily, member 14 1.3 1.E-03 
CSF2RB colony stimulating factor 2 receptor(granulocyte-macrophage) 1.0 7.E-03 
MAPK13 mitogen-activated protein kinase 13 1.2 3.E-02 
JUN jun proto-oncogene 0.8 1.E-02 
FOS FBJ murine osteosarcoma viral oncogene homolog 2.8 4.E-05 
MYD88 myeloid differentiation primary response gene (88) 0.6 4.E-02 
TLR2 toll-like receptor 2 0.8 4.E-02 
BCL2L1 BCL2-like 1 0.6 2.E-02 
IRAK3 interleukin-1 receptor-associated kinase 3 0.6 3.E-02 
LY86 lymphocyte antigen 86 -0.9 4.E-02 
CARD9 caspase recruitment domain family, member 9 1.1 5.E-02 
NCF2 neutrophil cytosolic factor 2 0.9 3.E-02 
NCF4 neutrophil cytosolic factor 4, 40kDa 1.2 3.E-02 
CD79A CD79a molecule, immunoglobulin-associated alpha -3.1 7.E-14 
CD79B CD79b molecule, immunoglobulin-associated beta -2.5 2.E-12 
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SOCS3 suppressor of cytokine signalling 3 1.0 8.E-09 
BTLA B and T lymphocyte associated -1.1 1.E-02 
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 1.1 4.E-02 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 1.9 4.E-06 
ITGAM integrin, alpha M  1.5 2.E-04 
TNF tumour necrosis factor 2.1 1.E-20 
CSF1 colony stimulating factor 1 (macrophage) 0.9 1.E-07 
CSF3R colony stimulating factor 3 receptor (granulocyte) 1.7 1.E-05 
CXCL9 chemokine (C-X-C motif) ligand 9 1.3 5.E-02 
CCL2 chemokine (C-C motif) ligand 2 1.0 1.E-02 
CXCR2 chemokine (C-X-C motif) receptor 2 1.8 4.E-04 
CCR1 chemokine (C-C motif) receptor 1 1.6 5.E-04 
CXCR5 chemokine (C-X-C motif) receptor 5 -1.8 1.E-02 
CX3CR1 chemokine (C-X3-C motif) receptor 1 1.2 2.E-03 
CXCL14 chemokine (C-X-C motif) ligand 14 1.2 2.E-03 
MMP9 matrix metallopeptidase 9  1.6 2.E-04 
MST1 macrophage stimulating 1 (hepatocyte growth factor-like) 1.9 3.E-02 
TNFRSF13C tumour necrosis factor receptor superfamily, member 13C -2.0 5.E-05 
IL18RAP interleukin 18 receptor accessory protein 1.5 3.E-04 
IL17RA interleukin 17 receptor A 0.9 2.E-02 
TNFRSF12A tumour necrosis factor receptor superfamily, member 12A 2.1 1.E-20 
PLCB2 phospholipase C, beta 2 1.2 8.E-03 
CASP3 caspase 3, apoptosis-related cysteine peptidase 0.7 4.E-04 
NAIP baculoviral IAP repeat-containing protein 1 1.0 4.E-02 
NLRP12 NACHT, LRR and PYD domains-containing protein 12 1.2 3.E-03 
MCP-1 chemokine (C-C motif) ligand 2 1.0 1.E-02 
PYGL glycogen phosphorylase, liver form 0.8 4.E-02 
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3.5. Discussion 
Although chemotherapy-induced peripheral neuropathy (CIPN) is one of the major causes of 
treatment cessation in patients receiving vincristine, oxaliplatin or cisplatin, no currently available 
treatments adequately control or prevent the development of this side effect [1, 330]. With the 
exception of cold-induced hyperalgesia in patients receiving oxaliplatin, the pain-related 
symptoms of CIPN are similar across all three drugs (Table 4). Importantly, these differences are 
replicated in animal models of CIPN, with oxaliplatin but not cisplatin and vincristine causing cold 
allodynia, while all compounds caused mechanical hypersensitivity (Fig. 12). However, the 
mechanisms leading to development of CIPN are poorly understood, multi-factorial and appear to 
be drug specific [1]. In this chapter, I have performed transcriptomic analysis of gene expression 
changes in DRGs from mice treated with vincristine, oxaliplatin or cisplatin, with a view to gain 
an understanding of the differential and shared mechanisms that contribute to the development of 
CIPN. The transcriptomic analysis of whole DRG allows for identification of genes that are highly 
up or down regulated in cells that are represented in high numbers in the heterogenous tissue and 
provides valuable insights into the changes in gene expression. However, major limitation of this 
techniques is that small changes in expression of genes that are expressed in cells with low 
representation in the tissue remain undetected. 
The whole DRGs for transcriptomic analysis were collected in early stage of acute neuropathy, 72 
hours after cisplatin or oxaliplatin treatment and 7days after vincristine treatment, to enable the 
identification of genes that cause the onset of CIPN symptoms. This approach allowed the 
identification of possible targets preventing the often accompanied neuronal damage and activation 
of immune system and early preventative pharmacological intervention.  
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Among the highly upregulated genes following vincristine administration were Atf3 (Activating 
Transcription Factor 3), a general marker for nerve damage and regeneration following injury of 
DRG neurons [331], and the neuropeptide neurotensin, which is known to be involved in neuronal 
damage [332, 333]. One of the highly down-regulated genes was Ms4a1, encoding the Membrane 
Spanning 4-Domains A1, also called the CD20 antigen, the target of several monoclonal antibodies 
(e.g. rituximab) used in the treatment of B cell lymphomas and leukaemias. The precise function 
of CD20 remains unknown, however this putative calcium channel is expressed on the surface of 
pro-B lymphocytes through to mature B-lymphocytes, where its expression is terminated upon 
differentiation into plasma cells [334]. As Ms4a1 is only expressed in a very limited number of 
DRG neurons, the observed gene expression changes likely arise from the population of non-
neuronal cells in whole DRGs [335].  
One major finding of my analysis was that vincristine treatment caused predominantly up-
regulation of genes, whereas gene expression was mostly down-regulated after treatment with 
oxaliplatin and cisplatin. This may be due to local recruitment of immune cells to the DRGs 
following vincristine administration. Vincristine has been shown to cause neuronal inflammation 
[207, 208] and altered excitability of peripheral neurons by affecting the immune system [175, 
180, 198, 199, 204, 208]. Consistent with these neuro-inflammatory effects, cell type enrichment 
analysis (Cten) and gene set enrichment analysis (GSEA) showed that vincristine administration 
is accompanied with gene expression changes typical for immune cell recruitment and 
inflammation. Additionally, vincristine caused the dysregulation of several genes that are involved 
in interleukin and pattern recognition receptor signalling, as well as immune cell chemotaxis, 
differentiation and activation (Fig. 19 and Table 7). For example, the interleukin-1 receptor, type 
I; interleukin-1 receptor, type II; interleukin-1 receptor antagonist; interleukin-1 receptor-
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associated kinase 3; and suppressor of cytokine signalling-3 were all upregulated and demonstrate 
the increased activity of the interleukin-one signalling pathway. Interleukin 1 beta (IL-1β) has been 
shown to directly communicate the presence of inflammation to nociceptors, by inducing the 
synthesis of nociceptor sensitizing substances, such as Nerve Growth Factor (NGF), Prostaglandin 
E2 (PGE2) and Cyclooxygenase 2 (COX2), by immune and non-immune cells [93, 94]. 
Additionally, IL-1β can amplify persistent current of tetrodotoxin-resistant voltage-gated sodium 
channels via p38-mitogen activated kinase (MAPK), leading to increased excitability of sensory 
neurons [95]. Interleukin-1β can be released via activation of inflammasomes such as the NLRP3, 
NLRP1, NLRC4 and AIM2 by immune cells [9, 42]. The NLRP3 is the best characterized from 
all inflammasomes and it is predominantly expressed by immune cells such as macrophages and 
neutrophils [336-338]. The activation of the Nod-like receptor protein 3 leads to recruitment of the 
inflammasome complex that activates caspase 1, an enzyme that cleaves pro-interleukin 1 beta and 
pro-interleukin 18 into their active forms [339]. Whether IL-1 signalling, and the Nod-like 
receptors are involved in development of vincristine induced peripheral neuropathy symptoms 
remains to be determined in future experiments. However, vincristine induced mechanical 
allodynia was prevented by minocycline, an antibiotic shown to inhibit caspase 1 expression [340], 
and in Tlr4-/- animals (Chapter 2, section 2.4.3.). Therefore, NLRP3 dependent release of IL-1β 
is a promising starting point for further investigation and the development of effective treatment 
strategies for vincristine induced peripheral neuropathy. 
Cisplatin-induced gene expression changes incorporated both neuropathic and inflammatory 
elements, with CTEN analysis of cisplatin-exposed DRGs identifying overlaps with both neuronal 
and immune cells. Additionally, GSEA identified overlaps with GO Biological processes involved 
in neuronal damage and the immune system, supporting a mixed neuro-immune pathology induced 
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by cisplatin. Overlaps of both cisplatin and oxaliplatin, but not vincristine, with DNA processing 
are consistent with the mechanisms of action of these drugs; with vincristine inhibiting the 
assembly of β-tubulin [23], while the platinum derivates oxaliplatin and cisplatin bind to DNA and 
interfere with replication, transcription and the cell cycle [13-16]. 
In contrast to vincristine and cisplatin, inflammatory mechanisms did not appear to contribute 
significantly to oxaliplatin-induced neuropathy. Specifically, GSEA of the oxaliplatin-treated 
group identified GO biological processes associated with neuronal damage and DNA and RNA 
processing. Furthermore, CTEN of the oxaliplatin-treated groups identified overlaps with neuronal 
cells, but not with immune cells. This result was somewhat surprising, as oxaliplatin-induced 
peripheral neuropathy has previously been associated with changes in immune system activation 
and regulation. For example, oxaliplatin-induced mechanical hyperalgesia and epidermal nerve 
fibre loss were prevented by the tetracycline minocycline, an antibiotic known to inhibit 
macrophages/monocytes and microglia [154, 194-196]. Oxaliplatin also led to increased levels of 
pro-inflammatory cytokines (IL-6, IL-8, IL-1β, TNF-α), which in turn can lead to sensitization of 
nociceptors [44, 90, 138, 190, 197-206]. It is possible that in oxaliplatin-induced neuropathy, 
neuronal damage and the associated changes in gene expression precede inflammatory processes, 
which may drive development of more chronic neuropathy symptoms. In addition, further research 
is required to determine if altered expression of inflammatory genes induced by treatment with 
vincristine and cisplatin causally contribute to the development of CIPN or are rather a reflection 
of glial or immune cell damage in DRGs. 
Although the symptoms of peripheral neuropathy following oxaliplatin, cisplatin or vincristine 
treatment appear to be relatively similar in nature, only few DEGs were shared between all agents. 
Curiously, these genes included integrin β2 like protein and lymphocyte antigen complex 6, which 
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are predominately expressed on immune cells [341, 342] while – perhaps disappointingly – no 
pain- or neuropathy-related genes were identified. However, DRGs were collected in early stage 
of mechanical allodynia, identifying DEGs associated with acute CIPN, whereas most studies 
identifying pain and neuropathy related genes asses the expression of DEGs associated with 
chronic pain or chronic CIPN [296]. Nevertheless, those results highlight the importance of 
inflammatory processes in development of CIPN and the role of integrin β2 like protein and 
lymphocyte antigen complex 6 in CIPN should be examined in future studies. 
Nonetheless, several DEGs emerging after treatment with individual agents have previously been 
associated with pain processing. For example, knockout of the Neurotensin receptor 1 or 
Endothelin Converting Enzyme 2 led to altered pain perception in mice [317, 319] while knockout 
of the Cholecystokinin B receptor was connected to functional TLR4 deficiency and a consequent 
reduction of neuropathic pain in mice [320]. Additionally, Activating Transcription Factor 3, 
Cholecystokinin B Receptor and Steroidogenic Acute Regulatory Protein were all found to be 
upregulated after neuronal injury, including spinal cord injury, burn injury and after treatment of 
C57BL6 mice with the chemotherapy agent paclitaxel [204, 321, 323, 343]. Similarly, expression 
of the gene encoding for Piccolo (presynaptic cytomatrix protein) was significantly increased in 
rat spinal dorsal horn after vincristine treatment and in a model of orofacial neuropathic pain [325, 
326]. Additionally, Zinc finger homeobox 2 knockout mice (Zfhx2 -/-) show deficits in pain 
sensitivity and a point mutation in the Zfhx2 gene results in deficits in pain sensitivity and is 
associated with insensitive phenotype in humans [327]. Whether DEGs that have no known 
association with pain are novel targets for the treatment or prevention of CIPN remains to be 
determined.  
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Additionally, oxaliplatin administration caused upregulation of genes including Prostaglandin-H2 
D-isomerase, an enzyme that catalyses the conversion of Prostaglandin H2 to Prostaglandin D2. 
This has previously been found to be upregulated in the serum of neuropathic rats after chronic 
constriction injury [324]. Interestingly, although treatment with oxaliplatin caused cold allodynia 
(Fig. 10) and previous studies suggested the involvement of Transient receptor potential cation 
channel, subfamily A, member 1 (TRPA1) in oxaliplatin-induced cold allodynia [168, 171, 344-
346], no changes in RNA-expression of thermosensitive TRP channels were observed in the 
present study. It is possible that these differences are due to differences in methods, analytical 
techniques or environmental influences. Alternatively, gene expression changes occurring as a 
consequence of oxaliplatin treatment may enhance neuronal excitability to cold stimuli in the 
absence of changes in the gene expression of thermosensitive TRP channels.  
3.6. Conclusion  
This chapter present a detailed overview and comparison of gene expression changes in DRG 
induced by short term treatment with the chemotherapeutic agents vincristine, oxaliplatin and 
cisplatin. Overall, oxaliplatin caused dysregulation of genes associated with neuronal function and 
cisplatin resulted in gene expression changes consistent with a mixed inflammatory and 
neuropathic pathology. Vincristine caused dysregulation of genes associated with immune system 
processes, predominantly genes involved in interleukin-1β signalling. The involvement of 
interleukin-1β and the associated immunological pathways in the pathology of VIPN will be 
addressed in the following Chapter 4 of this thesis and will allow the development of effective 
treatment strategies for VIPN. 
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4. CHAPTER 4: Vincristine-induced peripheral neuropathy is driven by canonical 
NLRP3 activation and IL-1β release 
4.1. Foreword 
This chapter investigates the involvement of NLRP3-dependent release of IL-1ß in the pathology of 
VIPN and the use of the interleukin-1 receptor antagonist anakinra as a safe and effective treatment 
for VIPN symptoms. It was prepared as a complete manuscript to be submitted in Science 
Translational Medicine (Hana Starobova, Mercedes Monteleone, Christelle Adolphe, Lena Batoon, 
Bryan Tay, Alexander Muelller , Evelyn Israel Nadar, Jennifer R. Deuis, Grace Pamo Lawrence, 
Amanda Mayor, Elissa Tolson, Christine Holley, Jean-Pierre Levesque, Allison Pettit, Brandon 
Wainwright, Kate Schroder, Irina Vetter (2020) Vincristine-induced peripheral neuropathy is driven 
by canonical NLRP3 activation and IL-1β release. Science in Translational Medicine.).  
The manuscript was amended partially to fit the style and flow of this thesis. Hana Starobova 
performed all behavioural experiments, blood and tissue sample collection, lactate dehydrogenase 
and Elisa assays and assisted with PDX drug efficacy studies. Hana Starobova wrote the manuscript 
and designed all figures. Flow cytometry of blood samples and immunohistochemistry of sciatic 
nerve and spleen were performed by Lena Batoon. Western Blots analysis was performed by 
Mercedes Monteleone. Human monocyte culture was prepared by Grace Pamo Lawrence. Generation 
of subcutaneous xenografts and PDX drug efficacy studies were performed with help of Christelle 
Adolphe, Elissa Tolson and Amanda Mayor.  
 
4.2. Introduction 
As outlined in Chapter 1 the exact pathophysiological mechanisms underlying VIPN remain unclear, 
which hampers the development of effective treatment strategies that could either prevent or control 
the symptoms of VIPN. Although vincristine targets microtubules, and impaired retrograde and 
anterograde transport has been suggested as one mechanism leading to altered sensory neuron 
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function, in Chapter 2 and Chapter 3, I provide evidence that vincristine-induced peripheral 
neuropathy (VIPN) incorporates significant neuro-inflammatory components. Vincristine in 
particular induces a striking upregulation of inflammatory genes in DRGs (Chapter 3), and release 
of pro-inflammatory cytokines and chemokines from immune cells including IL-1β, TNFα, IL-6 and 
CCL2 have been implicated in the development of VIPN [275, 291]. Indeed, a causative contribution 
of infiltrating peripheral macrophages into sciatic nerve and DRGs was also confirmed in CX3CR1- 
and CCR2-deficient mice, which develop less mechanical allodynia after treatment with vincristine 
[175, 347]. However, the signalling pathways leading to cytokine release from these infiltrating 
peripheral macrophages, as well as the contributions of these mechanisms to the development of 
vincristine-induced mechanical allodynia and gait disturbances are not known. In Chapter 3, I show 
that vincristine causes dysregulation of genes involved in activation of macrophages and interleukin-
1ß (IL-1ß) signalling in DRGs and therefore I thought to further investigate the mechanisms leading 
to release of IL-1ß by vincristine, its contribution to development of VIPN symptoms and the 
therapeutic potential of interleukin-1 receptor inhibition. 
IL-1ß can be released via activation of so-called inflammasomes such as the NLRP3, NLRP1, NLRC4 
and AIM2 [339, 348]. The NLRP3 is the best characterized inflammasome and the upregulation of 
NLRP3 in DRGs by chemotherapeutic agent bortezomid was shown to contribute to development of 
painful neuropathy in rodents [349]. It is predominantly expressed by immune cells such as 
macrophages and neutrophils and to a lesser extent by dendritic cells, microglia and DRGs [336-338]. 
The activation of the NLRP3-inflammasome requires, with some exceptions, two signals. The first 
signal is the priming of the NLRP3-inflammasome by endogenous molecules (e.g. tumour necrosis 
factor and IL-1ß) or microbial components, such as lipopolysaccharides, that activate tumour necrosis 
factor receptor, interleukin-one receptor or toll-like receptors leading to nuclear factor-кB dependent 
increase of NLRP3 and pro-IL-1ß expression [350, 351]. The second signal is the direct activation of 
NLRP3 via the canonical inflammasome by multiple cellular signalling events such as potassium 
efflux, changes in calcium signalling, increase in production of reactive oxygen species by 
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mitochondria or lysosomal leakage and release of cathepsin-B [352-355]. The activation of NLRP3 
leads to assembly of a multi-protein complex and recruitment of caspase-1, which then cleaves pro- 
IL-1ß and pro-interleukin-18 (pro-IL-18) into their active form [356-359]. Additionally, active 
caspase-1 cleaves the pore former pro-gasdermin D into its active form, inducing pyroptosis, an 
inflammatory cell death [360]. NLRP3 can also be activated indirectly via the non-canonical 
inflammasome and the so-called alternative inflammasome [361-365] (Fig. 20A). Activation of the 
NLRP3 inflammasome leads to release of active IL-1β, an inflammatory cytokine that regulates the 
function of various cells, such as immune and neuronal cells [348] (Fig. 20B). IL-1β is released at 
the site of inflammation and is a well-known pain-inducing molecule. Several rodent studies have 
shown that intraplantar or intraperitoneal injection of IL-1β causes severe hyperalgesia [366, 367]. 
IL-1β likely increases the excitability of nociceptors by altering the function of several neuronal ion 
channels and receptors, including transient receptor potential channels (TRPA1 and TRPV1), NMDA 
and GABA receptors, as well as voltage-gated K+, Na+ and Ca2+ channels [279, 368-372]. In this 
context, IL-1β can be considered to be a direct neuromodulator, and although the molecular signalling 
pathways leading to enhanced excitability have not been studied extensively, signalling via neuronal 
IL-1 receptors and activation of p38-mitogen-activated protein kinase appear to contribute 
mechanistically. Specifically, IL-1β alters the voltage-dependence of slow inactivation of 
tetrodotoxin (TTX)-resistant NaV current in sensory neurons and also enhances persistent TTX-
resistant current [279]. Importantly, IL-1β-induced mechanical allodynia is also relieved in mice 
lacking the TTX-resistant isoform NaV1.9 [367], supporting an important contribution of altered ion 
channel function to the neuromodulatory effects of IL-1β. Additionally, IL-1β also mediates 
production of endogenous molecules such as nerve growth factor, prostaglandin E2, cyclooxygenase-
2 and calcitonin-gene related peptide that may further contribute to peripheral sensitization [373-377] 
(Fig. 20B).  
Increased levels of IL-1β accompany a vast number of inflammatory and non-inflammatory diseases 
and pathological states such as Alzheimer’s disease, cancer or rheumatoid arthritis [378-381]. 
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Additionally, IL-1β was found to be upregulated in the blood of patients suffering from painful 
conditions, and in tissues of rodents in various models of inflammatory or non-inflammatory pain 
[296] [372, 382], underpinning the importance of IL-1β in disease pathology. However, increased 
levels of IL-1β do not necessarily involve activation of NLRP3 as IL-1β can also be released via 
alternative mechanisms, including activation of the NLRP1, NLRC4 and AIM2 inflammasomes [339, 
348].  
Activation of NLRP3 also leads to release of active interleukin-18 (IL-18), which has been found to 
mediate painful conditions such as muscle pain, cancer-induced bone pain and neuropathic pain [383-
385]. However, it is currently unclear whether IL-18 can also directly contribute to nociceptor 
sensitization, or whether these effects are secondary to other IL-18-induced signalling events. 
 
In this chapter, I demonstrate that vincristine elicits release of IL-1β from human and murine 
macrophages via a caspase-1-dependent, canonical NLRP3 signalling pathway and that VIPN fails to 
develop in IL-1R- and IL-1β-deficient mice. Importantly, the clinically used IL-1R-antagonist 
anakinra prevented development of vincristine-induced gait abnormalities and mechanical allodynia 
without affecting chemotherapy efficacy of vincristine, or tumour growth, in medulloblastoma 
patient-derived xenograft models. These results suggest that treatment with anakinra may be a viable 
clinical strategy to prevent development of VIPN without adversely affecting cancer treatment 
outcomes.  
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Figure 20. Putative mechanism of sensory nerve sensitization by IL-1β 
A) Priming of the NLRP3 inflammasome via activation of TLRs, IL-1R or TNFR in NFκB dependent 
manner in macrophages leads to increased expression of NLRP3 and pro-IL1β (blue arrows). The 
canonical activation of the NLRP3 (red arrows) by PAMPs, DAMPs, cathepsin B, K+ efflux or ROS 
leads to assembly of the NLRP3 inflammasome complex, activation of CASP1 and cleavage of pro-
IL-1β and GSMD. Active IL-1β is released by macrophages and exerts its effect via IL-1R on sensory 
nerves and surrounding cells. Active GSMD initiates pyroptosis. B) IL-1β increases the gene 
expression of COX-2, PEG-2 and CSF in keratinocytes in a NFκB /P38 mitogen kinase dependent 
manner. PEG sensitize peripheral nerves and CSF regulates differentiation, proliferation and survival 
of macrophages.  IL-1β increases excitability of nociceptors by altering the function of tetrodotoxin-
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resistant voltage-gated sodium channels via IL-1R and increases the gene expression in dorsal root 
ganglia in a NFκB / P38 mitogen kinase dependent manner. Substance P, CGRP and NGF sensitize 
further peripheral nerves. IL-1β: interleukin 1β, TLR: toll-like receptor; IL-1R: interleukin-1 
receptor; TNFR: tumor necrosis factor α receptor; NFκB: nuclear factor κB; NLRP3: NACHT, LRR 
and PYD domains-containing protein 3; PAMPs: pathogen-associated molecular pattern; DAMPs: 
damage-associated molecular pattern; ROS: reactive oxygen species; CASP1: caspase 1; CSFR: 
colony-stimulating factor receptor; GSMD: gasdermin D; NaV: voltage gated sodium channel; EP: 
prostaglandin E receptor; NK: neurokinin receptor; CGRP: calcitonin gene-related peptide; 
CALCRL: calcitonin gene-related peptide receptor; NGF: nerve growth factor; COX-2: 
cyclooxygenase type 2; PEG2: prostaglandin E2; CSF: colony stimulating factor; NMDAR: N-
methyl-D-aspartate receptor; KV: voltage gated potassium channel; CaV: voltage gated calcium 
channel; TRPV1: transient receptor potential channel vaniloid; TRPA1: transient receptor potential 
channel ankyrin; GABAR: gamma-aminobutyric acid receptor 
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4.3. Methods 
4.3.1. Animals and ethical approvals 
All behavioural experiments were performed with 8-10 week old adult wild type (C57BL/6J) mice 
or with Nlrp3-/-, Ice-/-(Casp1-/-/Casp11 null/null)[362], Casp11-/-, Gsdmd-/-, Il1r1-/-, Il1b-/-, NaV1.9 
-/- mice 
of mixed sex, noting that no differences between sexes were observed as stated previously in Chapter 
2, section 2.3.1.. Animals were housed with rodent chow and water ad libitum in groups of three to 
five per cage under 12-hour light-dark cycles. Ethics approval for in vivo experiments was obtained 
from the University of Queensland Animal Ethics Committee (see Chapter 1, section 2.3.1. and 
certificates of approval: Appendix 4, section 9.1.). 
4.3.2. Vincristine administration for neuropathy studies 
For assessment of mechanical allodynia vincristine sulphate (Sapphire Bioscience, Australia) was 
administered via intraperitoneal (i.p; 0.5 mg/kg) injection or via intraplantar (i.pl.; 10 μg; cumulative 
dose: 60 μg) injection and was prepared and administered as decribed in Chapter 2, section 2.3.2.. 
The injection schedule is displayed by arrows in all figure panels. For the assessment of gait 
abnormalities vincristine or vehicle (5% glucose) solution was administered via intraplantar injection 
(10 μg/10 μl/paw) as described in Chapter 2, section 2.3.2., the injection schedule is displayed by 
arrows in all figure panels. 
4.3.3. Oxaliplatin and cisplatin administration for neuropathy studies 
Oxaliplatin (Sapphire Bioscience, Australia, 40 μg; i.pl.) and cisplatin (Sigma Aldrich, 40 μg; i.pl.) 
were administered once via local intraplantar injection as described previously in Chapter 3, 
section 3.3.2.. 
4.3.4. Drug treatment 
Anakinra (Kineret®, Sobi) or MCC950 [277] were dissolved in PBS. Anakinra (100 mg/kg), MCC950 
(20 mg/kg) or PBS were administered by intraperitoneal (i.p.) injection once daily as described in 
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Chapter 2, section 2.3.2., together with each vincristine (i.p.; 0.5 mg/kg or i.pl.; 10 μg), oxaliplatin 
(40 μg; i.pl.) or cisplatin (40 μg; i.pl.) injection, as indicated by coloured arrows in corresponding 
figures.  
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4.3.5. Depletion of monocytes and granulocytes 
For depletion of granulocytes, mice were injected i.p. with 200 μg anti-Ly6G antibody or control 
antibody (Bio X Cell) 3 days prior to the first vincristine administration and then together with 
vincristine (i.p.; 0.5 mg/kg) injection as described previously in Chapter 2, section 2.3.2.. For 
depletion of monocytes, clodronate liposomes (10 μl/g of a 5 mg/ml solution) or control liposome-
encapsulated PBS (Liposoma Research) were injected i.p. 3 days prior to the first vincristine 
administration and then together with vincristine (i.p.; 0.5 mg/kg) injection as described previously 
in Chapter 2, section 2.3.2.. To confirm depletion of monocytes or granulocytes, the spleen, sciatic 
nerve or blood were collected after two doses of clodronate or Ly6G and/or 24 hours after the first 
vincristine (i.p.; 0.5 mg/kg) injection as described in section 4.3.7.. 
4.3.6. Human and murine macrophage inflammasome assays 
Human monocyte-derived macrophages were prepared as described previously [386]. Murine bone 
marrow-derived macrophages (BMMs) were isolated from C57BL6/J, Nlrp3-/-, Ice-/-, Casp11-/-, 
Gsdmd-/- mice. Mice were euthanized using CO2 and the femur and tibia was extracted using sterile 
surgical tweezer and scissors and placed in 70% ethanol. The femur and tibia were transferred to 
RPMI 1640 media (Life Technologies Australia Pty Ltd Invitrogen). Both ends of the femur and tibia 
were cut off to access the bone marrow. Both ends were flushed with RPMI 1640 media (Gibco) 
using a 10 ml syringe and 23G needle (Terumo Agani) until the bone appeared white and the bone 
marrow was collected in a 40 µm cell strainer (Falcon) placed on top of a 50 ml Falcon tube. In the 
end, the cell strainer was flushed with 5 ml RPMI media to wash out all cells. Finally, the cells were 
centrifuged @ 500g x 5 min and re-suspended in 2 ml of RPMI media and plated on square Sterilin 
plates (Thermo Fisher Scientific) with RPMI 1640 (Gibco) supplemented with 10% heat-inactivated 
fetal calf serum, GlutaMAX (Life Technologies) and recombinant human CSF-1 (150ng/ml; 
endotoxin-free, produced in insect cells by the University of Queensland Protein Expression Facility).  
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Differentiated macrophages (day 6) were plated at a density of 1 × 106 cells/ml in RPMI 1640 (Gibco) 
supplemented with 10% heat-inactivated fetal calf serum, GlutaMAX (Life Technologies) and 
recombinant human CSF-1 (150ng/ml; endotoxin-free, produced in insect cells by the University of 
Queensland Protein Expression Facility). For inflammasome assays, on day 7 of cell differentiation, 
culture media was replaced with OptiMEM (Life Technologies Australia Pty Ltd Invitrogen, plus 
CSF-1) with or without ultra-pure LPS (100 ng/ml; E. coli K12 InvivoGen, tlrl-peklps) for 3 hours, 
followed by treatment with vincristine (100 µM) for 4 hours. Nigericin (5µM; Sigma Aldrich) was 
added 1 h prior to supernatant collection.  
IL-1β secretion was quantified by ELISA (eBioscience IL-1β Ready-SET-Go!), according to the 
manufacturer's protocol. The release of lactate dehydrogenase (LDH) was quantified using the 
CytoTox96 Non-radioactive Cytotoxicity Assay (Promega) and plotted as a percentage of total 
cellular LDH (100% lysis control). Cell lysates and cell-free methanol/chloroform-precipitated 
supernatants were analysed by Western blot using standard methods [387], using antibodies against 
IL-1β (AF-401-NA, 1:1,000; R&D Systems), caspase-1 (casper-1, 1:1,000; AdipoGen), GSDMD 
(EPR19828, Abcam) and GAPDH (polyclonal rabbit antibody, 1:5,000; BioScientific).  
4.3.7. Tissue and blood isolation and preparation 
Mice were euthanized using carbon dioxide. For isolation of the sciatic nerve, both hindquarters were 
shaved using clippers (Braun®). A 1 cm long incision was made in the skin to expose the gluteal 
musculature. The sciatic nerve is localized between the gluteus maximus and the anterior head of the 
biceps femoris. The sciatic nerve was gently freed from the surrounding connective tissue using 
iridectomy scissors and tweezers and placed in ice cold 4% PFA (Appendix 2, section 8.3.). For 
isolation of the spleen, a 3 cm incision at the left of the peritoneal wall was made. The spleen, which 
is situated in the left superior abdominal quadrant, was exposed and carefully pulled free of the 
peritoneum, tearing the connective tissue using surgical scissors. The spleen was placed immediately 
in ice cold 4% PFA (Appendix 2, section 8.3.). Blood samples were collected post mortem via cardiac 
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puncture. For this the animal was placed on its back and the chest and abdomen were sprayed with 
70% ethanol. A 25G needle was attached to a 10 ml syringe and inserted in a 30º angle just below the 
xyphoid process. The plunger of the syringe was slightly retracted to create a vacuum inside the 
syringe and the plunger was slowly retracted to collect the blood. Blood samples were kept on ice 
and flow cytometry procedure was performed immediately after collection. 
4.3.8. Flow cytometry 
Cell suspensions were generated with 2% fetal calf serum (FCS) in phosphate-buffered saline (PBS) 
and then incubated with the appropriate antibody cocktail for 40 minutes in the dark and on ice with 
agitation. The myeloid antibody cocktail was made in Fc (fragment crystallisable antibody region) 
block and contained anti-F4/80-Alexa647 (clone BM8; AbD Serotec, Kidlington, UK), anti-CD115-
PE (clone AFS98; Biolegend, San Diego, CA, USA), anti-Ly6G PE/Cy7 (clone 1A8; Biolegend), 
anti-Ly6C APC/Fire 750 (clone HK1.4; Biolegend) and anti-CD11b BV510 (M1/70; Biolegend). 
Cells were washed, re-suspended in 100 μL 2% FCS in PBS. Specificity of staining was determined 
by comparison to unstained cells and appropriate isotype control cocktail. Five minutes prior to 
analysis, 5 μg/mL 7-amino actinomycin D (7AAD) (Life Technologies, CA, USA) was added to each 
tube to allow exclusion of dead cells. Cells were examined via flow cytometry on a Cytoflex flow 
cytometer (Beckman Coulter, Brea, CA) and data were analysed using FlowJo version 10 (Tree Star 
Data Analysis Software). Analyses were performed on live (7AAD-) cells after cell aggregate 
exclusion. Granulocytes were gated as CD11b+Ly6G+.  
4.3.9. Immunohistochemistry and histomorphometric methods 
Immunohistochemistry (IHC) of spleen and sciatic nerve tissues was performed on deparaffinised 
and rehydrated sections with unconjugated primary antibody against F4/80 (clone Cl:A3-1; rat anti-
mouse; Novus Biological, CO, USA), or relevant isotype control antibody (normal rat IgG2b; 
Biolegend, San Diego, CA, USA) as previously described [388]. Staining was imaged using either 
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Olympus BX50 microscope (Olympus, Tokyo, JP) or VS120 slide scanner (Olympus, Tokyo, JP) and 
analysed using Visiopharm software (Visiopharm, Denmark). 
All sections were de-identified and assessed in a blinded manner. Percent F4/80 staining area in 
spleen sections was quantified using an automated software-based approach to reduce or eliminate 
human bias. An algorithm was generated using the iterative training process within Visiopharm-
software to detect the distribution of diaminobenzidine chromogen (F4/80), hematoxylin (nuclei) and 
unstained areas which include blood vessels and extracellular matrix. A similar algorithm was applied 
to all spleen sections within an experiment. Number of F4/80+ cells in nerve tissues was quantified 
by manual counting of positive cells in 1.7±0.52 mm2 of tissue. For both histology-based 
quantification methods described above, each data point represents the mean of analyses at 3 sectional 
depths/sample that were at least 50 μm apart.  Statistically significant differences were determined 
using a two-tailed unpaired t-test or ordinary one-way ANOVA with Holm-Sidak’s multiple 
comparisons test in PRISM 8 (GraphPad Software, La Jolla, CA). A value of p <0.05 was considered 
statistically significant.   
4.3.10. Mechanical threshold measurements 
Mechanical paw withdrawal thresholds were assessed as described in Chapter 2, section 2.3.4..  
4.3.11. Gait analysis 
Gait disturbances were assessed as described in Chapter 2, section 2.3.6.. 
4.3.12. Generation of subcutaneous xenografts 
Studies were conducted using Group 3 MB PDX models (Med-211FH and Med-411FH) and a Shh 
MB PDX model (Med1712FH), generated in the Olson lab (Seattle) by implanting paediatric patient 
tumour tissue directly into the cerebellum of immunocompromised mice (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/Szj (NSG)) and propagating them exclusively via orthotopic transplant into mice, as 
previously described [389]. Med-211FH, Med-411FH and Med1712FH PDX tumour cells were 
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harvested from intracranial tumours of symptomatic donor mice. Tumour tissue was triturated 
through a 21-g needle in serum-free Dulbecco’s Modified Eagle’s Medium (DMEM) to generate a 
single cell suspension. Cells were filtered, centrifuged and re-suspended in serum-free DMEM 1:1 
with Matrigel to a concentration of 20,000 cells/µl. 100 µl of the tumour cell suspension (2x106 cells) 
was injected subcutaneously into each flank of NSG mice. 
4.3.13. PDX drug efficacy studies 
Mice were randomly assigned into therapeutic treatment groups via rolling enrolment. Mice were 
enrolled when subcutaneous tumours measured 200-300 mm3 in size and treatment was administered 
for 4 weeks or until maximum tumour size was reached (2000 mm3), requiring ethical collection. 
Vincristine treatment was administered via a single i.p. dose of 0.25 mg/kg (on day 1, day 3, day 
5/week x 4 weeks). Anakinra treatment commenced when subcutaneous tumours reached 100 mm3 
in size, allowing for a period of ‘pre-treatment’ prior to vincristine administration to maximize 
opportunities to observe effects on tumour progression. Anakinra was administered daily via a single 
i.p. dose of 100mg/kg. Tumour volume measurements were taken bi-weekly and mouse weights 
measured daily. Tumours were measured with calipers and tumour volume was calculated using the 
equation: ((Length x Width2)/2). 
4.3.14. Data and statistical analyses 
Data and statistical analyses were performed using GraphPad Prism Version 7.00. Unless otherwise 
specified, statistical significance was determined as * p-adjusted < 0.05 and was calculated using two-
way ANOVA with Tukey's multiple comparisons test or repeated measures two-way ANOVA with 
Sidak’s multiple comparisons test for behavioural data. All data are shown as mean ± standard error 
of the mean (SEM); n = 6 for all groups (3 females and 3 males), all experimental groups were 
compared to vehicle group (control) or baseline as indicated.   
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4.4. Results 
4.4.1. Neuro-inflammation causes vincristine-induced mechanical allodynia  
Patients treated with vincristine develop sensory disturbances such as hyperesthesia or altered 
responses to light touch and pinprick; as well as motoric disturbances including altered gait and foot 
drop syndrome [267, 390]. These symptoms are recapitulated in murine models based on 
intraperitoneal (i.p.) or intraplantar (i.pl.) administration of vincristine [175, 259, 391]. Specifically, 
as previously described, systemic and local treatment with vincristine (0.5 mg/kg, i.p.; 10 doses/12 
days or 10 µg, i.pl.; 6 doses/12 days) elicited pronounced mechanical allodynia, evidenced by a 
significant decrease of the mechanical paw withdrawal thresholds (Fig. 21A and Appendix 3, Table 
25S). In addition to mechanical allodynia, gait abnormalities were also apparent in animals treated 
with high dose of vincristine (10 μg; i.pl.) (Fig. 21B and Appendix 3, Table 25S) (paw print area (% 
contralateral)). In light of recent evidence suggesting a significant neuro-inflammatory component of 
VIPN [175, 291, 347], I sought to quantify the number of F4/80+ (pan-macrophage marker) cells in 
the sciatic nerve of vincristine-treated animals. In PBS-treated C57BL/6J mice, I observed a small 
number of F4/80+ cells consistent with levels expected in healthy tissue (6,577.8 ± 448.2 cells/ mm2; 
Fig. 21C and E). In contrast, treatment with vincristine (0.5 mg/kg; i.p.; 24h) caused considerable 
infiltration of F4/80+ cells into the sciatic nerve (12,994.4 ± 1,111.3 cells/ mm2; Fig. 21D and E; p 
<0.05 compared to PBS control). To confirm a causative contribution of infiltrating immune cells to 
VIPN, I next assessed vincristine-induced mechanical allodynia following depletion of granulocytes 
using an anti-Ly6G antibody and macrophages using clodronate liposomes. Compared with the 
isotype control antibody, treatment with anti-Ly6G antibody significantly reduced the proportion of 
granulocytes in circulating blood from 5.33 ± 0.88 % to 1.00 ± 0.00 % of total live cell counts as 
determined by flow cytometry (Fig. 21F). Similarly, treatment with liposomal clodronate both 
significantly (p <0.05) reduced the number of F4/80+ cells in the spleen (Fig. 21G-J; PBS control, 
6.73 ± 1.57 %; liposomal clodronate 2.94 ± 1.24%) and also reversed the number of F4/80+ cells in 
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the sciatic nerve of vincristine-treated animals to baseline levels (Fig. 21K). Consistent with 
infiltrating F4/80+ cells causally contributing to the development of VIPN, depletion of macrophages 
by liposomal clodronate prevented the vincristine-induced decrease of mechanical paw withdrawal 
threshold (Fig 21L; PWT: vincristine + PBS, 1.62 ± 0.23 g; vincristine + liposomal clodronate, 2.99 
± 0.15 g; p <0.001). In contrast, depletion of granulocytes did not affect vincristine-induced 
mechanical allodynia, as the mechanical thresholds of animals treated with anti-Ly6G (1.57 ± 0.30 
g) were not significantly (p > 0.05) different from those of isotype antibody-treated animals (1.24 ± 
0.17 g) (Fig. 21L).  
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Figure 21. Vincristine-induced peripheral neuropathy is driven by infiltrating macrophages. 
(A) Vincristine (black circles; 0.5 mg/kg; i.p.; n = 6) causes a decrease of mechanical paw withdrawal 
thresholds (PWT, assessed using an electronic von Frey apparatus) in C57BL/6J mice compared with 
PBS-treated animals (white circles; 10 μl/g i.p.; n = 6). Black arrows indicate the time points of 
vincristine administration. (B) Vincristine (black circles; 10 μg; i.pl.; n = 6) causes gait abnormalities, 
evidenced by a decrease of paw print area (cm2) of C57BL/6J mice relative to the contralateral control 
(PBS, white circles). Black arrows indicate the time points of vincristine administration. (C-E) 
Vincristine causes infiltration of F4/80+ cells into the sciatic nerve. Representative 
immunohistochemical images of sciatic nerve sections from C57BL/6J mice treated with vehicle (C; 
PBS; i.p.; 24 h) or vincristine (D) (0.5 mg/kg; i.p.; 24 h). F4/80+ cells (arrows) appear brown due to 
presence of diaminobenzidine chromogen. Scale bar; 50 μm. (E) Quantification of F4/80+ cells in 
sciatic nerve after treatment with vincristine (0.5 mg/kg; i.p.; 24 h) or vehicle (PBS; i.p.; 24 h) (F) 
Depletion of granulocytes in circulating blood after treatment with anti-Ly6G antibody (200 µg; i.p.; 
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1.00 ± 0.00 % of total live cell counts) compared with the isotype control antibody (200 µg; i.p.; 5.33 
± 0.88 % of total live cell counts) was confirmed by flow cytometry. (G-J) Depletion of macrophages 
was confirmed by quantitative anti-F4/80 staining of the spleen in animals treated with vehicle (PBS; 
i.p. 24 h) or liposomal clodronate (lip. clodronate; 50 μg/g i.p.; 24 h). (G and H) Representative 
F4/80+ immunohistochemistry images of spleen sections from PBS- and liposomal clodronate-treated 
animals. F4/80+ cells (arrows) appear brown due to presence of diaminobenzidine chromogen. Scale 
bar; 200 μm. (K) Compared to PBS-treated animals, treatment with liposomal clodronate (lip. 
clodronate; 50 μg/g i.p.; 24 h) significantly decreased the number of F4/80+ cells infiltrating the sciatic 
nerve of animals after vincristine (0.5 mg/kg, i.p.) administration. Dotted line; number of F4/80+ cells 
in naïve animals. (L) Depletion of macrophages with liposomal clodronate, but not granulocytes with 
anti-Ly6G, reverses development of vincristine-induced mechanical allodynia. Treatment with 
vehicle (PBS: white bars; 10 μl/g i.p.), liposomal clodronate (lip. clodronate: black bars; 50 μg/g i.p.), 
isotype antibody control (isotype: dark grey bars; 200 µg i.p.) or anti-Ly6G antibody (anti-ly6G: light 
grey bars; 200 µg i.p.) did not affect baseline paw withdrawal threshold. Following administration of 
vincristine (0.5 mg/kg, i.p., 24 h) only treatment with liposomal clodronate significantly reversed 
mechanical allodynia. Immunohistochemistry and flow cytometry were performed with help of Lena 
Batoon and Allison Pettit. Statistical significance was determined by repeated measures two-way 
ANOVA with Sidak’s multiple comparisons test (A, B), unpaired two-tailed t-test (E, F, J, K) and 
two-way ANOVA with Tukey’s multiple comparisons test (L) and defined as p <0.05. All data are 
shown as mean ± SEM; n = 3-6 for all groups. ∗p <0.05.  
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4.1.1. The NLRP3 inflammasome is required for vincristine-induced mechanical allodynia 
and gait abnormalities 
In light of increasing evidence suggesting a crucial contribution of the NLRP3 inflammasome to 
many diseases involving sterile inflammation, I next sought to investigate development of VIPN in 
Nlrp3-/- mice. Consistent with VIPN being likely mediated by infiltrating macrophages, Nlrp3 
deficiency prevented mechanical allodynia (Fig. 22A and Appendix 3, Table 18S) and gait 
abnormalities (Fig. 22B and Appendix 3, Table 19S) in mice treated with vincristine. The systemic 
and local administration of vincristine induced significantly higher paw withdrawal thresholds in 
Nlrp3-/- mice compared to wt littermates (Fig. 22A and Appendix 3, Table 18S). Similarly, the paw 
print area in Nlrp3 -/- mice treated with vincristine (10 μg; i.pl.) was significantly different from the 
littermate control group on days 4, 7 and 11 (Fig. 22B and Appendix 3, Table 19S) (p > 0.05; repeated 
measures Two-way ANOVA with Sidak multiple comparison test). Similar results were also observed 
in C57BL6/J mice treated with the selective NLRP3 inhibitor MCC950 [392], which were protected 
from both mechanical allodynia (Fig. 22A and Appendix 3, Table 18S) and gait abnormalities (Fig. 
22B and Appendix 3, Table 19S) induced by vincristine. Additionally, a complete reversal of 
mechanical allodynia induced by intraplantar injection of very low (100 ng) doses of vincristine, 
which only induced short-lasting local effects, in Nlrp3-/- animals was observed (data not shown). 
4.1.2. Vincristine induces IL-1β release from human and murine macrophages 
Activation of the NLRP3 inflammasome leads to release of interleukin 1β (IL-1β), a pro-
inflammatory cytokine known to sensitize nociceptors [279]. I thus next examined IL-1β release in 
macrophages treated with vincristine. In LPS-primed human monocyte-derived macrophages, 
treatment with vincristine (4 h; 100 μM) caused significant release of IL-1β (312.31 ± 169.14 pg/ml) 
compared to control (11.70 ± 4.56 pg/ml), although this was modest compared to the positive control 
and strong NLRP3 agonist, nigericin (5 μM; 2759.45 ± 399.35 pg/ml, 45min) (Fig. 22C). Similarly, 
vincristine (4 h; 100 μM) caused a modest but significant release of IL-1β in LPS-primed bone-
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marrow derived macrophages (BMMs) from C57BL6/J mice (Control: 0 ± 0 pg/ml; vincristine: 
231.50 ± 43.71 pg/ml; p <0.05) but not in unprimed macrophages (control: 0 ± 0 pg/ml; vincristine: 
0 ± 0 pg/ml) (Fig. 22D). To better understand the signalling pathways that lead to vincristine-induced 
IL-1β release, I also investigated the ability of vincristine to prime the NLRP3 inflammasome. 
Interestingly, vincristine-primed BMMs released negligible amounts of IL-1β in response to the 
NLRP3 activator nigericin (5 μM; 30.42 ± 2.76 pg/ml), while nigericin induced considerable IL-1β-
release in LPS-primed BMMs (4749.00 ± 194.50 pg/ml; Fig. 22E). To determine whether vincristine-
induced IL-1β release could occur as a result of cell death and subsequent release of DAMPs (danger-
associated molecular patterns), I also assessed LDH release in LPS primed and unprimed 
macrophages. However, LDH release was not observed under conditions leading to robust IL-1β 
release (negative control (+LPS): 7.164 ± 0.28 % max LDH release; vincristine: 12.09 ± 0.28 % max 
LDH, positive control (+LPS + nigericin 5µM): 85.00 ± 3.58 % max LDH release, Fig. 22F), 
suggesting that vincristine-induced NLRP3 activation is not a result of cell death-induced DAMP 
release.   
The NLRP3 inflammasome signals via caspase-1 to cleave and activate the pyroptotic effector 
gasdermin-D (GSDMD). NLRP3 can be activated directly via the canonical signalling pathway or 
indirectly via a non-canonical pathway, which requires caspase-11 (casp11). (for review see [393]). 
I thus next assessed IL-1β release in BMMs derived from wt, Nlrp3-/-, Ice-/-(Casp1-/-/Casp11 null/null) 
[362], Casp11-/- or Gsdmd-/- animals. Consistent with the crucial contribution of NLRP3 to 
vincristine-induced gait abnormalities and mechanical allodynia, vincristine-induced IL-1β release 
was abolished in BMMs isolated from Nlrp3-/- animals (10.09 ± 3.37 pg/ml; Fig. 22G) and after 
treatment with the NLRP3 inhibitor MCC950 (1.14 ± 1.14 pg/ml, data not shown). I also observed 
cleavage of pro-IL-1β, casp1 and GSDMD as a result of vincristine treatment (Fig. 22H). Indeed, IL-
1β release was also decreased in BMMs from Ice-/- animals (lacking caspase-1 and caspase-11; 
control: 2.46 ± 0.75 pg/ml; vincristine: 5.85 ± 2.65 pg/ml), but not significantly decreased in BMMs 
isolated from Casp11-/- animals (control: 10.53 ± 3.52 pg/ml; vincristine: 83.59 ± 21.06) or from 
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Gsdmd-/- animals (control: 14.56 ± 7.29 pg/ml; vincristine: 62.01 ± 6.15) (Fig. 22G). The molecular 
pattern of vincristine-induced IL-1β release is thus reminiscent of canonical NLRP3 activation 
induced by the prototypical agonist nigericin, which also caused cleavage of pro-IL-1β, casp1 and 
GSDMD (Fig. 22H) and release of mature IL-1β that is dependent on caspase-1 but not caspase-11 
(Fig. 23; Nigericin-induced IL-1β release in wt: 2369.80 ± 607.01 pg/ml; Nlrp3-/- 7.44 ± 1.82 pg/ml; 
from Ice-/- 15.93 ± 6.49 pg/ml; Casp11-/- 1666.36 ± 723.59 pg/ml); Gsdmd-/- 203.73 ± 77.46 pg/ml). 
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Figure 22. Vincristine leads to activation of the NLRP3-inflammasome and IL-1β release. 
(A) Mechanical allodynia induced by vincristine (0.5 mg/kg; i.p.) does not develop in Nlrp3-/- animals 
(green symbols) and is attenuated by the NLRP3 antagonist MCC950 (blue symbols; 20 mg/kg; i.p.) 
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compared to wt (dark grey symbols) and PBS-treated (black symbols) controls, respectively. Black 
arrows indicate vincristine administration schedule, coloured arrows indicate MCC950 treatment 
schedule. (B) The decrease in paw print area induced by vincristine (10 μg; i.pl.) is abolished in Nlrp3-
/- animals (dark green) and after treatment with MCC950 (dark blue; 20 mg/kg; i.p.) compared to wt 
(dark grey symbols) and PBS-treated (black symbols) controls, respectively. Black arrows indicate 
vincristine administration schedule, coloured arrows indicate MCC950 treatment schedule. Statistical 
significance was determined using two-way ANOVA with Tukey’s multiple comparisons test. All 
data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05 (C-D) Vincristine induces significant 
release of IL-1β in human (C) and mouse (D) LPS-primed macrophages (E) Incubation of BMMs 
with vincristine does not prime the NLRP3 inflammasome. Nigericin (5 µM) treatment leads to 
release of IL-1β in LPS-primed, but not vincristine-primed, macrophages. (F) Vincristine treatment 
does not induce significant cell death, expressed as % of Lactate Dehydrogenase (LDH) release of 
100% lysis control. (G) Vincristine-induced release of IL-1β is abolished in Nlrp3-/- and Ice-/-, but not 
in Casp11-/- and only partially in Gsdmd-/- LPS primed BMMs. (H) Cleaved IL-1β (p17) and caspase-
1 (p20) are found in supernatants of vincristine-treated C57BL6/J LPS primed bone marrow derived 
macrophages but not in supernatants of cells isolated from Nlrp3-/- animals. Elisa and western blot 
analysis were performed with help of Mercedes Monteleone and Kate Schroder. Statistical 
significance was determined using one-way ANOVA with Tukey’s multiple comparison. All data are 
shown as mean ± SEM; n = 3 for all groups. ∗p <0.05. 
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Figure 23. Nigericin-induced IL-1β release in LPS-primed C57BL6/J, Nlrp3-/-, Ice-/-, Casp11-/- and 
Gsdmd-/- bone marrow derived macrophages. 
Statistical significance was determined using ordinary one-way ANOVA with multiple comparison. 
All data are shown as mean ± SEM; n = 3 for all groups. ∗p <0.05. 
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The canonical NLRP3-signalling pathway contributes to vincristine-induced mechanical 
allodynia 
To confirm the contribution of the NLRP3 pathway to the development of mechanical 
hypersensitivity and gait disturbances in vivo, I next investigated changes in paw withdrawal 
threshold and paw print area in Ice-/-, Casp11-/- and Gsdmd-/- animals following treatment with 
vincristine. Indeed, vincristine-induced mechanical allodynia was significantly reduced (p <0.05, 
repeated measures two-way ANOVA with Sidak’s multiple comparison correction) in Ice-/-, and 
Gsdmd-/- animals but not in Casp11-/- , compared to wt controls (Fig. 24A-C, and Appendix 3, Table 
20S and 21S). Specifically, the vincristine-induced decrease in PWT was attenuated in Ice-/- animals 
for the first 7 days and PWT values were significantly different (*, p <0.05) from wt animals (dotted 
line, cohort control as in Fig. 22A) on day 1,2 ,4 and 7 (Fig. 24A). Similarly, mechanical allodynia 
was attenuated in Gsdmd-/- animals, with PWT values significantly different from cohort controls 
(Fig. 24C and Appendix 3, Table 20S and 21S). In Casp11-/- animals, PWTs were not significantly 
different from wt controls (Fig. 24B and Appendix 3, Table 20S and 21S).  
To confirm that NLRP3-mediated IL-1β release contributes to the phenotype of vincristine-induced 
neuropathy, I also quantified mechanical allodynia in Il1b-/- and Il1r1-/- mice lacking IL-1β and the 
IL-1 receptor, respectively (Fig. 24D and E). Strikingly, Il1b-/- animals did not develop mechanical 
allodynia (p > 0.05; repeated measures Two-way ANOVA time factor comparison with Dunnett's 
multiple comparisons test) and PWTs oscillated around baseline values. Accordingly, PWTs in Il1b-
/- animals were significantly (p <0.05) different at all time points compared to cohort littermate control 
(Fig. 24D and Appendix 3, Table 22S and 23S). Similarly, the PWTs of Il1r1-/- animals were 
significantly (p <0.05) higher than control at day 1, 2 and 4 (Fig. 24E and Appendix 3, Table 22S 
and 23S). 
Sensory neurons can sense IL-1β, with this cytokine directly activating and sensitizing nociceptors 
via modulation of tetrotodoxin-resistant voltage-gated sodium channels (NaV) [279, 367]. 
Specifically, NaV1.9
-/- animals display partially reduced mechanical allodynia after intraplantar 
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injection of IL-1β [367], and I thus sought to assess whether vincristine-induced mechanical 
sensitization also involves NaV1.9. Indeed, consistent with the phenotype observed after direct 
administration of IL-1β, NaV1.9-/- animals were partially protected from vincristine-induced 
mechanical allodynia, with PWTs significantly different from controls on day 1 and 2 of vincristine 
treatment (Fig. 24F, and Appendix 3, Table 22S and 23S). 
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Figure 24. The canonical NLRP3-signalling pathway contributes to vincristine-induced mechanical 
allodynia. 
Mechanical allodynia induced by treatment with vincristine (black arrows; 0.5 mg/kg; i.p.) is 
attenuated in (A) Ice-/- animals (orange symbols); dotted line and light grey symbols are cohort 
controls also shown in Fig. 21A; not attenuated in (B) Casp11-/- animals (purple symbols) relative to 
wt controls (black symbols); attenuated in (C) Gsdmd-/- animals (pink symbols); dotted line and light 
grey symbols are cohort controls also shown in panel B; (D) Il1b-/- animals relative to wt controls 
(black symbols) and (E) Il1r1-/- animals; dotted line and light grey symbols are cohort controls also 
shown in panel D. (F) In NaV1.9
-/- animals, mechanical allodynia induced by vincristine (0.5 mg/kg; 
i.p.) is partially attenuated; dotted line and light grey symbols are cohort controls also shown in panel 
D. Statistical significance was determined using repeated measures two-way ANOVA with Sidak’s 
multiple comparisons test. All data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05.  
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4.1.3. The canonical NLRP3-signalling pathway contributes to vincristine-induced gait 
disturbances 
To confirm that both mechanical allodynia and gait disturbances induced by vincristine are driven by 
similar mechanisms, I next also assessed gait disturbances in Ice-/-, Casp11-/-, Gsdmd-/-, Il1b-/-, Il1r1-
/- and NaV1.9
-/- animals. Similar to my findings with vincristine-induced mechanical allodynia, the 
decrease in paw print area following vincristine treatment (10 μg; i.pl.) was partially inhibited in Ice-
/- animals and significantly different from cohort controls (dotted line, control data shown in Fig. 
22B) on days 7 and 11 (Fig. 25A and Appendix 3, Table 24S).  
Consistent with the results shown in Fig. 24B, vincristine-induced gait abnormalities were also 
decreased in Gsdmd-/- animals (Fig. 25C and Appendix 3, Table 24S). Interestingly, Casp11-/- 
animals were also partially protected from gait abnormalities (Fig. 25B and Appendix 3, Table 24S) 
implying that motoric neuropathy involves additional signalling pathways or cell types. Compared 
with the cohort control, paw print area values were significantly different for both Gsdmd-/- and 
Casp11-/- animals on multiple days (Fig. 25B and C and Appendix 3, Table 24S). Additionally, Il1b-
/- animals were protected from development of gait disturbances, with the paw print area of Il1b-/- 
mice significantly (p <0.05) increased compared to cohort controls (Fig. 25D and Appendix 3, Table 
25S). Il1r1-/- mice also only slowly developed a partial gait disturbance (Fig. 25E and Appendix 3, 
Table 25S), with paw print area values significantly different from cohort control (dotted line, control 
data shown in Fig. 25D) on days 4 and 7. In contrast, Nav1.9 -/- animals were not protected from 
vincristine-induced gait disturbances, although there was a non-significant trend towards increased 
paw print areas on days 4 and 7 (Fig. 25F and Appendix 3, Table 25S). 
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Figure 25. The canonical NLRP3-signalling pathway contributes to vincristine-induced gait 
disturbances. 
Gait disturbances, evidenced by a decrease in the ipsilateral paw print area (shown as % of 
contralateral), induced by treatment with vincristine (black arrows; 10 μg; i.pl.) is attenuated in (A) 
Ice-/- animals (orange symbols); dotted line and light grey symbols are cohort controls also shown in 
Fig. 21B; (B) Casp11-/- animals (purple symbols) relative to wt controls (black symbols); (C) Gsdmd-
/- animals (pink symbols); dotted line and light grey symbols are cohort controls also shown in panel 
B; (D) Il1b-/- animals relative to wt controls (black symbols) and (E) Il1r1-/- animals; dotted line and 
light grey symbols are cohort controls also shown in panel D. (F) In NaV1.9
-/- animals, gait 
disturbances induced by vincristine are not significantly decreased; dotted line and light grey symbols 
are cohort controls also shown in panel D. Statistical significance was determined using repeated 
measures two-way ANOVA with Sidak’s multiple comparisons test. All data are shown as mean ± 
SEM; n = 6 for all groups. ∗p <0.05. 
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4.1.4. The IL-1R antagonist anakinra prevents development of vincristine-induced 
mechanical allodynia and gait disturbances 
NLRP3-mediated diseases such as familial cold auto-inflammatory syndrome (FCAS) are currently 
treated with biologics targeting IL-1β signalling, including the IL-1R antagonist anakinra. I thus 
sought to evaluate the effect of anakinra on the development of vincristine-induced mechanical 
allodynia and gait disturbances. Co-administration of anakinra (100m/kg; i.p.) with vincristine (0.5 
mg/kg; i.p. or 10 μg; i.pl.) significantly decreased mechanical hypersensitivity over the 11 days of 
treatment (Fig. 25A and Appendix 3, Table 26S), with PWT values of the anakinra-treated group 
being significantly higher than the vehicle-treated group at all time points. Similarly, the development 
of gait abnormalities was delayed by treatment with anakinra (100 mg/kg; i.p) and was significantly 
different from vehicle controls (PBS; i.p.) (Fig. 26B and and Appendix 3, Table 26S). However, 
anakinra treatment did not have any positive effect on oxaliplatin and cisplatin induced mechanical 
allodynia (Fig. 27). 
4.1.5. Treatment with anakinra does not adversely affect tumour progression or vincristine 
efficacy in medulloblastoma patient-derived xenograft models  
My data convincingly demonstrate that symptoms of vincristine-induced neuropathy, including 
mechanical allodynia and gait disturbances, are mediated by NLRP3-dependent IL-1β release, and 
that the IL-1R antagonist anakinra can prevent development of these adverse effects. However, a key 
consideration of putative anti-allodynic treatments is their effect on tumour progression and 
chemotherapy efficacy. As vincristine is commonly used for the treatment of childhood 
medulloblastomas, I thus sought to investigate the effect of anakinra administration in 
medulloblastoma patient-derived xenograft (PDX) models. The detailed drug injection schedule is 
shown in Fig. 26C. No significant difference was observed between the groups treated with saline 
(i.p.) or anakinra (i.p., 100 mg/kg) in the number of days required for Med-211FH and Med-411FH 
tumours to reach maximum tumour size (2000 mm3) (Fig. 26D and E) (saline: 10-18 days to reach 
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maximum volume; anakinra: 11-18 days to reach maximum volume). Similarly, the slowly growing 
Med1712FH tumours progressed at rates indistinguishable from control during prolonged (28 day) 
anakinra administration (data not shown). Treatment with anakinra also did not affect the ability of 
vincristine to induce complete tumour regression, with quantitative analysis of mice co-treated with 
anakinra and vincristine revealing no significant difference in the number of days for vincristine to 
induce complete tumour regression (Fig. 26F and G and not shown) (vincristine: 11-18 days till the 
complete tumour regression, vincristine + anakinra: 11-18 days till the complete tumour regression, 
saline or anakinra: no tumour regression, data not shown). Overall, these results demonstrate that 
anakinra administration reduces vincristine-induced neuropathy without adversely affecting cancer 
progression or chemotherapy efficacy. 
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Figure 26. Anakinra treatment prevents the development of vincristine-induced peripheral 
neuropathy without significant effect on tumour progression or chemotherapy efficacy. 
(A) In animals receiving vincristine (0.5 mg/kg; i.p.), co-administration of anakinra (purple symbols; 
100 mg/kg; i.p.) fully prevents development of mechanical allodynia compared to animals treated 
with vehicle (black symbols; PBS i.p.). Black arrows, vincristine administration; purple arrows, 
anakinra/PBS administration schedule. (B) Gait disturbances induced by administration of vincristine 
(10 μg; i.pl.) are significantly (p <0.05) delayed in animals treated with anakinra (purple symbols; 
100 mg/kg; i.p.) compared to animals treated with vehicle (black symbols; PBS i.p.). Black arrows, 
vincristine administration; purple arrows, anakinra/PBS administration schedule. Statistical 
significance was determined using repeated measures two-way ANOVA with Sidak’s multiple 
comparisons test. All data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05. (C) Detailed 
time schedule of drug administration in Med-211FH and Med-411FH medulloblastoma patient-
derived xenograft models. Mice were injected with Med-211FH and Med-411FH medulloblastoma 
cells and tumour volume measurements were taken bi-weekly. Anakinra (light purple, i.p., 100 
mg/kg) or saline (light orange, i.p.) treatment commenced when subcutaneous tumours reached 100 
mm3 in size (stage 1). Vincristine (dark orange, i.p., 0.25mg/kg), anakinra (light purple i.p., 100 
mg/kg), saline (light orange, i.p.) or anakinra (i.p., 100 mg/kg) + vincristine (i.p., 0.25mg/kg) (dark 
purple) injections commenced when subcutaneous tumours reached 300 mm3 in size (stage 2) and 
treatment was administered for 4 weeks daily or until maximum tumour size was reached (2000 mm3). 
(D and E) Effect of anakinra on tumour growth in Med-211FH and Med-411FH medulloblastoma 
patient-derived xenograft models. Daily treatment with anakinra (light purple; 100 mg/kg i.p.) had 
no effect on time to reach maximum tumour size (2000 mm3) in animals with a subcutaneously 
implanted Med-211FH (C) or Med-411FH (D) tumour compared to controls (light orange symbols). 
(F and G) Effect of anakinra on vincristine-induced complete tumour regression in Med-211FH and 
Med-411FH medulloblastoma patient-derived xenograft models. Daily treatment with anakinra (dark 
purple symbols; 100 mg/kg i.p.) had no effect on the ability of vincristine (0.25mg/kg i.p. three 
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times/week for 4 weeks) to induce regression of Med-211FH (F) or Med-411FH (G) tumours 
compared to control animals treated only with vincristine (dark orange symbols). Medulloblastoma 
patient-derived xenograft model studies were performed with help of Christelle Adolphe, Elissa 
Tolson, Amanda Mayor and Brandon Wainwright. Statistical significance was determined using two-
sided t-test and defined as p <0.05. 
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Figure 27. Effect of anakinra treatment on oxaliplatin and cisplatin induced mechanical allodynia. 
Anakinra treatment (100mg/kg, i.p.) does not have effect on oxaliplatin and cisplatin induced 
mechanical allodynia. Statistical significance was determined by one-way ANOVA and defined as p 
<0.05 compared to control (VC i.pl.; OX i.pl. or CIS i.pl.. All data are shown as mean ± SEM; n = 6 
for all groups. ∗p <0.05. 
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4.2. Discussion 
Vincristine-induced neuropathy – a term describing impaired sensory, autonomic and motor neuron 
function occurring during treatment with the anti-cancer agent vincristine – remains a particularly 
troublesome side effect of chemotherapy that is currently managed largely through dose adjustments, 
and that can have severe impacts on quality of life. The vinca alkaloids are typically considered 
cytotoxic anti-cancer drugs that act during cellular mitosis due to their effects on microtubules. These 
effects have also been postulated to contribute to neurotoxicity due to effects on the anterograde 
transport of neuronal proteins [394-396]. However, in recent years it has become increasingly clear 
that vincristine-induced neuropathy is not simply a cell type-specific consequence of the known 
pharmacological activity of vincristine, but a complex symptom involving considerable neuro-
inflammatory components. Specifically, vincristine has been shown to induce infiltration of 
circulating monocytes into peripheral nerves, with CX3CR1-positive cells contributing to initiation, 
and CCR2-positive cells contributing to maintenance of vincristine-induced neuropathy [175, 347]. 
Similarly, vincristine treatment leads to a striking upregulation of genes related to immune cell 
recruitment and inflammatory processes in DRG, consistent with a functional contribution of 
infiltrating immune cells to vincristine-induced neuronal dysfunction [259, 291]. However, the 
molecular signalling pathways underpinning these processes have remained elusive. As a major 
molecular complex mediating macrophage-induced inflammation, I thus investigated whether the 
NLRP3 inflammasome drives vincristine-induced neuropathy.  
NLRP3 is an innate immune sensor for microbial infections, as well as host-derived DAMPs, that 
signal cell damage or stress under sterile inflammatory conditions [397, 398]. Activation of NLRP3 
and its signalling adaptor (ASC) leads to recruitment of the cysteine protease caspase-1, forming a 
complex termed the inflammasome [397, 398]. This unleashes caspase-1 protease activity, which in 
turn cleaves and activates the pro-inflammatory cytokines IL-1β and IL-18, as well as the cell 
executioner gasdermin-D [399-401]. Collectively, these so-called canonical NLRP3 signalling 
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processes result in secretion of pro-inflammatory cytokines and often induces a type of inflammatory 
cell death known as pyroptosis [402-405]. However, caspase-1-dependent release of IL-1β can also 
occur in a gasdermin-D independent manner without induction of pyroptosis [406]. Release of 
cytokines after treatment with vincristine has been reported clinically as well as in a range of animal 
models [407]. Notably, my results show for the first time that vincristine directly causes NLRP3-
dependent IL-1β release, paralleled by cleavage of pro-gasdermin-D and caspase-1, in mouse 
macrophages (Fig. 16C-H). Although IL-1β release was modest compared to the prototypical NLRP3 
activator nigericin, this is perhaps not surprising given that vincristine causes predominantly 
symptoms of peripheral neuropathy, but not systemic inflammation such as fever, which is apparent 
in sepsis or NLRP3-mediated conditions such as Cryopyrin-associated periodic syndrome (CAPS) 
[402]. Moreover, the priming and activation of the NRLP3 requires multiple signals (for review see 
[408]) and the exact conditions leading to NLRP3 dependent release of IL-β in vivo during 
pathological conditions are difficult to reproduce in experimental settings. Therefore, further studies, 
investigating the exact molecular mechanisms leading to vincristine induced activation of NLRP3 
and its contribution to VIPN will be examined in future studies. The concentration of vincristine used 
in those experiments was rather high (100 µM), however, the development of vincristine-induced 
neuropathy appears to incorporate a substantial time- in addition to dose-dependent factor, with lower 
doses of vincristine leading to slower development of neuropathy symptoms [371]. Thus, further 
studies investigating the time-dependence of IL-1β release from macrophages would be of 
considerable interest. Nonetheless, vincristine-induced allodynia and gait disturbances were 
significantly reduced in Nlrp3-/-, Casp1-/-, Gsdmd-/-, Il1b-/- and Il1r1-/- mice, suggesting that 
inflammasome activation and cytokine release likely occurs in immune cells in close proximity to 
sensory neurons and that these processes are crucial for development of neuropathy. As I examined 
the effects of global NLRP3 knockout on VIPN development, a cell specific knockout of NLRP3, for 
example in macrophages and primary sensory neurons using for example, Cre floxed mice would 
help to reveal the contribution of different cell types in development of VIPN and should be addressed 
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in future studies. Nevertheless, the interpretation of any findings from Cre floxed animals would need 
to be viewed with caution. For example, Advillin-Cre mice are often touted “sensory-neuron specific” 
[409], however, this actin regulatory protein belonging to the gelsolin/villin family is involved in 
macrophage phagocytosis and cytoskeletal remodelling [410]. Interestingly, vincristine-induced IL-
1β release was only apparent in primed macrophages, but vincristine was unable to prime the 
inflammasome, with no IL-1β release apparent in macrophages co-treated with vincristine and 
nigericin (Fig. 16E). The mechanisms leading to vincristine-mediated NLRP3 activation thus seem 
to differ from the microtubule-stabilizing chemotherapeutic paclitaxel, which does not cause IL-1β 
release in LPS-primed macrophages, but can directly prime macrophages leading to activation of 
caspase-1 by inflammasome-activating signals such as nigericin or ATP [411]. These results are 
consistent with my previous observation that vincristine-induced neuropathy is reduced in Tlr4-/- mice 
[259], although the endogenous signals leading to macrophage priming and NLRP3 activation in vivo 
in response to vincristine treatment remain unclear. However, NLRP3 is expressed in different cell 
types, including DRG [335, 412], and primary sensory neurons and satellite cells were shown to 
produce IL-1β [413, 414]. Moreover, sensory neuron specific knockout of NLRP3 attenuates 
postoperative mechanical hypersensitivity [415] and increased expression of NLRP3 in rodent DRG 
was shown to contribute to development of painful neuropathy following bortezomid administration 
[349]. Therefore, the contribution of other immune or non-immune cell types and the role of neuronal 
NLRP3 in development of VIPN remains unclear and requires further studies. While specifically the 
expression of NLRP3 was not assessed, several studies reported differential expression of NLRP3 in 
murine models of CIPN [261, 416, 417]. However, increased expression of NLRP3 alone does not 
provide evidence of the NLRP3 activation, hence I examined NLRP3 dependent release of IL-1β in 
wt and NLRP3-/- bone marrow derived macrophages and confirmed the activation of NLRP3 and 
caspase 1 using western blots. Nevertheless, the differential expression of NLRP3 and other 
molecules involved in the NLRP3 dependent release of IL-1β in specific cell types, may provide 
further information and will be assessed in future studies.  
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The NLRP3 inflammasome has also recently been implicated in post-surgical pain, where mechanical 
allodynia was significantly attenuated in male, but less so in female Nlrp3-/- mice [418]. Interestingly, 
the phenotype of female global Nlrp3-/- mice was recapitulated in female sensory neuron-specific 
Nlrp3-/- mice, suggesting an important role for immune cell-associated NLRP3 in males. In contrast, 
I observed no sex-specific differences in vincristine-induced neuropathy [259] and macrophage 
depletion using liposomal clodronate prevented mechanical allodynia equally in male and female 
animals. These results suggest that NLRP3-expressing mast cells or neutrophils may have a sex-
specific role in post-surgical pain [415], whereas vincristine-induced neuropathy is driven by 
macrophage activation pathways common to both males and females. While it may be tempting to 
speculate that the NLRP3 inflammasome could contribute to inflammatory pain more broadly, it was 
previously reported that burns injury-induced allodynia and neuropathic pain in the spared nerve 
injury model develop independently of NLRP3 [419, 420], highlighting the complexities of model- 
and modality-specific pain mechanisms. 
In addition to IL-1β, activation of the NLRP3 inflammasome can also lead to maturation and release 
of IL-18, which may contribute to the development of pain via activity at the IL-18-receptor [421]. 
Indeed, while I did not specifically assess the effects of vincristine on IL-18 release, contributions of 
cytokines other than IL-1β to vincristine-induced neuropathy cannot be ruled out, although several 
lines of evidence – including significant reductions in both mechanical allodynia and gait disturbances 
in Il1b-/- mice, Il1r1-/- mice and after treatment with anakinra – support a major role for IL-1β 
signalling. The observation that Il1b deletion appears to provide stronger protection than that 
observed in Il1r1-/- mice suggests that IL-1α may provide a protective role in this model. It is 
intriguing to note that microglia are enriched for IL-1α, while peripheral macrophages are enriched 
for IL-1β [422]. Accordingly, treatment with a poorly blood spinal cord barrier-permeable IL1 
receptor antagonist such as anakinra could be expected to ameliorate pro-nociceptive IL-1β  signalling 
in the periphery but without affecting potentially protective IL-1α signalling centrally. Such a 
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mechanism could explain why anakinra appeared to perform better than Il1r Kos, and will require 
further studies. 
Interestingly, anakinra and vincristine are both relatively poorly blood-brain-barrier-permeant, 
suggesting that vincristine-induced neuropathy is predominantly a peripherally-driven pathology, 
despite previous reports of vincristine-induced inflammatory changes in the spinal cord [423]. While 
activation of central microglia or astrocytes may contribute to vincristine-induced neuropathy, it is 
possible that these changes occur downstream of peripheral sensitization, and indeed, I also observed 
a complete reversal of mechanical allodynia induced by intraplantar injection of very low (100 ng) 
doses of vincristine, which only induces short-lasting local effects, in Nlrp3-/- and Ice-/- animals (data 
not shown). Irrespective of its site of action, IL-1β is well known to elicit sensory neuron sensitization 
via post-translational modification of a range of ion channels, including transient receptor potential 
channels TRPA1 and TRPV1, NMDA and GABA receptors, as well as voltage- gated K+, Ca2+ and 
Na+ channels [279, 368-372]. Notably, intradermal injection of IL-1β causes pain hypersensitivity 
that is reduced, but not entirely abrogated, in NaV1.9
-/- animals [367, 424], a phenotype that was 
mirrored in vincristine-treated animals. While the modest reduction in vincristine-induced allodynia 
in NaV1.9
-/- animals could be considered disappointing, this observation is perhaps consistent with 
IL-1β enhancing neuronal excitability through multiple effectors. Indeed, these mechanisms might 
explain why a range of conventional and adjuvant analgesics targeting these neuronal signalling 
pathways have failed to show efficacy in vincristine-induced neuropathy, and suggest that targeting 
NLRP3- or IL-1β signalling is a much more promising analgesic strategy.  
However, a major consideration must necessarily be the effect of any analgesic treatment on tumour 
progression and chemotherapy efficacy, particularly in case of inflammasome-targeting treatments 
where emerging evidence suggests varied disease-modifying effects. For example, tumour 
progression and metastasis of melanoma, gastric and colon cancer were shown to be driven by IL-1β 
[425-428] and thus inhibition of IL-1β signalling might be beneficial. On the other hand, IL-1β was 
also shown to contribute to the regression of murine B16 melanoma hepatic metastases [429]. In the 
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context of the most common oncology indications for vincristine treatment, such as 
medulloblastomas, the role of NLRP3- and IL-1β-signalling is less clear. My results show for the first 
time that anakinra has, at a minimum, no detrimental effects on patient-derived medulloblastoma 
growth or vincristine-mediated tumour regression. My studies thus suggest that addition of anakinra 
to certain chemotherapy regimens may be a viable treatment approach for the prevention of 
vincristine-induced neuropathy. However, the positive effect of anakinra on the development of 
neuropathy symptoms seems to be substance specific, as I did not observe any increase of mechanical 
thresholds following the co-treatment with anakinra and oxaliplatin or anakinra and cisplatin. The 
clinical efficacy of these interventions, as well as the contribution of NLRP3 signalling to 
chemotherapy-induced neuropathy induced by other agents, remains to be determined for each cancer 
type and chemotherapy regimen individually. Ultimately, the treatment approach of co-administering 
anakinra alongside vincristine aims to reduce suffering of patients treated with vincristine, and will 
enable patients to carry through with chemotherapy, which in turn will lead to better outcomes for 
cancer patients who are undergoing treatment with vincristine. 
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4.3. Conclusion 
In summary, this study shows for the first time that vincristine activates the NLRP3 inflammasome 
via the canonical signalling pathway leading to release of IL-1β without inducing pyroptosis and that 
inhibition of NLRP3 or IL-1β signalling prevents development of vincristine-induced mechanical 
hypersensitivity and gait abnormalities. Moreover, I have delineated novel contributions of 
inflammasome pathway members and associated proteins, including caspase-1 and gasdermin-D, to 
sensory neuron dysfunction for the first time and suggest that based on the mechanistic insights 
described herein, repurposing of biologics targeting IL-1β signalling is a highly promising approach 
to improve the therapeutic window of vincristine. 
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5.  CHAPTER 5: Overall discussion and conclusion 
Much effort has been invested in the understanding of the mechanism of vincristine induced 
peripheral neuropathy (VIPN) development and to find effective treatments controlling this side 
effect of vincristine [1]. However, up to date there is not an effective treatment which would prevent, 
or control the symptoms of VINP leaving vincristine treated cancer patients, especially children, with 
an additional heavy burden that decreases their quality of life and their survival chance [75, 292]. 
This project aimed to understand the mechanism of development of VIPN, to identify new targets 
and to test new preventative therapies for VIPN.  
In chapter two I presented a new animal model of VIPN that allowed me to reproduce several 
sensorimotor symptoms of VIPN. Although the new model, based on i.pl. injections, is rather 
different to conventional VIPN models that use i.p. injections, it is a useful tool for future 
pharmacological studies. It reproduced, beside the usual mechanical allodynia seen following i.p. 
injections, also mechanical and heat hypoalgesia and gait disturbances. Moreover, the local injections 
of vincristine allowed me to isolate vincristine effects on peripheral nerves and led to dysregulation 
of a vast number of genes expressed in DRGs and surrounding cells, such as infiltrating immune cells, 
providing valuable insights into VIPN pathology. Additionally, the transcriptomic analysis of whole 
DRG following i.pl. administration of vincristine, oxaliplatin or cisplatin presented in chapter three, 
allowed me to compare the changes in RNA expression profiles following the treatment of all three 
drugs in peripheral nerves and provided valuable insights into CIPN pathology in general. 
In chapter four I presented that vincristine causes NLRP3 and caspase-1 dependent release of IL-1β 
and that the inhibition of NLRP3 by MCC950 or IL-1R by anakinra protected vincristine treated 
animals from development of mechanical allodynia and gait disturbances. Moreover, my results were 
supported by the fact that Nlrp3-/- and Il1β-/- animals did not develop those symptoms of VIPN. My 
results clearly showed that NLRP3 signalling and IL-1β play a crucial role in development of VIPN 
and that the inhibition of those signalling pathways is an effective strategy preventing vincristine 
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induced sensory-motor neuropathy development. The results presented in this thesis provide valuable 
insights into the pathology of VIPN, but also raise some additional questions. 
For example, to date there is only a handful of specific NLRP3 inhibitors with various mechanisms 
of NLRP3 inhibition. The small-molecule MCC950 inhibits the canonical and non-canonical 
activation of the NLRP3 inflammasome [277], while the ketone metabolite β-hydroxybutyrate 
inhibits only the canonical activation of the NLRP3 inflammasome via inhibition of potassium efflux 
[430]. The Type I Interferons, including IFN-α and IFN-β, inhibit the NLRP3 dependent production 
of IL-1β and IL-18 through yet unknown mechanism [431]. Additionally, the induction of autophagy 
by e.g. resveratrol or the inhibition of NLRP3 expression by MicroRNA-223 inhibits NLRP3 
activation [432, 433]. However, only few of the above-mentioned inhibitors were tested in clinical 
studies and the lack of use of effective NLRP3 inhibitors in the clinical practice raises the question 
whether NLRP3 is a promising target to treat VIPN. Therefore, further studies are required for deeper 
understanding of the effect of NLRP3 inhibition on peripheral nerve sensitization and VIPN. 
Additionally, the activation of NLRP3 is an important signal that regulates the immune response and 
the various side effects caused by the inhibition of NLRP3 could be detrimental for patients. For 
example, the inhibition of NLRP3 inhibits the first defensive response to bacterial infections and may 
results in increased susceptibility of patients to infectious diseases. Another important question is 
whether patients will profit more from direct NLRP3 inhibition or rather form targeting the IL-1β 
effects. The activation of NLRP3 also leads to release of IL-18, a cytokine with important immune-
regulatory effects and to cleavage of gasdermin-D and pyroptosis, both amplifying the immune 
response.  
On the other hand, NLRP3 dependent caspase-1 activation was shown to cleave the glucocorticoid 
receptor (GCR), leading to lower cellular levels of GCR, contributing to the glucocorticoid resistance 
of primary leukaemia cells from patients resistant to prednisolone treatment [434]. Therefore, the 
direct inhibition of NLRP3 could have positive effect on glucocorticoid resistance, which commonly 
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develops following the treatment of many anti-cancer regimen, containing glucocorticoids and 
vincristine and leads to higher risk of early treatment failures [435-438]. 
In chapter four I showed that Il1β-/- and Il1r-/- animals and animals treated with the specific IL-1R 
receptor inhibitor anakinra were protected from VIPN and that anakinra had no effect on tumour 
progression and vincristine efficacy in meduloblastoma PDX models. Therefore, anakinra treatment 
appears to be a safe addition to vincristine for the tested meduloblastoma cell lines, but the effect of 
anakinra on other cancer types remains to be determined in future studies and has to be carefully 
examined because the inhibition of NLRP3 dependent IL-1β release may drastically influence the 
tumour progression. For example, the tumour progression and metastasis of melanoma, gastric and 
colon cancer were shown to be driven by IL-1β [425-428], whereas the inhibition of IL-1β delayed 
the regression of the murine B16 melanoma hepatic metastases [429].  
Nevertheless, the use of anakinra as a preventative treatment of VIPN also have many advantages. 
For example, anakinra has been used for decades in the clinical practice for the treatment of 
inflammatory diseases, such as rheumatoid arthritis and has a well-defined adverse effect profile. 
Anakinra is administered subcutaneously and the administration can be performed comfortably at 
home by the patient. Additionally, many cancer patients have concomitant diseases, such as cancer 
induced bone pain, post-operative pain or rheumatoid arthritis, in which NLRP3 or IL-1β has been 
implied to be the driving component, and the inhibition of those targets may have altogether positive 
outcomes on patients health and disease progression [418, 439-442].  
Moreover, I showed that vincristine causes NLRP3 dependent release of IL-1β in macrophages and 
the depletion of macrophages, but not neutrophils, protected animals from development of 
mechanical allodynia following vincristine administration, underpinning that NLRP3 and 
macrophages play a crucial role in development of VIPN. However, it is still not known how 
vincristine activates the NLRP3 inflammasome in macrophages and the involvement of other cell 
types and will be considered and investigated in future studies. Similarly, the exact mechanism of 
NLRP3 activation by vincristine is unknown and will be investigated in future studies.  
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Altogether, results presented in this thesis provide invaluable insights in the mechanism of vincristine 
induced peripheral neuropathy development and chemotherapy induced neuropathy in general. 
Moreover, my findings provided evidence that anakinra will be a safe addition to chemotherapy 
regimens, preventing VIPN development and provides preliminary data for future basic research and 
clinical studies.   
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7.  Appendix 1: Alphabetical list of Materials 
Name  Source  Catalogue No. 
7-amino actinomycin D   Life Technologies  A1310 
Anakinra (Kineret®)  Sobi  
 
Anti- caspase-1   AdipoGen  casper-1 
Anti-CD115-PE  Biolegend, San Diego, CA, USA  clone AFS98 
Anti-CD11b BV510  Biolegend, San Diego, CA, USA  M1/70 
Anti-F4/80   Novus Biological, CO, USA  clone Cl:A3-1 
Anti-F4/80-Alexa647   AbD Serotec, Kidlington, UK  clone BM8 
Anti-IL-1β   R&D Systems  SCZ-SCAF-401-NA 
Anti-Ly6C APC/Fire 750  Biolegend, San Diego, CA, USA  clone HK1.4 
Anti-Ly6G PE/Cy7   Biolegend, San Diego, CA, USA  clone 1A8 
BD ultrafine insulin syringe  BD  324920 
C57BL6/J mice  UQ central breeding facility, 
Herston, Queensland, Australia 
 
 
Casp11-/-  mice  TASQ/UQBR, AIBN Building 
#75, The University of Queensland 
St Lucia QLD 4072, Australia 
 
 
CatwalkXT   Noldus Information Technology, 
Netherlands 
 
 
Cell strainer   Bio-Strategy Pty Limited   BDAA352340 
Cisplatin (cis-
Diammineplatinum(II) 
dichloride) 
 Sigma Aldrich  C2210000 
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Clodronate liposomes   Liposoma Research  CP-005-005 
Control liposome-encapsulated 
PBS  
 Liposoma Research  CP-005-005 
CytoTox96 Non-radioactive 
Cytotoxicity Assay (LDH Kit) 
 Promega Corporation   G1780 
Digital Vernier calipers   Kincrome, Vic, Australia  
 
DMEM  Thermo Fisher Scientific  A4192101 
Dulbecco’s phosphate buffered 
saline 
 Life Technologies Australia Pty 
Ltd Invitrogen 
 14190250 
Electronic von Frey apparatus   MouseMet, Topcat Metrology Ltd, 
United Kingdom 
 
 
Fetal calf serum  Focus Bioscience Pty Ltd  35-076-CV  
Gabapentin  Sigma Aldrich  PHR1049-1G 
GAPDH   BioScientific  2275-PC-100 
Glucose  Sigma Aldrich  G8270-100G 
GlutaMAX  Life Technologies Australia Pt  35050061 
GSDMD  Abcam  EPR19828 
Gsdmd -/- mice  TASQ/UQBR, AIBN Building 
#75, The University of Queensland 
St Lucia QLD 4072, Australia 
 
 
Hamilton glass syringe  Sigma Aldrich  20788 
Hargreaves test  IITC Life Science Inc.  
 
Human CSF-1   Produced in insect cells by the 
University of Queensland Protein 
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Expression Facility, Queensland, 
Australia 
Ice-/- mice  TASQ/UQBR, AIBN Building 
#75, The University of Queensland 
St Lucia QLD 4072, Australia 
 
 
Il1b-/-  BRF Breeding Facility, 
Translational Research Institute, 
Queensland, Australia 
 
 
Il1r1-/-  BRF Breeding Facility, 
Translational Research Institute, 
Queensland, Australia 
 
 
Isoflurane Isoflo Abbott    Provet Queensland   ISOF 04 
Isotype control antibody for 
F4/80  
 Biolegend, San Diego, CA, USA  normal rat IgG2b 
Ketamine   Provided by Translational 
Research Institute, Queensland, 
Australia 
 
 
LPS-EK Ultrapure  Jomar Life Research (Life 
Research Pty Ltd) 
 2068-78-2 
LY6G control antibody with 
endotoxin <0.5eu/mg 
 Bio X Cell, Assay Matrix Pty Ltd   BE0089-5mg 
LY6G mouse antibody with 
<0.5eu/mg 
 Bio X Cell, Assay Matrix Pty Ltd   BE0075-1-5mg 
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MCC950   Provided by Avril Robertson, 
Institute for Molecular Bioscience, 
Queensland, Australia 
 
 
Med1712FH cells  generated in the Olson lab, Seattle 
Children's Research Institute, 
Seattle, USA 
 
 
Med-211FH cells  generated in the Olson lab, Seattle 
Children's Research Institute, 
Seattle, USA 
 
 
Med-411FH cells  generated in the Olson lab, Seattle 
Children's Research Institute, 
Seattle, USA 
 
 
Meloxicam  ABCAM Australia Pty Ltd   ab141955 
Minocycline   Sigma Aldrich  M9511-250MG 
MouseMet Thermal  MouseMet, Topcat Metrology Ltd, 
United Kingdom)  
 
 
NaV1.9-/-   University of Queensland's 
Biological Resources, The 
Pharmacy Australia Centre of 
Excellence, Queensland, Australia 
 
 
Nigericin   Sigma Aldrich  N7143-5MG 
Nlrp3 -/- mice  TASQ/UQBR, AIBN Building 
#75, The University of Queensland 
St Lucia QLD 4072, Australia 
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NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/Szj mice 
 The Jackson Laboratory  005557/NSG 
OptiMEM  Life Technologies Australia Pty 
Ltd Invitrogen 
 31985070 
Oxaliplatin  Sigma Aldrich  O9512-5MG 
Paraformaldehyde powder, 95%  Sigma Aldrich  158127-500G 
Ugo basile hot/cold plate  Stoelting  55075 
R&D Systems mouse IL-1 beta 
kit  
 In Vitro Technologies Pty Ltd  RDSDY401 
RNAlatter   Invitrogen  AM7021 
RNeasy Mini Kit  Qiagen Pty Ltd  D583 
RPMI 1640 media   Life Technologies Australia Pty 
Ltd Invitrogen 
 R7388-500ML 
Sterilin plates   Thermo Fisher Scientific  SLN109  
Tissue-Tek O.C.T. compound  ProSciTech  IA018 
Tlr4-/- mice   TASQ/UQBR, AIBN Building 
#75, The University of Queensland 
St Lucia QLD 4072, Australia 
 
 
Vincristine sulphate  Sapphire Bioscience, Australia  A10973 
Welch® peristaltic pump  Sigma Aldrich  3200C-02 
Xylazine   Provided by Translational 
Research Institute, Queensland, 
Australia 
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8. Appendix 2: Supplementary methods 
8.1. Phosphate-buffered saline (PBS), pH7.4 
Composition: 
• 137 mM NaCl 
• 2.7 mM KCl 
• 10 mM NaH2PO4 (Sodium phosphate, dibasic) 
• 1.8 mM KH2PO4 (Potassium phosphate, dibasic) 
• dH2O 
8.2. Glucose 5 % solution for injection 
Composition: 
• 5 g Glucose 
• 100 ml Phosphate-buffered saline (PBS), pH7.4 
8.3. Paraformaldehyde solution 4% 
Composition: 
• Paraformaldehyde powder (40 g) 
• 1X PBS (1 L)  
• NaOH (1 N) and HCl (Dilute) for pH adjustment 
8.4. Decalcification solution 
Composition: 
• 666 ml dH2O  
• 333 ml concentrated HCl (32%) 
• 1.8 g Tartrate/tartaric acid 
• 0.9 g ethylenediaminetetraacetic acid (EDTA) 
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8.5. Organic Compound Tissue 50% in PBS 
Composition: 
• 50 ml Organic Compound Tissue  
• 50 ml Phosphate-buffered saline (PBS), pH7.4 
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9. Appendix 3: Supplementary Data 
Table 8S. Mechanical paw withdrawal threshold following single daily injections of vincristine. 
Mechanical paw withdrawal threshold (PWT) values following single daily injections of vincristine 
(i.pl; 10 µl solution containing 10 µg, 1 µg, 100 ng, 1 ng, 100 pg, 10 pg, 1 pg or i.p.; 10 µl/g solution 
containing 0.5 mg/kg) or vehicle (i.pl; 10 µl 5% glucose or i.p.; 10 µl/g PBS) measured using an 
electronic von Frey instrument (MouseMet, TopCat Metrology). Data shown as mean and standard 
error of mean of 6 animals (3 males and 3 females). (*p <0.05). 
ti
m
e 
(d
ay
s)
 10 µg VC 
i.pl. 
 
1 µg VC i.pl. 
 
100 ng VC 
i.pl. 
 
10 ng VC i.pl. 
 
1 ng VC i.pl. 
 
100 pg VC 
i.pl. 
 
MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N 
-1 3.3 0.1 6 3.2 0.1 6 3.2 0.2 6 3.2 0.1 6 3.0 0.1 6 3.1 0.1 6 
0 1.4* 0.1 6 1.4* 0.1 6 2.7 0.3 6 2.6 0.3 6 2.8 0.2 6 2.9 0.0 6 
1 1.1* 0.2 6 1.1* 0.1 6 1.4* 0.3 6 1.7* 0.2 6 2.1* 0.2 6 2.8 0.2 6 
2 1.9* 0.3 6 1.5* 0.1 6 1.1* 0.1 6 1.3* 0.2 6 1.3* 0.2 6 2.2* 0.3 6 
4 3.9 0.3 6 2.9 0.3 6 1.5* 0.3 6 1.5* 0.1 6 1.0* 0.2 6 1.6* 0.4 6 
7 4.7* 0.2 6 3.8 0.3 6 2.8 0.2 6 1.4* 0.3 6 1.6* 0.2 6 1.8* 0.3 6 
9 4.7* 0.2 6 4.4* 0.2 6 2.8 0.2 6 1.7* 0.2 6 1.6* 0.2 6 1.7* 0.1 6 
11 5.6* 0.3 6 4.9* 0.4 6 3.1 0.2 6 1.9* 0.4 6 1.9* 0.1 6 1.9* 0.4 6 
15 6.0* 0.3 6 5.6* 0.1 6 3.2 0.1 6 2.1* 0.3 6 1.6* 0.1 6 2.7 0.3 6 
25.
0 
4.8* 0.1 6 3.8 0.4 6 2.7 0.2 6 1.6* 0.2 6 2.1* 0.3 6 2.8 0.1 6 
                   
ti
m
e 
(d
ay
s)
 
10 pg VC i.pl. 
 
1 pg VC i.pl. 
 
5% glucose 
i.pl. 
0.5 mg/kg VC 
i.p. 
PBS i.p. 
 
   
MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N    
-1 3.2 0.1 6 3.3 0.1 6 3.0 0.1 6 3.4 0.1 6 3.0 0.1 6    
0 2.9 0.2 6 2.9 0.2 6 3.2 0.1 6 3.0 0.1 6 3.2 0.1 6    
1 3.0 0.1 6 2.9 0.1 6 3.2 0.1 6 1.5* 0.2 6 3.2 0.2 6    
2 2.8 0.2 6 2.8 0.2 6 3.0 0.1 6 1.3* 0.1 6 3.1 0.1 6    
4 2.3 0.3 6 2.6 0.3 6 3.1 0.1 6 1.3* 0.1 6 3.1 0.1 6    
7 2.7 0.3 6 2.8 0.1 6 3.2 0.1 6 1.6* 0.2 6 3.2 0.1 6    
9 2.2* 0.3 6 2.3 0.3 6 3.3 0.1 6 1.9* 0.2 6 3.1 0.2 6    
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11 3.1 0.1 6 2.3 0.3 6 3.2 0.1 6 1.8* 0.2 6 3.1 0.1 6    
15 2.6 0.2 6 2.4 0.1 6 3.1 0.1 6 1.7* 0.2 6 3.1 0.1 6    
25 1.9* 0.1 6 1.7* 0.1 6 3.2 0.1 6 2.4 0.2 6 3.3 0.1 6    
VC: vincristine; i.pl.: intraplantar injection; i.p.: intraperitoneal injection. 
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Table 9S. Thermal paw withdrawal threshold following administration of vincristine. 
Thermal paw withdrawal threshold (PWT) values following single daily injection of vincristine (i.pl; 
10 µl solution containing 10 µg, 1 µg, 100 ng, 1 ng, 100 pg, 10 pg, 1 pg or i.p.; 10 µl/g solution 
containing 0.5 mg/kg) or vehicle (i.pl; 10 µl 5% glucose or i.p.; 10 µl/g PBS) assessed using 
MouseMet Thermal (TopCat Metrology). Data shown as mean and standard error of mean of 6 
animals (3 males and 3 females). (*p <0.05). 
ti
m
e 
(d
ay
s)
 
10 µg VC i.pl. 
 
1 µg VC i.pl. 
 
100 ng VC 
i.pl. 
 
10 ng VC 
i.pl. 
 
1 ng VC i.pl. 
 
100 pg VC 
i.pl. 
 
MEAN 
SE
M 
N MEAN 
SE
M 
N MEAN 
SE
M 
N 
MEA
N 
SE
M 
N 
MEA
N 
SE
M 
N 
MEA
N 
SE
M 
N 
-1 50.0 0.4 6 49.9 0.4 6 49.5 0.2 6 50.0 0.3 6 49.8 0.3 6 49.7 0.5 6 
0 50.0 0.6 6 50.6 0.5 6 49.7 0.3 6 48.5 0.5 6 48.2 0.5 6 49.6 0.1 6 
1 49.1 0.4 6 48.4 0.6 6 50.0 0.5 6 49.9 0.2 6 49.2 0.3 6 49.4 0.5 6 
2 49.1 0.6 6 50.1 0.9 6 48.9 0.2 6 48.7 0.5 6 49.6 0.3 6 49.4 0.5 6 
4 53.7* 0.4 6 52.6* 0.3 6 49.7 0.6 6 49.4 0.3 6 49.1 0.6 6 49.1 0.5 6 
7 55.0* 0.0 6 55.0* 0.0 6 50.9 0.4 6 49.4 0.4 6 49.1 0.6 6 49.5 0.6 6 
9 55.0* 0.0 6 55.0* 0.0 6 52.5* 1.0 6 49.4 0.2 6 49.4 0.2 6 48.9 0.5 6 
11 55.0* 0.0 6 55.0* 0.0 6 51.2 0.5 6 48.8 0.2 6 49.3 0.4 6 49.2 0.5 6 
15 55.0* 0.0 6 55.0* 0.0 6 50.9 0.6 6 48.6 0.4 6 49.4 0.2 6 49.6 0.6 6 
25 55.0* 0.0 6 52.6* 0.6 6 50.0 0.1 6 50.1 0.5 6 49.7 0.6 6 50.1 0.5 6 
 
 
 
 
                 
ti
m
e 
(d
ay
s)
 
10 pg VC i.pl. 
 
1 pg VC i.pl. 
 
5% glucose 
i.pl. 
0.5 mg/kg 
VC i.p. 
PBS i.p. 
 
   
MEAN 
SE
M 
N MEAN 
SE
M 
N MEAN 
SE
M 
N 
MEA
N 
SE
M 
N 
MEA
N 
SE
M 
N    
-1 49.9 0.4 6 50.0 0.3 6 49.7 0.4 6 50.4 0.2 6 42.9 7.4 6    
0 49.4 0.4 6 48.9 0.5 6 49.6 0.6 6 50.9 0.2 6 43.0 7.4 6    
1 48.9 0.5 6 48.4 0.3 6 49.8 0.3 6 51.1 0.4 6 42.8 7.4 6    
2 49.2 0.5 6 48.2 0.7 6 49.6 0.4 6 50.4 0.4 6 42.7 7.3 6    
4 49.6 0.4 6 48.7 0.4 6 49.9 0.3 6 50.4 0.5 6 42.9 7.4 6    
7 48.3 0.3 6 47.4 1.1 6 50.0 0.3 6 49.4 0.4 6 42.8 7.4 6    
9 48.6 1.0 6 48.2 0.7 6 49.4 0.3 6 49.0 0.4 6 42.3 7.3 6    
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11 48.9 0.3 6 48.6 0.5 6 48.6 0.2 6 49.2 0.4 6 41.9 7.2 6    
15 48.7 0.3 6 49.0 0.2 6 49.4 0.3 6 49.6 0.3 6 42.3 7.3 6    
25 49.8 0.4 6 49.1 0.5 6 49.7 0.4 6 49.9 0.4 6 42.6 7.3 6    
VC: vincristine; i.pl.: intraplantar injection; i.p.: intraperitoneal injection. 
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Table 10S. Paw thickness following single daily injection of vincristine. 
Paw thickness values, 30 min after single daily injection of vincristine (i.pl; 10 µl solution containing 
10 µg, 1 µg, 100 ng, 1 ng, 100 pg, 10 pg, 1 pg or i.p.; 10 µl/g solution containing 0.5mg/kg) or vehicle 
(i.pl; 10 µl 5% glucose or i.p.; 10 µl/g PBS) were assessed using a digital Vernier caliper (Kincrome, 
Vic, Australia). Data shown as mean and standard error of the mean in percent of the contralateral 
hind paw of 6 animals (3 males and 3 females).Values expressed as percent of the contralateral hind 
paw. (*p <0.05). 
ti
m
e 
(d
ay s)
 10 µg VC i.pl. 
 
1 µg VC i.pl. 
 
100 ng VC i.pl. 
 
10 ng VC i.pl. 
 
1 ng VC i.pl. 
 
100 pg VC i.pl. 
 
MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N 
-1 98.8 0.9 6 100.6 1.1 6 98.3 1.0 6 100.6 0.3 6 100.6 0.4 6 99.6 0.2 6 
0 152.4* 16.1 6 110.3 5.2 6 126.8 6.2 6 120.6 5.6 6 120.6 5.5 6 95.1 5.9 6 
1 167.0* 4.4 6 120.5 10.5 6 139.9* 3.5 6 128.3* 4.2 6 132.0 6.0 6 111.2 6.0 6 
2 176.5* 9.4 6 134.7* 14.1 6 117.6 5.6 6 120.4 5.5 6 122.2 12.4 6 110.4 3.5 6 
4 164.5* 3.8 6 120.1 11.0 6 143.2* 9.3 6 126.2* 3.8 6 144.7* 3.1 6 107.9 4.1 6 
7 140.6* 6.0 6 132.4* 13.3 6 115.9 6.0 6 129.4* 8.2 6 112.1 3.9 6 116.4 3.4 6 
9 204.7* 6.4 6 119.9 8.9 6 120.6 11.0 6 140.6* 7.3 6 117.3 7.5 6 104.6 1.1 6 
11 158.3* 6.9 6 127.0* 13.9 6 111.7 5.7 6 142.6* 7.1 6 113.7 7.2 6 106.6 2.0 6 
15 130.9* 9.1 6 106.2 4.7 6 100.5 0.6 6 100.0 0.7 6 95.4 5.1 6 100.1 0.8 6 
25 129.6* 4.3 6 101.7 2.4 6 100.0 0.8 6 99.8 0.3 6 101.0 0.5 6 100.2 1.7 6 
                   
 
 
                  
ti
m
e 
(d
ay
s)
 
10 pg VC i.pl. 
 
1 pg VC i.pl. 
 
5% glucose i.pl. 
 
0.5 mg/kg VC 
i.p. 
PBS i.p. 
 
   
MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N    
-1 99.8 0.2 6 100.3 0.5 6 98.8 1.7 6 99.7 0.8 6 99.1 0.9 6    
0 103.8 1.9 6 102.2 2.5 6 109.2 6.8 6 100.3 0.5 6 100.4 0.4 6    
1 101.8 1.6 6 100.8 0.9 6 106.1 2.6 6 100.7 0.5 6 99.8 0.6 6    
2 112.3 2.4 6 97.9 8.8 6 101.5 0.9 6 99.7 0.6 6 99.6 0.7 6    
4 111.9 2.1 6 103.6 1.7 6 108.7 2.6 6 99.6 0.4 6 99.4 0.4 6    
7 109.4 1.8 6 107.5 0.7 6 111.3 8.3 6 99.5 0.3 6 100.6 1.2 6    
9 105.3 2.1 6 102.2 1.5 6 118.5 10.0 6 99.9 0.4 6 100.5 1.0 6    
11 109.2 1.3 6 106.5 1.3 6 115.4 4.6 6 100.2 0.3 6 100.4 0.9 6    
232 
 
 
15 101.1 0.7 6 101.4 1.2 6 101.2 1.0 6 99.9 0.4 6 100.4 0.6 6    
25 99.9 0.2 6 100.1 0.4 6 100.7 0.6 6 100.2 0.4 6 99.8 0.5 6    
VC: vincristine; i.pl.: intraplantar injection; i.p.: intraperitoneal injection.  
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Table 11S. Paw print area expressed in percent of the contralateral paw following daily injections 
of vincristine. 
Ipsilateral paw print area expressed in percent of the contralateral paw following daily injections of 
vincristine (i.pl; 10 µl solution containing 10 µg, 1 µg, 100 ng or i.p.; 10 µl/g solution containing 0.5 
mg/kg) or vehicle (i.pl; 10 µl 5% glucose or i.p.; 10 µl/g PBS) was assessed using the CatwalkXT 
platform (Noldus Information Technology, Netherlands). Print area is the average of paw contact area 
with the glass platform (in cm2). Data shown as mean and standard error of the mean in percent of 
the contralateral hind paw of 6 animals (3 males and 3 females). Values expressed as percent of the 
contralateral hind paw. (*p <0.05). 
ti
m
e 
(d
ay
s)
 
 
10 µg VC i.pl. 
 
1 µg VC i.pl. 
 
100 ng VC i.pl. 
 
5% glucose i.pl. 
 
0.5 mg/kg VC 
i.p. 
PBS i.p. 
 
MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N 
-1 102.8 6.5 6 110.2 6.6 6 121.6 12.3 6 110.2 2.9 6 112.2 11.3 6 112.2 11.3 6 
0 95.5 3.6 6 101.4 4.4 6 105.1 4.8 6 96.7 8.0 6 98.1 6.7 6 105.7 6.0 6 
1 84.5 4.6 6 96.6 7.3 6 92.6 6.5 6 86.3 5.5 6 99.2 5.9 6 90.6 4.4 6 
2 95.5 3.6 6 96.3 6.4 6 95.5 6.7 6 99.0 7.8 6 101.6 6.9 6 94.8 8.9 6 
4 18.5* 7.2 6 92.5 9.5 6 96.9 5.0 6 102.7 12.6 6 99.1 11.8 6 95.7 5.6 6 
7 15.8* 4.7 6 88.2* 8.0 6 105.3 6.3 6 111.4 5.5 6 101.9 5.9 6 112.0 7.0 6 
9 13.3* 3.4 6 88.8* 9.5 6 97.6 4.0 6 103.5 5.5 6 105.8 6.0 6 104.2 5.4 6 
11 1.2* 1.2 6 67.3* 8.9 6 98.7 7.7 6 103.2 4.1 6 104.7 7.9 6 100.5 3.7 6 
15 1.6* 1.6 6 106.8 3.5 6 92.6 7.9 6 100.9 5.4 6 93.9 7.1 6 105.5 1.8 6 
25 19.4* 9.0 6 78.7* 3.4 6 107.1 13.2 6 99.2 9.7 6 83.3 10.0 6 90.7 10.1 6 
VC: vincristine; i.pl.: intraplantar injection; i.p.: intraperitoneal injection. 
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Table 12S. Full list of differentially expressed genes following vincristine administration. 
Full list of differentially expressed genes following vincristine administration. Genes are sorted 
according to the Padj values. 
Gene name Base Mean log2FoldChange P value Padj 
Nts 1865.7 4.1 4.62E-61 8.48E-57 
Sprr1a 511.1 6.3 2.92E-57 2.68E-53 
Atf3 1962.5 4.5 2.36E-55 1.44E-51 
Ecel1 355.0 5.1 3.97E-41 1.82E-37 
Cckbr 145.0 5.1 1.59E-34 5.84E-31 
Gadd45a 804.3 1.7 2.02E-28 6.17E-25 
Star 203.8 4.3 4.59E-28 1.2E-24 
Ms4a1 121.4 -4.0 6.03E-27 1.38E-23 
Gpr151 159.1 3.6 8.43E-25 1.72E-21 
Tnfrsf12a 245.2 2.1 7.31E-24 1.22E-20 
Plaur 330.3 1.9 6.7E-24 1.22E-20 
Npy 66.4 3.6 5.13E-20 7.85E-17 
Ucn 48.6 4.3 7.59E-20 1.07E-16 
Lipn 30.4 4.5 2.04E-19 2.68E-16 
Smim3 220.4 1.6 3.57E-18 4.38E-15 
Lgals3 905.9 1.7 4.16E-18 4.77E-15 
Stmn4 392.0 2.3 3.88E-17 3.95E-14 
Gm19980 52.5 -3.2 3.86E-17 3.95E-14 
Pou2af1 82.8 -2.8 6.27E-17 6.06E-14 
Cd79a 53.1 -3.1 7.77E-17 7.13E-14 
Fgf3 58.2 3.8 8.83E-17 7.72E-14 
Rag1 71.1 -3.5 1.02E-16 8.51E-14 
Cd19 95.7 -3.1 2.37E-16 1.9E-13 
Slfn14 438.3 2.3 1.42E-15 1.09E-12 
Trib3 102.8 1.9 2.04E-15 1.5E-12 
Cd79b 143.7 -2.5 2.27E-15 1.6E-12 
Mthfd2 558.2 1.1 2.94E-15 2E-12 
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Faim3 33.1 -3.1 1.88E-14 1.24E-11 
Trim58 124.0 2.2 3.24E-14 2.05E-11 
Tmcc2 3447.2 1.6 5.58E-14 3.41E-11 
Sez6l 317.4 2.5 6.44E-14 3.81E-11 
Vpreb3 27.0 -3.4 3.76E-13 2.16E-10 
Chac1 125.7 1.8 7.79E-13 4.34E-10 
Flrt3 1158.9 1.8 9.9E-13 5.34E-10 
Apol11b 666.9 2.4 1.94E-12 1.02E-09 
Fcrla 53.8 -2.9 2.35E-12 1.2E-09 
Qrfpr 21.6 3.4 3.67E-12 1.82E-09 
Sox11 222.1 2.4 4.67E-12 2.26E-09 
2010005H15Rik 13.9 3.6 8.25E-12 3.88E-09 
Oas1e 13.6 3.5 1.72E-11 7.79E-09 
Pim1 465.0 1.4 2.87E-11 1.26E-08 
Lamb3 38.7 2.2 3.48E-11 1.47E-08 
Adam8 460.7 1.6 3.52E-11 1.47E-08 
Colec10 37.1 2.7 4.94E-11 2.01E-08 
F930017D23Rik 64.3 2.0 1.41E-10 5.51E-08 
Trim10 839.6 2.0 2.32E-10 8.68E-08 
Gal 264.4 2.0 4.6E-10 1.62E-07 
Abca13 558.1 1.9 7.78E-10 2.69E-07 
Kif22 227.4 1.4 9.35E-10 3.18E-07 
Pax5 39.7 -2.5 1.03E-09 3.45E-07 
Slc4a1 7055.8 1.8 1.08E-09 3.53E-07 
Wfdc3 35.8 2.2 1.62E-09 5.22E-07 
Liph 31.7 2.4 2.03E-09 6.42E-07 
Ranbp10 1334.0 1.2 2.08E-09 6.46E-07 
Gm11427 60.3 2.1 2.19E-09 6.69E-07 
Blk 34.7 -2.1 2.69E-09 8.1E-07 
Lrrc15 39.3 2.1 3.1E-09 9.18E-07 
Slc25a37 3858.0 1.7 3.23E-09 9.29E-07 
Lrrc17 77.2 1.4 3.24E-09 9.29E-07 
Rsad2 2778.8 1.8 3.71E-09 1.04E-06 
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Ppp1r15a 1252.8 1.2 3.75E-09 1.04E-06 
Gypa 1598.7 2.0 4.47E-09 1.22E-06 
Itgb2l 442.8 2.0 4.78E-09 1.29E-06 
Rin1 82.9 1.4 6.69E-09 1.78E-06 
Sema6a 925.6 1.5 7.09E-09 1.86E-06 
Epb4.2 908.4 1.9 7.55E-09 1.95E-06 
S100a11 362.7 1.0 9.2E-09 2.35E-06 
Tuba1c 217.1 1.5 1.02E-08 2.57E-06 
Xpo7 3862.4 1.3 1.07E-08 2.66E-06 
Ucn2 11.0 3.0 1.25E-08 3.07E-06 
Oas3 473.0 1.9 1.48E-08 3.54E-06 
Tspo2 212.7 1.8 2.01E-08 4.72E-06 
Tubb6 538.3 1.3 2.08E-08 4.83E-06 
Spib 152.9 -2.3 2.38E-08 5.46E-06 
Dyrk3 160.2 1.2 2.47E-08 5.59E-06 
Kel 500.4 1.9 2.55E-08 5.7E-06 
Ltf 6958.3 1.9 2.71E-08 5.92E-06 
Crlf1 74.3 1.4 3.02E-08 6.53E-06 
Padi4 256.4 1.9 3.39E-08 7.24E-06 
Cd177 1120.9 1.8 4.13E-08 8.61E-06 
Tmem88b 149.6 1.5 4.34E-08 8.96E-06 
4930438A08Rik 84.8 1.9 4.9E-08 0.00001 
Calml4 151.5 -1.1 5.13E-08 1.04E-05 
Csf3r 635.7 1.7 5.57E-08 1.11E-05 
Lcn2 2723.3 1.9 5.95E-08 1.17E-05 
1300017J02Rik 137.0 1.7 6.26E-08 1.22E-05 
Epb4.1 4533.6 1.3 6.36E-08 1.23E-05 
Mmp8 1554.0 1.9 7.62E-08 1.46E-05 
Aqp9 115.1 1.7 9.23E-08 1.75E-05 
Isg20 518.2 1.6 9.5E-08 1.78E-05 
Nfil3 180.4 1.1 9.76E-08 1.81E-05 
Fam129c 77.9 -2.1 1.08E-07 1.97E-05 
H2-T24 371.1 1.6 1.22E-07 0.000022 
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Specc1 1560.5 1.3 1.27E-07 2.27E-05 
Yjefn3 140.3 1.2 1.77E-07 3.13E-05 
Spta1 1638.0 1.6 1.96E-07 3.43E-05 
Cd300lf 166.4 1.7 2.2E-07 0.000038 
Chi3l3 2829.9 1.8 2.35E-07 4.04E-05 
Fosl1 10.0 2.8 2.41E-07 4.09E-05 
Slfn4 1127.1 2.2 2.48E-07 4.12E-05 
Mxd1 1171.1 1.5 2.49E-07 4.12E-05 
Fcer2a 15.4 -2.4 2.57E-07 4.21E-05 
Nfe2 459.6 1.8 2.99E-07 4.86E-05 
Tnfrsf13c 29.1 -2.0 3.2E-07 5.15E-05 
Htr3a 914.2 -1.2 3.45E-07 0.000055 
Ngp 7374.3 1.8 3.66E-07 5.79E-05 
Hrk 85.1 1.9 3.75E-07 5.84E-05 
Rhag 374.1 1.8 3.76E-07 5.84E-05 
Rbm38 459.0 1.6 4.08E-07 6.25E-05 
B430306N03Rik 219.0 1.8 4.4E-07 6.67E-05 
Slc6a4 87.8 1.7 5.19E-07 7.75E-05 
Slc15a3 141.5 1.4 7.45E-07 0.00011 
Pglyrp1 334.8 1.7 7.56E-07 0.000111 
Mylk3 94.2 1.6 8.92E-07 0.00013 
Dhrs11 405.9 1.5 9.98E-07 0.000144 
Trem3 136.1 1.9 1.08E-06 0.000154 
Itgam 1358.8 1.5 1.17E-06 0.000167 
Lin7b 110.5 -1.0 1.22E-06 0.000171 
Trem1 71.5 1.7 1.27E-06 0.000177 
Ltb4r1 121.4 1.7 1.31E-06 0.00018 
Fst 155.8 1.0 1.32E-06 0.00018 
Rab44 284.0 1.6 1.33E-06 0.000181 
Taf7l 7.0 2.7 1.37E-06 0.000183 
1700003F12Rik 17.5 2.1 1.38E-06 0.000183 
1100001G20Rik 325.7 1.9 1.39E-06 0.000183 
Il1f9 111.5 1.9 1.38E-06 0.000183 
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42797 261.0 1.2 1.4E-06 0.000183 
Mmp9 1759.9 1.6 1.43E-06 0.000186 
Fam46c 4727.3 1.3 1.66E-06 0.000213 
Mgam 95.4 1.7 1.76E-06 0.000223 
E2f2 1034.3 1.3 1.76E-06 0.000223 
Hdc 310.5 1.6 1.99E-06 0.000249 
Gcnt1 375.3 1.3 1.99E-06 0.000249 
Nbeal2 631.5 1.1 2.36E-06 0.000291 
Gng8 63.8 -1.2 2.51E-06 0.000307 
Il18rap 292.8 1.5 2.54E-06 0.000309 
Acvr1c 91.7 1.5 2.74E-06 0.000331 
Il1rn 125.2 1.8 3.01E-06 0.000359 
Fhdc1 530.3 1.2 3.06E-06 0.000362 
Cxcr2 391.8 1.8 3.2E-06 0.000375 
Hmbs 1073.7 1.4 3.43E-06 0.000398 
Trim15 6.5 2.6 3.55E-06 0.00041 
Ermap 752.6 1.5 3.88E-06 0.000446 
Btnl10 388.6 1.5 4.01E-06 0.000457 
Fpr1 152.4 1.8 4.4E-06 0.000497 
Gch1 245.4 1.2 4.41E-06 0.000497 
Ccr1 278.7 1.6 4.53E-06 0.000507 
Slc16a10 504.2 1.3 4.77E-06 0.00053 
Apobr 264.5 1.3 4.94E-06 0.000547 
Htr3b 139.1 -1.3 5.04E-06 0.000554 
S100a9 16019.5 1.7 5.6E-06 0.000608 
C3 1637.2 1.2 5.98E-06 0.000643 
Gda 2802.2 1.1 5.96E-06 0.000643 
F730016J06Rik 144.6 1.3 7.24E-06 0.00076 
Gm5152 5.4 2.5 7.86E-06 0.00082 
1810033B17Rik 252.7 1.8 8.39E-06 0.000871 
Ifitm6 393.3 1.7 8.81E-06 0.000908 
S100a8 11207.9 1.8 0.00001 0.001028 
Hk3 420.2 1.4 1.04E-05 0.001061 
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Cryba2 36.9 1.6 1.06E-05 0.001074 
Camp 2574.1 1.7 1.19E-05 0.001181 
Slc43a1 540.6 1.3 1.26E-05 0.001239 
Cd33 366.8 1.2 1.28E-05 0.001247 
Alas2 5259.3 1.4 0.000013 0.001259 
Adpgk 1153.0 1.2 1.38E-05 0.001335 
Tnfrsf14 277.0 1.3 1.49E-05 0.001406 
Retnlg 1533.8 1.6 1.51E-05 0.00142 
Clec4e 114.8 1.8 1.57E-05 0.001466 
Ube2c 317.1 1.5 1.67E-05 0.001557 
Lrrc2 15.9 1.9 1.68E-05 0.001561 
Ikzf3 112.9 -1.4 1.84E-05 0.00169 
Gpr119 28.9 1.5 1.86E-05 0.001703 
Xdh 854.5 1.2 0.000019 0.001718 
Prss56 4.9 2.4 1.96E-05 0.001743 
Gm11714 9.1 2.2 1.96E-05 0.001743 
mmu-mir-6236 2978.6 1.1 1.97E-05 0.001743 
Fpr2 205.1 1.7 2.06E-05 0.001812 
Kcnk16 9.0 2.3 2.14E-05 0.001858 
Ankrd22 62.0 1.9 2.25E-05 0.001935 
Myh7 289.8 1.8 2.27E-05 0.001951 
Ncf1 1067.3 1.4 2.31E-05 0.001977 
Samd11 155.4 1.3 2.33E-05 0.001978 
Rasgrp4 254.2 1.3 2.43E-05 0.002048 
5930412G12Rik 47.8 1.2 2.45E-05 0.002055 
C5ar1 248.6 1.2 2.54E-05 0.002116 
Cxcl14 68.7 1.2 2.76E-05 0.002265 
Isg15 411.0 1.5 2.89E-05 0.002359 
Nr4a3 57.5 1.2 3.01E-05 0.002449 
Tal1 477.4 1.4 3.25E-05 0.00262 
AI662270 382.5 1.4 3.33E-05 0.002667 
9830107B12Rik 52.6 1.6 3.39E-05 0.002696 
Myo1f 769.9 1.2 3.47E-05 0.002749 
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Gm867 32.8 1.7 3.58E-05 0.002821 
Car2 3738.4 1.3 3.63E-05 0.002848 
Pilra 157.1 1.5 3.66E-05 0.002862 
Gpr141 146.7 1.3 3.78E-05 0.002941 
Pilrb1 45.2 1.5 3.91E-05 0.003026 
Hp 847.3 1.5 0.00004 0.003085 
Nlrp12 76.3 1.2 4.06E-05 0.003117 
F630028O10Rik 1360.3 1.5 4.16E-05 0.003184 
Slpi 160.5 1.5 4.27E-05 0.003251 
Clec5a 213.2 1.6 0.000044 0.00334 
Slc16a3 199.3 1.3 4.47E-05 0.00338 
1700024P16Rik 62.2 1.4 4.58E-05 0.003444 
Trim30b 144.2 1.6 4.88E-05 0.00364 
Atp8b4 413.9 1.3 5.19E-05 0.003856 
Cdcp1 6.4 2.3 5.62E-05 0.004124 
Tmprss11bnl 6.4 2.3 5.86E-05 0.004288 
Slfn1 233.1 1.6 5.91E-05 0.004294 
Siglece 104.1 1.4 5.97E-05 0.004318 
Slc1a7 12.8 2.1 6.04E-05 0.00433 
Ly6g 79.3 1.7 6.49E-05 0.004602 
Tspan33 467.8 1.3 6.79E-05 0.004791 
Lin28a 56.9 1.7 6.83E-05 0.004805 
Slco4c1 57.8 1.5 6.87E-05 0.004811 
Sdc1 1036.6 1.0 6.99E-05 0.004878 
Fbp1 34.0 -1.2 7.61E-05 0.005251 
Gata1 122.4 1.6 7.66E-05 0.005266 
Wdr63 5.0 2.2 8.24E-05 0.00562 
Tnni1 83.5 1.2 8.27E-05 0.00562 
Tnnc1 58.4 1.4 0.000084 0.005691 
Pirb 436.8 1.3 8.66E-05 0.005848 
1700042G15Rik 4.9 2.2 9.05E-05 0.006084 
Rhd 439.6 1.5 9.23E-05 0.006183 
Igsf6 361.9 1.3 9.43E-05 0.006271 
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Chrnb3 63.6 -1.1 9.69E-05 0.006424 
Adm2 4.8 2.2 9.87E-05 0.006519 
Fam132b 18.2 2.0 0.000102 0.006678 
Ccdc88b 308.5 1.2 0.000105 0.006846 
Klk5 18.7 -1.6 0.000106 0.006917 
RP23-308M1.2 78.1 1.2 0.000111 0.007129 
Gm10371 16.5 1.6 0.000116 0.007351 
Mgst2 65.9 1.4 0.000117 0.007351 
Fgr 284.7 1.3 0.000116 0.007351 
Lyz2 10990.7 1.2 0.000117 0.007351 
Dennd2c 167.2 1.1 0.000117 0.007351 
Apol8 137.0 1.3 0.000119 0.007415 
Nfam1 517.6 1.2 0.000122 0.007565 
Ppox 619.8 1.0 0.000123 0.007591 
Plcb2 316.0 1.2 0.000135 0.008256 
Itgal 305.1 1.1 0.000138 0.008369 
Pnp2 30.2 1.4 0.00014 0.008415 
Spi1 356.4 1.0 0.00014 0.008415 
Mfsd2b 281.7 1.3 0.000146 0.008723 
Asprv1 55.4 1.4 0.000148 0.008791 
Chi3l7 14.5 2.0 0.000148 0.008793 
Mnda 37.7 1.2 0.000158 0.009352 
Gad1-ps 34.5 1.5 0.000169 0.009935 
Cd22 69.2 -1.4 0.00017 0.009935 
Sowaha 217.1 1.2 0.000174 0.010118 
Clec4d 91.5 1.6 0.000174 0.01012 
Ceacam1 268.7 1.1 0.000175 0.010157 
Snx22 111.0 1.2 0.000182 0.010499 
Chi3l1 308.5 1.3 0.000185 0.010621 
Itgb2 1043.1 1.2 0.000189 0.010836 
Cdc25c 41.8 1.4 0.000201 0.011251 
Soat2 43.7 1.0 0.000201 0.011251 
Btla 77.0 -1.1 0.000199 0.011251 
242 
 
 
Tlr13 288.2 1.1 0.000204 0.011366 
4930426D05Rik 9.9 -2.0 0.000209 0.011639 
Hapln3 36.5 -1.2 0.000212 0.011698 
Mki67 4329.2 1.3 0.000214 0.011764 
Gpnmb 198.5 1.0 0.000216 0.011841 
Ccl2 94.7 1.0 0.000218 0.011898 
Cenpf 595.0 1.3 0.000229 0.012463 
Aoc2 55.9 1.2 0.000233 0.012618 
Pif1 69.7 1.4 0.000245 0.012985 
Cxcr5 16.0 -1.8 0.000243 0.012985 
Ipcef1 219.6 1.2 0.00025 0.013083 
Mroh2b 47.6 -1.3 0.000249 0.013083 
Alox5ap 484.5 1.2 0.000253 0.0132 
Cenpe 418.3 1.1 0.000257 0.013366 
Tnfaip2 506.8 1.3 0.000258 0.013386 
Gdf15 7.5 1.9 0.000264 0.013639 
Plbd1 699.5 1.2 0.000278 0.014277 
Srxn1 6400.2 1.0 0.000283 0.014453 
Tmprss11f 6.1 2.0 0.000291 0.014777 
Oprd1 146.0 -1.4 0.000298 0.015017 
Ly6c2 427.4 1.4 0.000305 0.015122 
Cybb 1934.5 1.2 0.000306 0.015122 
Cpb1 91.7 -1.1 0.000304 0.015122 
Gm13415 4.7 2.0 0.000308 0.015208 
Hbb-bt 14196.5 1.2 0.000309 0.015208 
Gp49a 189.1 1.3 0.000326 0.015901 
Galnt6 137.6 1.2 0.000339 0.016502 
Rag2 7.2 -2.0 0.000341 0.016515 
Lmo2 627.4 1.0 0.000344 0.016619 
Cdca3 192.5 1.2 0.000347 0.016697 
Gm24407 926.3 -1.2 0.000351 0.016885 
Gm16194 48.4 1.2 0.000357 0.017094 
Nms 10.5 1.7 0.000361 0.017193 
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Tmem86b 56.0 1.1 0.000365 0.017356 
Il1r2 59.6 1.6 0.000375 0.01763 
Prc1 406.6 1.1 0.000375 0.01763 
Pde6b 22.7 1.6 0.000402 0.018624 
Rnd1 71.1 1.4 0.000404 0.018654 
Fcer1g 502.3 1.0 0.000404 0.018654 
5830416P10Rik 104.3 1.2 0.000406 0.018678 
Ffar2 35.3 1.5 0.000416 0.019052 
Dhrs9 130.2 1.5 0.000427 0.019456 
Doc2b 27.4 1.4 0.000426 0.019456 
Myl3 38.6 1.6 0.00044 0.019916 
Ube2l6 1489.0 1.0 0.000445 0.020062 
Iglv3 5.2 -2.0 0.000468 0.020996 
Mmel1 12.2 1.7 0.000482 0.021347 
Trim59 321.7 1.2 0.000484 0.021347 
Kif14 176.2 1.1 0.000481 0.021347 
Ighv1-12 9.3 2.0 0.000489 0.021537 
Svopl 17.0 1.4 0.000519 0.022741 
Arl11 58.0 1.2 0.000527 0.02298 
Bpgm 2255.5 1.0 0.000539 0.023385 
Cldn13 185.0 1.4 0.000554 0.023911 
Fes 462.5 1.0 0.000565 0.024228 
Tnf 32.2 1.3 0.000582 0.024832 
Gm7361 12.4 1.7 0.000593 0.025074 
Duox2 9.7 1.6 0.000593 0.025074 
Igll1 14.7 -1.5 0.000594 0.025074 
Fam109b 173.3 1.0 0.000604 0.025296 
Dusp2 31.8 -1.2 0.000603 0.025296 
Ncf4 264.3 1.2 0.000619 0.025695 
Cebpe 109.3 1.4 0.000629 0.026017 
Depdc1b 120.8 1.1 0.000648 0.026693 
Ifnlr1 82.7 1.2 0.000655 0.026897 
Crh 9.6 1.8 0.000709 0.028471 
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Mapk13 72.4 1.2 0.000711 0.028487 
Klf1 202.3 1.3 0.000743 0.029411 
6720416L17Rik 40.3 -1.2 0.000743 0.029411 
Cd300lb 181.5 1.2 0.000748 0.029513 
Mst1 8.8 1.9 0.000779 0.030368 
Scnn1a 33.0 1.3 0.000786 0.030521 
Alox5 251.2 1.1 0.000793 0.030727 
Pilrb2 75.9 1.4 0.000819 0.031588 
Hemgn 643.1 1.4 0.000863 0.032686 
Nusap1 383.0 1.2 0.000891 0.033434 
Btn1a1 6.8 1.8 0.000924 0.034351 
Gm17344 18.5 1.4 0.000927 0.034398 
AA467197 30.4 1.5 0.000947 0.034967 
Hbq1b 39.3 1.2 0.000946 0.034967 
Anxa1 2434.4 1.2 0.000974 0.035767 
Nxpe5 39.6 1.1 0.000974 0.035767 
Bin2 264.7 1.1 0.000981 0.035967 
1700014D04Rik 5.2 1.8 0.001003 0.036379 
Siglecg 85.9 -1.2 0.001007 0.036461 
Tnnt1 70.0 1.2 0.001063 0.038191 
Gm13881 8.3 1.7 0.001083 0.038603 
Naip2 178.3 1.0 0.001099 0.0389 
Sycp2 22.8 1.4 0.001117 0.039377 
Slc35f4 206.3 -1.0 0.001124 0.039538 
Gm765 683.2 -1.1 0.001142 0.039997 
Ctse 763.2 1.2 0.001149 0.040194 
Ska1 33.1 1.4 0.001154 0.040223 
Olr1 49.7 1.2 0.001177 0.040685 
Rac2 840.4 1.1 0.001188 0.040994 
Gpr97 144.4 1.2 0.001246 0.042488 
Epor 109.1 1.1 0.001255 0.042679 
Oas2 183.4 1.1 0.001305 0.044044 
Arhgef39 72.0 1.1 0.001382 0.046204 
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Selplg 357.4 1.0 0.001424 0.047228 
Kcnmb1 380.8 -1.1 0.001426 0.047228 
Card9 122.4 1.1 0.001439 0.047297 
Clec4a2 213.2 1.1 0.001443 0.047297 
Chrna6 579.4 -1.1 0.00144 0.047297 
Myl2 66.8 1.4 0.001457 0.047422 
Cdca8 136.3 1.1 0.001498 0.048593 
A530064D06Rik 46.4 1.4 0.001529 0.049348 
Cxcl9 118.9 1.3 0.001535 0.049445 
Rdh12 66.1 1.1 0.001545 0.049656 
Gm24265 1101.6 -1.1 0.001562 0.049774 
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Table 13S. Full list of differentially expressed genes following oxaliplatin administration. 
Full list of differentially expressed genes following oxaliplatin administration. Genes are sorted 
according to the Padj values.  
Gene name Base Mean log2FoldChange P value Padj 
Snhg11 8548.6 -1.9 6.5E-175 1.2E-170 
Mirg 673.3 -1.9 2.3E-99 2.21E-95 
Meg3 11086.8 -2.1 1.19E-74 7.45E-71 
Malat1 160992.5 -1.3 6.65E-69 3.13E-65 
Fam189b 4825.6 -1.2 5.67E-67 2.14E-63 
9530059O14Rik 1501.0 -2.1 5.75E-65 1.8E-61 
Wasf1 729.5 -1.8 9.39E-61 2.53E-57 
A930011O12Rik 440.6 -1.9 3.09E-57 7.28E-54 
Zfhx2 603.6 -2.0 1.41E-55 2.95E-52 
Syn1 3897.9 -1.6 2.02E-55 3.8E-52 
Clip3 3206.9 -2.0 6.36E-55 1.09E-51 
Miat 4064.6 -1.6 1.85E-51 2.91E-48 
Gm26871 318.7 -2.3 5.59E-49 8.09E-46 
Scrt2 320.4 -1.8 7.73E-47 1.04E-43 
Gm26945 205.7 -2.6 4.25E-46 5.34E-43 
A330076H08Rik 240.0 -2.0 3.78E-45 4.45E-42 
Zmiz2 963.9 -1.3 2.54E-44 2.81E-41 
Srrm1 1037.4 -1.2 3.43E-44 3.59E-41 
Luc7l2 3013.8 -1.1 7.24E-44 6.85E-41 
A330023F24Rik 568.0 -1.6 7.28E-44 6.85E-41 
Gm27000 215.0 -1.9 1.63E-43 1.4E-40 
Rfx7 795.2 -1.4 4.49E-41 3.68E-38 
Pcbp2 2343.8 -1.4 5.35E-41 4.2E-38 
Tubb4a 6130.1 -1.4 1.09E-40 8.21E-38 
Fus 1068.6 -1.4 1E-39 7.14E-37 
C230004F18Rik 384.0 -1.5 1.02E-39 7.14E-37 
Ptgds 6291.7 1.7 1.12E-38 7.54E-36 
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Fmn2 891.2 -1.2 2.32E-38 1.5E-35 
Brd4 1039.4 -1.5 1.4E-37 8.8E-35 
Gm15675 364.2 -1.6 1.46E-37 8.84E-35 
B3galt1 2098.7 -1.1 5.95E-37 3.39E-34 
Ncor2 2158.0 -1.3 7.39E-37 4.09E-34 
Vsnl1 1886.3 -1.5 2.29E-35 1.23E-32 
Sos1 4708.6 -1.5 4.18E-35 2.19E-32 
Cpeb2 3680.3 -1.3 6.8E-35 3.46E-32 
Kcnc3 974.7 -1.4 2.23E-34 1.1E-31 
2810055G20Rik 444.1 -1.4 2.46E-34 1.19E-31 
Vamp2 3497.9 -1.1 1.09E-33 5.12E-31 
Atn1 447.4 -1.3 4.97E-33 2.28E-30 
Ubqln2 2041.4 -1.4 8.47E-33 3.63E-30 
Sec24a 720.5 -1.3 1.02E-31 4.17E-29 
Cherp 487.3 -1.2 1.28E-31 5.13E-29 
Dnm3 11249.2 -1.4 1.52E-31 5.96E-29 
Col24a1 360.8 -1.4 1.74E-31 6.69E-29 
4632427E13Rik 422.8 -1.2 2.87E-31 1.08E-28 
Atxn2 1698.8 -1.2 2.95E-31 1.09E-28 
Vma21 1059.2 -1.2 3.73E-31 1.35E-28 
Gatad2b 367.1 -1.3 8.67E-31 3.08E-28 
Atxn2l 1225.8 -1.1 4.52E-30 1.58E-27 
Fcho2 1141.4 -1.0 4.97E-30 1.7E-27 
Srrm2 8691.8 -1.3 8.88E-30 2.99E-27 
Ids 9182.4 -1.3 2.84E-29 9.37E-27 
Coro6 447.3 -1.3 4.26E-29 1.38E-26 
Pom121 459.3 -1.3 7.17E-29 2.29E-26 
Coro2b 2166.8 -1.2 1.17E-28 3.61E-26 
Syvn1 763.4 -1.0 1.36E-28 4.14E-26 
Rnpc3 567.8 -1.1 1.43E-28 4.27E-26 
Naa15 2967.5 -1.2 2.24E-28 6.6E-26 
Ylpm1 1709.1 -1.2 2.97E-28 8.6E-26 
Cadm2 1636.6 -1.1 3.39E-28 9.69E-26 
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Nav2 639.2 -1.1 8.66E-28 2.34E-25 
Zmiz1 1181.3 -1.1 8.68E-28 2.34E-25 
Qser1 1157.5 -1.1 2.23E-27 5.84E-25 
Fmnl1 1348.7 -1.1 2.6E-27 6.71E-25 
Parvb 1388.8 -1.2 3.96E-27 1.01E-24 
Ptpn23 1068.9 -1.3 7.42E-27 1.84E-24 
Arhgap17 1216.9 -1.1 8.96E-27 2.19E-24 
Tia1 843.6 -1.0 1.07E-26 2.56E-24 
Nfat5 3612.7 -1.2 1.4E-26 3.3E-24 
Lmtk3 147.3 -1.8 1.49E-26 3.46E-24 
AI593442 3506.0 -1.1 1.79E-26 4.12E-24 
Ppp2r2a 1933.7 -1.1 2.81E-26 6.3E-24 
Wasl 3814.9 -1.1 3.09E-26 6.85E-24 
Cdc73 1813.4 -1.1 4.66E-26 1.02E-23 
Ireb2 3723.8 -1.1 8.43E-26 1.83E-23 
Synj1 6079.9 -1.2 1.14E-25 2.45E-23 
Fam65a 692.3 -1.4 3.08E-25 6.37E-23 
Arsb 789.6 -1.1 3.45E-25 7.06E-23 
Auts2 1047.1 -1.1 3.67E-25 7.43E-23 
Mamld1 414.1 -1.2 3.78E-25 7.57E-23 
Gucy1a2 1713.4 -1.1 4.45E-25 8.82E-23 
Cacna1a 2807.4 -1.1 4.6E-25 9.02E-23 
Prrc2c 6309.1 -1.1 2.83E-24 4.97E-22 
Ppargc1a 787.6 -1.0 4.68E-24 8.16E-22 
Plagl1 1178.0 -1.1 9.03E-24 1.56E-21 
Aak1 5526.4 -1.1 1.36E-23 2.3E-21 
Fam98b 367.3 -1.1 1.39E-23 2.34E-21 
R3hdm1 1003.4 -1.2 2.22E-23 3.66E-21 
Kmt2e 1574.4 -1.0 3.14E-23 5.14E-21 
Mnt 479.5 -1.1 5.5E-23 8.85E-21 
2310061I04Rik 361.0 -1.3 6.52E-23 1.03E-20 
Ep300 1376.4 -1.0 6.69E-23 1.04E-20 
Inpp5j 686.2 -1.2 7.56E-23 1.17E-20 
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Rph3a 6796.0 -1.1 1.19E-22 1.8E-20 
Vtn 869.0 1.1 2.11E-22 3.15E-20 
Enah 2436.4 -1.1 2.95E-22 4.38E-20 
Scaf4 443.3 -1.1 3.25E-22 4.71E-20 
Pura 10790.0 -1.0 4.38E-22 6.3E-20 
Gm16586 316.3 -1.2 5.01E-22 7.15E-20 
Prr12 403.2 -1.1 5.55E-22 7.87E-20 
Dhx9 4211.4 -1.1 8.12E-22 1.12E-19 
Proser1 238.1 -1.5 1.22E-21 1.63E-19 
Ncoa6 742.3 -1.2 1.32E-21 1.74E-19 
B830012L14Rik 111.5 -2.2 1.43E-21 1.87E-19 
Dvl3 477.2 -1.2 2.47E-21 3.13E-19 
Onecut2 3063.2 -1.2 4.27E-21 5.26E-19 
Arid1a 1757.2 -1.1 4.66E-21 5.7E-19 
Zfp804a 1083.2 -1.2 7.57E-21 9.03E-19 
Kif2a 3986.3 -1.1 8.21E-21 9.67E-19 
Zfhx4 936.7 -1.0 2.09E-20 2.42E-18 
Kmt2d 2855.9 -1.2 2.19E-20 2.52E-18 
Atp1a3 11935.7 -1.0 2.33E-20 2.65E-18 
Gm17066 172.5 -1.5 3.86E-20 4.35E-18 
4930447C04Rik 266.7 -1.1 5.97E-20 6.7E-18 
Peg10 426.1 -1.2 6.95E-20 7.67E-18 
Alg2 2296.7 -1.0 8.6E-20 9.42E-18 
Zfp703 247.9 -1.2 9.35E-20 1.01E-17 
Nfia 2364.0 -1.0 2.65E-19 2.71E-17 
Cbll1 352.2 -1.3 2.98E-19 3.01E-17 
Efna5 622.6 -1.1 3.27E-19 3.3E-17 
Rps6ka3 6135.0 -1.0 5.85E-19 5.65E-17 
Fign 462.2 -1.2 1.03E-18 9.6E-17 
Tmem131 2212.8 -1.0 1.17E-18 1.08E-16 
Zdbf2 206.7 -1.2 1.21E-18 1.11E-16 
Gt(ROSA)26Sor 278.3 -1.2 1.75E-18 1.57E-16 
Polr2a 2332.4 -1.1 2.04E-18 1.8E-16 
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Mrgprb5 326.1 -1.1 3.58E-18 3.03E-16 
Ppp2r5e 2188.2 -1.0 4.04E-18 3.35E-16 
Gm12940 188.1 -1.4 4.97E-18 4.05E-16 
9330132A10Rik 530.2 -1.1 8.09E-18 6.45E-16 
Zbtb33 635.5 -1.1 8.67E-18 6.89E-16 
Tbc1d15 1018.7 -1.0 9.57E-18 7.51E-16 
mt-Nd5 5186.4 -1.1 1.32E-17 1.02E-15 
Celsr2 1742.0 -1.1 1.62E-17 1.23E-15 
Kmt2a 2466.3 -1.0 1.84E-17 1.38E-15 
Ccnk 215.0 -1.2 1.86E-17 1.39E-15 
Pld5 1022.8 -1.1 2.53E-17 1.85E-15 
Hdx 340.8 -1.1 2.57E-17 1.87E-15 
Arhgap33 205.3 -1.3 3.6E-17 2.55E-15 
Srgap1 1418.7 -1.1 5.97E-17 4.03E-15 
Ctxn1 283.3 -1.1 7.89E-17 5.27E-15 
Tanc2 4073.4 -1.1 8.8E-17 5.82E-15 
Dgkk 141.0 -1.6 9.58E-17 6.24E-15 
Zmat1 276.1 -1.1 1.66E-16 1.05E-14 
Cldn11 543.8 1.1 1.7E-16 1.07E-14 
Parp4 1488.7 -1.0 3.77E-16 2.25E-14 
Neto1 199.0 -1.2 4.15E-16 2.47E-14 
Naf1 208.6 -1.1 8.91E-16 5.03E-14 
ATF7 789.7 -1.0 1.06E-15 5.86E-14 
Gm23600 61.5 -1.7 3.88E-15 2.05E-13 
Gm14443 126.5 -1.3 4.14E-15 2.17E-13 
Mbd6 203.5 -1.2 1.72E-14 8.01E-13 
Wnk2 649.5 -1.0 3.86E-14 1.72E-12 
Slc22a8 89.1 1.5 7.16E-14 3.1E-12 
Ranbp3l 136.0 1.5 1.42E-13 5.95E-12 
Srrm4 174.5 -1.2 1.74E-13 7.01E-12 
Phlda1 155.1 -1.2 2.21E-13 8.73E-12 
Plvap 236.4 1.1 2.4E-13 9.42E-12 
Slc6a20a 282.8 1.2 3.8E-13 1.46E-11 
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Aldh1a2 200.4 1.1 4.65E-13 1.75E-11 
Syngap1 237.3 -1.0 5E-13 1.87E-11 
Tox2 150.8 -1.2 5.06E-13 1.89E-11 
Setd1b 319.5 -1.1 5.74E-13 2.1E-11 
Pianp 86.1 -1.3 8.61E-13 3.07E-11 
Gjb6 193.3 1.2 9.5E-13 3.36E-11 
Gm10167 131.2 -1.2 1.35E-12 4.66E-11 
Atp13a5 215.6 1.2 4.97E-12 1.6E-10 
Gm21846 21.3 -1.9 5.18E-12 1.66E-10 
Grid2ip 99.8 -1.3 6.76E-12 2.1E-10 
Trp53i11 242.7 1.1 7.98E-12 2.45E-10 
Palm2 462.8 -1.1 9.48E-12 2.88E-10 
Slc22a6 53.1 1.6 2.01E-11 5.6E-10 
Fmod 207.6 1.2 2.07E-11 5.73E-10 
Msln 98.7 1.4 4.39E-11 1.14E-09 
1500015O10Rik 326.9 1.2 5.52E-11 1.42E-09 
Pclo 7846.7 -1.5 1.43E-10 3.44E-09 
Celf5 94.7 -1.2 1.61E-10 3.81E-09 
Fgfbp1 60.8 1.5 1.72E-10 4.05E-09 
Raph1 1357.0 -1.3 2.18E-10 5.07E-09 
Col7a1 95.3 -1.2 4.73E-10 1.05E-08 
Alas2 124.9 1.4 4.82E-10 1.07E-08 
Bmp4 87.7 1.3 5.84E-10 1.28E-08 
Gm4117 75.5 -1.2 6.15E-10 1.34E-08 
Chrnb3 159.4 -1.0 6.41E-10 1.4E-08 
Nova1 117.8 -1.0 7.59E-10 1.62E-08 
Dpp4 202.6 1.1 7.84E-10 1.67E-08 
Tmem119 146.3 1.1 8.03E-10 1.7E-08 
Sp2 99.4 -1.1 2.21E-09 4.38E-08 
Gm26601 45.4 -1.4 2.67E-09 5.22E-08 
Slc12a3 22.2 -1.6 2.98E-09 5.8E-08 
Creb5 66.1 -1.3 3.29E-09 6.32E-08 
Wipf3 1842.8 -1.3 3.56E-09 6.8E-08 
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Fut9 50.9 -1.3 9.64E-09 1.71E-07 
Shisa6 55.2 -1.3 1.66E-08 2.82E-07 
BC024978 103.7 -1.1 1.76E-08 2.97E-07 
Klhdc7a 46.9 1.4 1.84E-08 3.1E-07 
Zfpm2 112.1 -1.0 2.89E-08 4.69E-07 
Prg4 144.4 1.2 4.48E-08 7.04E-07 
Snord107 26.6 -1.5 5.22E-08 8.12E-07 
Gm25981 11.4 -1.5 5.24E-08 8.13E-07 
2900056M20Rik 51.3 -1.2 6.43E-08 9.78E-07 
mt-Ti 37.7 -1.3 1.12E-07 1.62E-06 
Gm26514 38.7 -1.3 1.38E-07 1.96E-06 
Adam4 47.1 -1.3 1.51E-07 2.14E-06 
Rnf165 46.5 -1.2 1.95E-07 2.69E-06 
Mir1188 18.8 -1.4 2.08E-07 2.86E-06 
Bsn 5185.7 -1.1 2.58E-07 3.45E-06 
Nav1 4588.8 -1.0 2.72E-07 3.62E-06 
Nova2 122.0 -1.0 3.93E-07 5.02E-06 
Kcnq3 1824.2 -1.0 4.36E-07 5.51E-06 
Nr4a3 40.7 -1.3 4.71E-07 5.92E-06 
Tnfrsf11b 84.2 1.0 7.19E-07 8.74E-06 
Gm26890 36.5 -1.2 7.45E-07 9.01E-06 
Hbb-bs 1968.2 1.3 9.92E-07 1.17E-05 
Mgp 1005.6 1.0 9.99E-07 1.18E-05 
Gdf10 68.2 1.0 1.05E-06 1.22E-05 
A130050O07Rik 18.0 -1.3 1.05E-06 1.23E-05 
D630014O11Rik 8.6 -1.3 1.06E-06 1.24E-05 
Gm4787 33.4 -1.2 1.18E-06 1.36E-05 
Gm14703 51.7 1.2 1.27E-06 1.46E-05 
AY036118 4212.5 -1.0 1.4E-06 1.59E-05 
Gm26582 70.7 1.1 1.62E-06 1.81E-05 
Gm9930 11.7 -1.3 1.65E-06 1.84E-05 
Papolb 44.4 -1.1 1.73E-06 1.93E-05 
Map1a 49153.5 -1.0 1.9E-06 2.09E-05 
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Cpz 49.8 1.2 2.29E-06 2.47E-05 
Mir341 11.1 -1.3 2.37E-06 2.54E-05 
Gm26691 39.7 -1.1 2.47E-06 2.64E-05 
Osr1 57.5 1.1 2.77E-06 2.93E-05 
Myo1h 19.9 1.3 2.83E-06 2.98E-05 
Mir679 8.8 -1.3 2.95E-06 3.1E-05 
Eqtn 10.6 -1.3 3.03E-06 3.17E-05 
1700022I11Rik 16.6 1.3 3.21E-06 3.34E-05 
Dapl1 24.5 1.3 3.31E-06 3.43E-05 
4930473A02Rik 16.1 1.3 4.7E-06 4.67E-05 
B230325K18Rik 66.4 -1.0 5.95E-06 5.78E-05 
Serpinb6c 35.4 1.1 6.62E-06 6.34E-05 
Vmn2r84 6.2 -1.2 7.21E-06 6.85E-05 
Gm12186 32.3 -1.1 7.6E-06 7.2E-05 
Gm26883 92.7 1.1 8.6E-06 8.04E-05 
Slc16a11 35.7 1.2 8.97E-06 8.35E-05 
Gm26814 26.6 -1.2 9.53E-06 8.8E-05 
Gm26543 10.7 -1.2 9.92E-06 9.11E-05 
Ifltd1 37.7 1.1 1.4E-05 0.000123 
Gm26930 23.4 -1.2 1.48E-05 0.000129 
Ly6c2 41.6 1.1 1.51E-05 0.000132 
Tmem88 40.9 1.0 1.53E-05 0.000134 
Hbb-bt 432.2 1.2 1.64E-05 0.000142 
Gm25848 30.3 -1.1 1.8E-05 0.000154 
Plac8 40.2 1.1 1.84E-05 0.000157 
Sell 42.6 1.1 2.02E-05 0.00017 
Itgb2l 35.4 1.1 2.1E-05 0.000176 
Lrg1 45.2 1.0 2.42E-05 0.0002 
Wdr86 45.5 1.0 2.45E-05 0.000202 
Hba-a2 214.4 1.1 2.82E-05 0.000227 
D130062J21Rik 34.5 -1.1 3.11E-05 0.000249 
BC068157 25.5 -1.1 3.33E-05 0.000263 
4930405O22Rik 22.4 -1.1 4.21E-05 0.000324 
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Gm14493 21.4 1.1 4.53E-05 0.000347 
Gm22205 7.8 -1.1 4.73E-05 0.00036 
Gm14824 16.4 -1.1 5.16E-05 0.00039 
A430106G13Rik 16.5 -1.1 5.21E-05 0.000393 
Gm5466 21.8 -1.1 5.22E-05 0.000393 
Ear6 12.9 1.1 5.27E-05 0.000397 
Clec5a 26.2 1.1 5.54E-05 0.000414 
Gm11653 15.3 -1.1 5.75E-05 0.000428 
Gm13479 20.4 -1.1 5.95E-05 0.000441 
Dbp 423.3 1.0 6.3E-05 0.000462 
Gm20491 12.6 -1.1 6.49E-05 0.000474 
Gm26825 18.7 1.1 7.14E-05 0.000517 
Gm12841 10.9 1.1 7.56E-05 0.000543 
Mir1898 11.8 -1.1 8.36E-05 0.000593 
Gm26530 10.6 1.1 8.69E-05 0.000613 
Gm13627 8.3 -1.1 8.73E-05 0.000615 
Gm17097 9.3 -1.1 8.83E-05 0.000621 
Gm14776 7.5 -1.0 9.39E-05 0.000656 
Gm26944 26.1 -1.0 9.52E-05 0.000664 
Mir1193 6.3 -1.0 9.6E-05 0.000668 
Gm24564 14.0 -1.1 0.000103 0.000717 
Gm19967 23.9 -1.0 0.000108 0.000744 
Mir453 10.7 -1.1 0.00011 0.000757 
6430590A07Rik 23.4 -1.0 0.000111 0.000759 
Fat2 25.4 1.0 0.000122 0.000826 
Mir5125 13.9 -1.1 0.000132 0.000886 
AC121784.1 6.2 -1.0 0.000141 0.000937 
Pou6f2 28.5 -1.0 0.000162 0.00106 
Tfap2a 22.5 -1.0 0.000163 0.001062 
Ear1 9.5 1.0 0.000166 0.001079 
Gm9817 14.7 1.1 0.000177 0.001141 
Ccl21a 23.8 1.0 0.000185 0.001188 
Mir3070a 9.8 -1.0 0.000192 0.001224 
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Hba-a1 318.0 1.0 0.000223 0.001392 
Gm26723 85.9 1.0 0.000266 0.001617 
Gm13650 10.9 -1.0 0.000271 0.001642 
Gm14827 13.7 -1.0 0.000273 0.001652 
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Table 14S. Full list of differentially expressed genes following cisplatin administration. 
Full list of differentially expressed genes following cisplatin administration. Genes are sorted 
according to the Padj values.  
Gene name Base Mean log2FoldChange P value Padj 
Snhg11 8555.1 -1.7 2.4E-153 4.5E-149 
Pclo 7476.1 -1.9 9.66E-67 8.87E-63 
 Syn1 3713.4 -1.7 1.39E-63 8.5E-60 
Zfhx2 591.6 -2.0 2.11E-63 9.67E-60 
Wasf1 718.4 -1.7 4.38E-61 1.61E-57 
Raph1 1278.3 -1.7 6.94E-59 2.12E-55 
9530059O14Rik 1502.3 -1.9 2.96E-56 7.77E-53 
Clip3 3162.3 -1.8 1.1E-54 2.53E-51 
Ncor2 2131.5 -1.3 1.85E-52 3.77E-49 
Ylpm1 1690.0 -1.1 2.74E-49 5.03E-46 
Malat1 163316.0 -1.1 5.07E-47 8.47E-44 
Wipf3 1737.5 -1.7 9.32E-46 1.43E-42 
Dnm3 10855.2 -1.5 5.76E-45 8.14E-42 
Cpeb2 3614.8 -1.2 8E-45 1.05E-41 
Ptpn23 1023.7 -1.4 1.16E-44 1.42E-41 
Pcbp2 2296.0 -1.3 1.38E-44 1.58E-41 
Sos1 4657.9 -1.4 5.06E-44 5.46E-41 
Fam65a 654.7 -1.5 2.09E-43 2.13E-40 
Srrm2 8415.3 -1.3 4.23E-43 4.09E-40 
Plagl1 1103.7 -1.2 4.53E-42 4.16E-39 
Nfat5 3468.0 -1.2 5.79E-42 5.06E-39 
Gm26871 319.6 -2.0 6.63E-42 5.53E-39 
Gm26945 203.8 -2.4 3.08E-40 2.46E-37 
Gucy1a2 1624.7 -1.2 7.08E-39 5.42E-36 
Polr2a 2199.0 -1.3 3.84E-38 2.82E-35 
Ubqln2 1977.4 -1.4 1.54E-37 1.09E-34 
Ids 9247.1 -1.1 1.71E-37 1.16E-34 
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Tubb4a 5986.3 -1.3 3.12E-37 2.05E-34 
Cdc73 1787.6 -1.1 3.49E-37 2.21E-34 
Parp4 1375.1 -1.2 3.73E-37 2.28E-34 
Brd4 1028.1 -1.4 9.92E-37 5.87E-34 
Gm15675 353.7 -1.5 1.11E-34 6.01E-32 
Ntrk3 3056.4 -1.1 1.1E-34 6.01E-32 
Fus 1084.2 -1.2 1.29E-34 6.75E-32 
Rfx7 786.2 -1.2 6.44E-34 3.2E-31 
Naa15 2901.3 -1.1 8.11E-34 3.92E-31 
Cacna1a 2708.6 -1.2 1.07E-33 5.03E-31 
Miat 4146.7 -1.3 1.12E-33 5.13E-31 
Ppp2r2a 1849.7 -1.2 1.74E-33 7.8E-31 
Ank3 15155.8 -1.2 3.27E-33 1.43E-30 
Atxn2 1691.2 -1.1 3.43E-33 1.46E-30 
Tmem131 2104.0 -1.1 7.3E-33 3.05E-30 
Prrc2c 6107.1 -1.1 9.64E-33 3.93E-30 
A330023F24Rik 580.5 -1.3 1.5E-32 6E-30 
Vamp2 3409.6 -1.1 1.81E-32 7.08E-30 
C230004F18Rik 382.3 -1.4 4.35E-32 1.67E-29 
Kif2a 3847.1 -1.1 1.1E-31 4.04E-29 
4932438A13Rik 8230.4 -1.0 1.66E-31 5.97E-29 
Ireb2 3587.8 -1.1 2.16E-31 7.63E-29 
Arid1a 1706.2 -1.1 3.27E-31 1.13E-28 
Scrt2 324.8 -1.5 3.82E-31 1.3E-28 
Synj1 5844.6 -1.2 5.46E-31 1.82E-28 
Aak1 5312.3 -1.1 1.16E-30 3.67E-28 
Fmn2 896.8 -1.0 1.39E-30 4.34E-28 
Gm15800 11681.1 -1.2 2.68E-30 8.19E-28 
AI593442 3429.3 -1.1 3.24E-30 9.75E-28 
Dync1h1 72241.4 -1.1 4.57E-30 1.33E-27 
Ank2 57721.0 -1.2 1.29E-29 3.6E-27 
Pitpnm2 5288.2 -1.1 1.64E-29 4.49E-27 
Wasl 3754.3 -1.0 2.24E-29 6.05E-27 
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Rps6ka3 5891.5 -1.1 3.35E-29 8.79E-27 
Pld5 1008.0 -1.0 3.85E-29 9.96E-27 
Disp2 7229.5 -1.1 1.05E-28 2.65E-26 
Fam189b 4841.2 -1.1 1.25E-28 3.1E-26 
Rph3a 6546.4 -1.1 1.7E-28 4.17E-26 
Atxn2l 1206.3 -1.0 2.01E-28 4.85E-26 
Coro2b 2113.3 -1.2 2.18E-28 5.2E-26 
Dhx9 4067.7 -1.2 1.31E-27 3E-25 
Ryr2 4270.2 -1.2 2.1E-27 4.71E-25 
Gatad2b 358.6 -1.2 2.67E-27 5.91E-25 
A930011O12Rik 452.2 -1.5 2.92E-27 6.38E-25 
Fry 5969.0 -1.0 5.75E-27 1.19E-24 
Cacna1b 5234.0 -1.0 6.59E-27 1.34E-24 
Prune2 129862.4 -1.1 7.32E-27 1.48E-24 
Sec24a 721.2 -1.1 9.56E-27 1.89E-24 
Ubr4 15926.3 -1.0 1.05E-26 2.02E-24 
Atn1 440.9 -1.2 1.41E-26 2.69E-24 
Mirg 707.8 -1.4 2.16E-26 4E-24 
A330076H08Rik 249.8 -1.6 2.19E-26 4.02E-24 
Map1b 229414.3 -1.1 2.98E-26 5.39E-24 
Tanc2 3939.4 -1.1 4.8E-26 8.55E-24 
Proser1 232.3 -1.5 6.03E-26 1.05E-23 
Enah 2387.2 -1.1 1.51E-25 2.57E-23 
Srgap1 1360.3 -1.2 1.98E-25 3.3E-23 
Ahnak2 20653.3 -1.1 2.33E-25 3.85E-23 
Pom121 442.4 -1.3 2.42E-25 3.97E-23 
Zmiz2 978.5 -1.0 2.78E-25 4.51E-23 
Fam98b 347.5 -1.2 6.38E-25 9.76E-23 
Ncoa6 735.3 -1.1 1.08E-24 1.6E-22 
D10Bwg1379e 5434.3 -1.1 1.64E-24 2.35E-22 
Zfhx4 908.7 -1.0 4.57E-24 6.18E-22 
Arsb 783.6 -1.0 4.58E-24 6.18E-22 
Nf1 9972.1 -1.1 8.4E-24 1.09E-21 
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Scaf4 435.6 -1.1 9.68E-24 1.23E-21 
Ppp2r5e 2101.6 -1.0 1.1E-23 1.39E-21 
Efna5 613.9 -1.0 1.61E-23 2.01E-21 
Celsr2 1642.8 -1.2 2.98E-23 3.58E-21 
Ankrd52 4000.3 -1.0 3.65E-23 4.32E-21 
Astn1 3045.7 -1.0 6.8E-23 7.85E-21 
Sdk2 719.6 -1.1 8.12E-23 9.26E-21 
B830012L14Rik 109.0 -2.1 8.32E-23 9.43E-21 
Mast1 3910.8 -1.0 9.84E-23 1.11E-20 
Trim67 1919.8 -1.2 9.91E-23 1.11E-20 
Onecut2 3020.7 -1.1 1.67E-22 1.81E-20 
Parvb 1359.5 -1.1 1.89E-22 2.03E-20 
Zfp804a 1057.3 -1.2 3.32E-22 3.46E-20 
Dgkk 133.7 -1.7 7.76E-22 7.82E-20 
Kmt2d 2824.1 -1.1 1.13E-21 1.13E-19 
Col24a1 370.6 -1.2 1.75E-21 1.69E-19 
Inpp5j 677.8 -1.1 3.04E-21 2.78E-19 
Cherp 492.1 -1.0 1.41E-20 1.19E-18 
Vsnl1 1933.2 -1.2 1.65E-20 1.39E-18 
Mrgprb5 310.9 -1.2 1.66E-20 1.4E-18 
Mamld1 406.2 -1.1 1.89E-20 1.57E-18 
Esrrg 1004.5 -1.1 2.46E-20 2E-18 
Cntnap1 3271.3 -1.0 2.46E-20 2E-18 
Dvl3 461.9 -1.1 7.16E-20 5.59E-18 
Peg10 422.5 -1.1 7.4E-20 5.75E-18 
Zfp703 242.6 -1.2 9.83E-20 7.48E-18 
Srgap3 4753.7 -1.1 1.12E-19 8.39E-18 
Kcnq3 1770.7 -1.1 1.39E-19 1.03E-17 
Hdx 325.1 -1.2 6.07E-19 4.21E-17 
2310061I04Rik 362.9 -1.1 1.06E-18 7.18E-17 
Gm27000 224.3 -1.4 1.75E-18 1.17E-16 
Gm23600 56.2 -2.0 1.8E-18 1.2E-16 
Zbtb33 627.1 -1.0 2.85E-18 1.85E-16 
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Fign 462.2 -1.1 6.43E-18 3.92E-16 
Tox2 139.1 -1.4 2.53E-17 1.46E-15 
Prr12 394.3 -1.1 2.71E-17 1.55E-15 
Gm16586 316.1 -1.0 5.36E-17 2.97E-15 
Hba-a2 216.0 1.6 2.73E-16 1.38E-14 
2810055G20Rik 457.0 -1.1 3.08E-16 1.55E-14 
Zmat1 266.0 -1.1 3.11E-16 1.55E-14 
Coro6 453.1 -1.1 1.21E-15 5.7E-14 
Lcn2 198.5 1.4 1.26E-15 5.89E-14 
Zdbf2 198.2 -1.2 2.32E-15 1.06E-13 
Meg3 11445.5 -1.5 2.46E-14 1E-12 
Alas2 130.1 1.6 3.75E-14 1.49E-12 
Cacna1e 564.7 -1.0 1.25E-13 4.64E-12 
Neto1 198.1 -1.0 2.27E-13 8.09E-12 
Slfn4 93.7 1.3 1.4E-12 4.49E-11 
Gm12940 197.0 -1.0 1.5E-12 4.76E-11 
Arhgap33 208.7 -1.1 1.81E-12 5.7E-11 
Map1a 46234.8 -1.2 2.69E-12 8.16E-11 
Palm2 454.9 -1.1 3.75E-12 1.11E-10 
Arhgdib 181.6 1.4 4.6E-12 1.33E-10 
Mpo 117.7 1.3 6.97E-12 1.97E-10 
Srrm4 170.6 -1.2 9.61E-12 2.68E-10 
Gm10167 128.2 -1.1 1.46E-11 3.92E-10 
Hist1h2bb 171.3 1.1 5.09E-11 1.26E-09 
Lmtk3 160.1 -1.2 5.62E-11 1.38E-09 
Atp1a3 10967.7 -1.1 6.88E-11 1.67E-09 
Cd177 105.6 1.3 1.36E-10 3.15E-09 
Gm14443 125.4 -1.2 1.48E-10 3.39E-09 
Itgb2l 43.1 1.6 2E-10 4.52E-09 
Hist1h1a 168.6 1.1 3.6E-10 7.79E-09 
Gm21846 21.2 -1.7 4.95E-10 1.04E-08 
Grid2ip 98.7 -1.2 5.79E-10 1.21E-08 
Tyrobp 197.6 1.0 5.89E-10 1.22E-08 
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Bsn 4979.4 -1.2 1.07E-09 2.15E-08 
Hp 114.6 1.1 2.65E-09 5.07E-08 
Rac2 100.5 1.1 2.89E-09 5.48E-08 
Hist1h2bm 68.2 1.3 3.51E-09 6.59E-08 
Ltf 656.8 1.4 3.9E-09 7.24E-08 
Pianp 87.9 -1.1 5.05E-09 9.14E-08 
Epx 25.6 1.6 5.94E-09 1.07E-07 
Ly6c2 48.2 1.4 1.1E-08 1.89E-07 
Hist1h2bn 93.5 1.1 1.43E-08 2.41E-07 
Hist1h1b 130.4 1.1 1.48E-08 2.49E-07 
Tmem119 137.3 1.0 1.49E-08 2.5E-07 
Kcnc3 940.9 -1.2 2.11E-08 3.46E-07 
Pgm5 118.4 1.0 2.56E-08 4.15E-07 
Ranbp3l 114.0 1.2 3.1E-08 4.96E-07 
Nav1 4479.1 -1.0 3.6E-08 5.71E-07 
Hbb-bs 1857.4 1.4 4.75E-08 7.35E-07 
Gm25981 10.8 -1.5 6.47E-08 9.81E-07 
BC024978 102.0 -1.0 6.8E-08 1.03E-06 
Gm24564 11.9 -1.5 6.96E-08 1.05E-06 
Fmod 200.1 1.1 9.18E-08 1.35E-06 
Shisa6 54.5 -1.2 1.28E-07 1.83E-06 
Gm6088 69.1 -1.1 1.47E-07 2.06E-06 
2900056M20Rik 49.2 -1.2 1.49E-07 2.09E-06 
Ncf4 45.5 1.2 1.72E-07 2.38E-06 
Hist1h3b 46.2 1.3 2.01E-07 2.74E-06 
Gm26601 45.2 -1.2 2.58E-07 3.46E-06 
Klhdc7a 46.7 1.3 2.65E-07 3.54E-06 
Rab44 47.9 1.2 2.98E-07 3.94E-06 
Ear6 14.3 1.4 3.02E-07 3.98E-06 
Gypa 53.3 1.3 3.53E-07 4.59E-06 
Nr4a3 40.2 -1.3 3.85E-07 4.98E-06 
Trim10 30.0 1.3 4.02E-07 5.2E-06 
B230325K18Rik 63.1 -1.1 4.96E-07 6.31E-06 
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Siah3 65.4 -1.0 6.09E-07 7.61E-06 
Creb5 67.7 -1.0 6.66E-07 8.26E-06 
Gm20491 11.3 -1.3 8.2E-07 9.99E-06 
Snord107 26.8 -1.3 9.45E-07 1.14E-05 
Cxcr2 32.2 1.3 9.68E-07 1.16E-05 
Fgfbp1 53.2 1.2 1.14E-06 1.35E-05 
Hist1h2bk 30.7 1.2 1.43E-06 1.66E-05 
Selplg 57.5 1.1 1.46E-06 1.68E-05 
Hbb-bt 465.8 1.3 1.58E-06 1.81E-05 
Ifitm6 35.2 1.3 1.59E-06 1.82E-05 
Gm26514 37.9 -1.2 1.73E-06 1.97E-05 
Krt19 55.5 1.1 2.18E-06 2.43E-05 
Hist1h2ab 70.0 1.1 2.2E-06 2.45E-05 
Slc22a8 74.1 1.1 2.34E-06 2.59E-05 
Slc12a3 23.4 -1.3 2.42E-06 2.67E-05 
Igsf6 67.7 1.0 2.52E-06 2.78E-05 
Hba-a1 321.6 1.2 2.65E-06 2.91E-05 
D130062J21Rik 31.9 -1.3 3.01E-06 3.26E-05 
Adam4 47.1 -1.1 3.62E-06 3.85E-05 
Plac8 39.0 1.2 4.2E-06 4.38E-05 
Msln 77.6 1.0 4.22E-06 4.4E-05 
Sell 44.4 1.2 4.5E-06 4.67E-05 
Rnf165 46.5 -1.1 4.64E-06 4.78E-05 
Gm5466 19.7 -1.3 5.04E-06 5.13E-05 
Hk3 76.7 1.0 5.69E-06 5.71E-05 
Hist1h3a 31.1 1.2 5.7E-06 5.71E-05 
Ctsg 22.0 1.2 7.21E-06 7.05E-05 
Prss34 18.5 1.2 7.27E-06 7.1E-05 
Gm25788 86.4 -1.0 9.23E-06 8.78E-05 
Slc22a6 41.0 1.1 1E-05 9.49E-05 
Apol11b 14.4 1.2 1.05E-05 9.85E-05 
Camp 267.6 1.1 1.26E-05 0.000117 
Mir5125 13.1 -1.2 1.36E-05 0.000125 
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Ccr1 44.3 1.1 1.6E-05 0.000145 
Alox15 9.2 1.1 1.7E-05 0.000153 
Ctse 49.1 1.0 2.2E-05 0.000193 
AY036118 3721.2 -1.1 2.28E-05 0.000199 
Prg2 104.7 1.2 2.32E-05 0.000202 
Chi3l3 250.7 1.1 2.38E-05 0.000206 
S100a9 1531.2 1.1 2.45E-05 0.000212 
Tmem88 39.4 1.0 2.62E-05 0.000224 
Hist1h3c 55.8 1.0 2.93E-05 0.000249 
Mir1188 19.5 -1.1 2.96E-05 0.000251 
Gm26448 195.3 -1.1 3.14E-05 0.000265 
P2ry13 35.8 1.0 3.86E-05 0.000317 
Gm13627 7.6 -1.1 3.96E-05 0.000325 
Osr1 54.8 1.0 4.26E-05 0.000346 
Gm26814 26.5 -1.1 4.52E-05 0.000365 
S100a8 1057.0 1.1 5.33E-05 0.000422 
Prg3 8.3 1.1 5.59E-05 0.000441 
Hist1h3i 31.8 1.0 7.44E-05 0.000568 
Padi4 30.1 1.0 8.59E-05 0.000642 
A430106G13Rik 15.8 -1.1 9.23E-05 0.000684 
BC068157 24.9 -1.0 9.56E-05 0.000705 
1100001G20Rik 30.2 1.0 0.000105 0.000769 
Gm26530 11.4 1.1 0.000106 0.000773 
Ear1 12.5 1.0 0.000114 0.000829 
Cdr1 9.3 -1.0 0.000123 0.000885 
Gm14776 7.3 -1.0 0.000125 0.000899 
Mir341 11.4 -1.0 0.000234 0.001556 
Cd5l 11.2 1.0 0.000237 0.001571 
Fcnb 15.3 1.0 0.000243 0.001608 
Gm26543 11.1 -1.0 0.000261 0.001708 
Gm9817 14.7 1.0 0.000288 0.001864 
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Table 15S. Cell type enrichment analysis of differentially expressed genes in L3 - L5 dorsal root 
ganglia following vincristine, oxaliplatin and cisplatin administration. 
Cell type enrichment analysis of differentially expressed genes in L3 - L5 DRG following 
vincristine, oxaliplatin and cisplatin administration. Cell type enrichment analysis was performed 
using the CTEN tool and the score was generated using one-sided, Fisher's Exact test for 
enrichment and it is shown as the -log10 of the Benjamini-Hochberg (BH) adjusted P-values. 
Scores > 20 optimally minimize the false positive rate (FPR). Lps: lipopolysaccharide, Hrs: hours, 
Peri: peripheral. 
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Cell type Score 
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Cell type Score 
Bone 
Marrow 
157.5 Olfactory 
Bulb 
9.9 Bone Marrow 13.6 
Bone 147.0 Cerebral 
Cortex  
9.4 Bone 11.4 
Granulocytes 84.1 Hypothalamus 8.2 Granulocytes 10.5 
Macrophage 
Bone 
Marrow Lps 
6Hrs 
41.7 Cerebellum 8.1 Cerebral 
Cortex 
9.4 
Spleen 38.8 Cerebral 
Cortex 
7.8 Dorsal Root 
Ganglia 
9.2 
Macrophage 
Bone 
Marrow Lps 
24 Hrs 
38.6 Amygdala 6.6 Olfactory Bulb 9.1 
Osteoclasts 37.5 Pituitary 6.4 Spinal Cord 8.4 
Macrophage 
Bone 
Marrow Lps 
2Hrs 
34.8 Nucleus 
Accumbens 
6.2 Hypothalamus 8.3 
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Macrophage 
Peri Lps 
7Hrs 
33.8 Hippocampus 6.0 Cerebral 
Cortex  
7.9 
Macrophage 
Bone 
Marrow 
30.7 Dorsal 
Striatum 
5.9 Nucleus 
Accumbens 
7.6 
Macrophage 
Peri Lps 
1Hrs 
29.3 Spinal Cord 5.4 Cerebellum 7.5 
Macrophage 
Peri  
27.8 Dorsal Root 
Ganglia 
4.5 Amygdala 7.3 
Microglia 27.5 Retina 4.3 Hippocampus 7.2 
Granulo- 
Mono-
progenitor 
26.5 Umbilical 
Cord 
2.9 Pituitary 7.2 
RAW 264.7 
Cells 
25.3 Retinal 
Pigment 
Epithelium 
2.8 Dorsal 
Striatum 
5.5 
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Table 16S. Differentially expressed genes shared between vincristine and/or oxaliplatin and/or 
cisplatin. 
The gene identifiers were converted into gene names using DAVID Bioinformatics Resources 6.8, 
NIAID/NIH the Gene Name Batch Viewer tool. 
Vincristine & Oxaliplatin & Cisplatin 
Gene and gene symbol 
aminolevulinic acid synthase 2, erythroid (Alas2) 
hemoglobin, beta adult t chain (Hbb-bt) 
integrin beta 2-like (Itgb2l) 
lymphocyte antigen 6 complex, locus C2 (Ly6c2) 
nuclear receptor subfamily 4, group A, member 3 (Nr4a3) 
  
Vincristine & Oxaliplatin 
Gene and gene symbol 
aminolevulinic acid synthase 2, erythroid (Alas2) 
cholinergic receptor, nicotinic, beta polypeptide 3 (Chrnb3) 
C-type lectin domain family 5, member a (Clec5a) 
hemoglobin, beta adult t chain (Hbb-bt) 
integrin beta 2-like (Itgb2l) 
lymphocyte antigen 6 complex, locus C2 (Ly6c2) 
nuclear receptor subfamily 4, group A, member 3 (Nr4a3) 
  
Vincristine & Cisplatin 
Gene and gene symbol 
aminolevulinic acid synthase 2, erythroid (Alas2) 
apolipoprotein L 11b (Apol11b) 
cathelicidin antimicrobial peptide (Camp) 
cathepsin E (Ctse) 
CD177 antigen (Cd177) 
chemokine (C-C motif) receptor 1 (Ccr1) 
chemokine (C-X-C motif) receptor 2 (Cxcr2) 
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glycophorin A (Gypa) 
haptoglobin (Hp) 
hemoglobin, beta adult t chain (Hbb-bt) 
hexokinase 3 (Hk3) 
immunoglobulin superfamily, member 6 (Igsf6) 
integrin beta 2-like (Itgb2l) 
interferon induced transmembrane protein 6 (Ifitm6) 
lactotransferrin (Ltf) 
lipocalin 2 (Lcn2) 
lymphocyte antigen 6 complex, locus C2 (Ly6c2) 
neutrophil cytosolic factor 4 (Ncf4) 
nuclear receptor subfamily 4, group A, member 3 (Nr4a3) 
peptidyl arginine deiminase, type IV (Padi4) 
RAB44, member RAS oncogene family (Rab44) 
RAS-related C3 botulinum substrate 2 (Rac2) 
S100 calcium binding protein A8 (calgranulin A)(S100a8) 
S100 calcium binding protein A9 (calgranulin B)(S100a9) 
schlafen 4 (Slfn4) 
selectin, platelet (p-selectin) ligand (Selplg) 
tripartite motif-containing 10 (Trim10) 
  
Oxaliplatin & Cisplatin 
Gene and gene symbol 
a disintegrin and metallopeptidase domain 4 (Adam4) 
aminolevulinic acid synthase 2, erythroid (Alas2) 
AP2 associated kinase 1 (Aak1) 
arylsulfatase B (Arsb) 
AT rich interactive domain 1A (SWI-like)(Arid1a) 
ataxin 2 (Atxn2) 
ataxin 2-like (Atxn2l) 
ATPase, Na+/K+ transporting, alpha 3 polypeptide (Atp1a3) 
atrophin 1 (Atn1) 
Bassoon (Bsn) 
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bromodomain containing 4 (Brd4) 
cadherin, EGF LAG seven-pass G-type receptor 2 (Celsr2) 
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
(Cacna1a) 
calcium homeostasis endoplasmic reticulum protein (Cherp) 
cAMP responsive element binding protein 5 (Creb5) 
CAP-GLY domain containing linker protein 3 (Clip3) 
cDNA sequence AY036118 (AY036118) 
cDNA sequence BC024978 (BC024978) 
cell division cycle 73, Paf1/RNA polymerase II complex component 
(Cdc73) 
collagen, type XXIV, alpha 1 (Col24a1) 
coronin 6 (Coro6) 
coronin, actin binding protein, 2B (Coro2b) 
cytoplasmic polyadenylation element binding protein 2 (Cpeb2) 
DEAH (Asp-Glu-Ala-His) box polypeptide 9 (Dhx9) 
diacylglycerol kinase kappa (Dgkk) 
dishevelled segment polarity protein 3 (Dvl3) 
dynamin 3 (Dnm3) 
enabled homolog (Drosophila) (Enah) 
enolase 1, alpha non-neuron pseudogene (Gm20491) 
eosinophil-associated, ribonuclease A family, member 1 (Ear1) 
eosinophil-associated, ribonuclease A family, member 6 (Ear6) 
ephrin A5(Efna5) 
expressed sequence AI593442 (AI593442) 
family with sequence similarity 189, member B (Fam189b) 
family with sequence similarity 65, member A (Fam65a) 
family with sequence similarity 98, member B (Fam98b) 
fibroblast growth factor binding protein 1 (Fgfbp1) 
Fibromodulin (Fmod) 
Fidgetin (Fign) 
formin 2 (Fmn2) 
fused in sarcoma (Fus) 
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GATA zinc finger domain containing 2B (Gatad2b) 
glutamate receptor, ionotropic, delta 2 (Grid2) interacting protein 1 
(Grid2ip) 
guanylate cyclase 1, soluble, alpha 2 (Gucy1a2) 
hemoglobin alpha, adult chain 1 (Hba-a1) 
hemoglobin alpha, adult chain 2 (Hba-a2) 
hemoglobin, beta adult s chain (Hbb-bs) 
hemoglobin, beta adult t chain (Hbb-bt) 
highly divergent homeobox (Hdx) 
iduronate 2-sulfatase (Ids) 
inositol polyphosphate 5-phosphatase J (Inpp5j) 
integrin beta 2-like (Itgb2l) 
iron responsive element binding protein 2 (Ireb2) 
kelch domain containing 7A (Klhdc7a) 
kinesin family member 2A (Kif2a) 
lemur tyrosine kinase 3 (Lmtk3) 
lymphocyte antigen 6 complex, locus C2 (Ly6c2) 
lysine (K)-specific methyltransferase 2D (Kmt2d) 
MAS-related GPR, member B5 (Mrgprb5) 
mastermind-like domain containing 1 (Mamld1) 
maternally expressed 3 (Meg3) 
Mesothelin (Msln) 
metastasis associated lung adenocarcinoma transcript 1 (non-coding 
RNA) (Malat1) 
microRNA 1188 (Mir1188) 
microRNA 341 (Mir341) 
microRNA 5125 (Mir5125) 
microtubule-associated protein 1 A (Map1a) 
miRNA containing gene (Mirg) 
myocardial infarction associated transcript (non-protein coding) (Miat) 
N(alpha)-acetyltransferase 15, NatA auxiliary subunit (Naa15) 
neuron navigator 1 (Nav1) 
neuropilin (NRP) and tolloid (TLL)-like 1 (Neto1) 
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nuclear factor of activated T cells 5 (Nfat5) 
nuclear pore membrane protein 121 (Pom121) 
nuclear receptor coactivator 6 (Ncoa6) 
nuclear receptor co-repressor 2 (Ncor2) 
nuclear receptor subfamily 4, group A, member 3 (Nr4a3) 
nucleophosmin 1 pseudogene (Gm14776) 
odd-skipped related 1 (Drosophila) (Osr1) 
one cut domain, family member 2 (Onecut2) 
paralemmin 2 (Palm2) 
parvin, beta (Parvb) 
paternally expressed 10 (Peg10) 
phospholipase D family, member 5 (Pld5) 
piccolo (presynaptic cytomatrix protein) (Pclo) 
PILR alpha associated neural protein (Pianp) 
placenta-specific 8 (Plac8) 
pleiomorphic adenoma gene-like 1 (Plagl1) 
poly (ADP-ribose) polymerase family, member 4 (Parp4) 
poly(A) binding protein, cytoplasmic 4 pseudogene (Gm5466) 
poly(rC) binding protein 2 (Pcbp2) 
polymerase (RNA) II (DNA directed) polypeptide A (Polr2a) 
potassium voltage gated channel, Shaw-related subfamily, member 3 
(Kcnc3) 
potassium voltage-gated channel, subfamily Q, member 3 (Kcnq3) 
predicted gene 14443 (Gm14443) 
predicted gene 15675 (Gm15675) 
predicted gene 9817 (Gm9817) 
predicted gene, 26871 (Gm26871) 
predicted pseudogene 10167 (Gm10167) 
proline and serine rich 1 (Proser1) 
proline rich 12 (Prr12) 
proline-rich coiled-coil 2C (Prrc2c) 
protein phosphatase 2, regulatory subunit B, alpha (Ppp2r2a) 
protein phosphatase 2, regulatory subunit B', epsilon (Ppp2r5e) 
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protein tyrosine phosphatase, non-receptor type 23 (Ptpn23) 
rabphilin 3A( Rph3a) 
RAN binding protein 3-like (Ranbp3l) 
Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 
(Raph1) 
regulatory factor X, 7 (Rfx7) 
Rho GTPase activating protein 33 (Arhgap33) 
ribosomal protein S6 kinase polypeptide 3 (Rps6ka3) 
RIKEN cDNA 2310061I04 gene (2310061I04Rik) 
RIKEN cDNA 9530059O14 gene (9530059O14Rik) 
RIKEN cDNA A330023F24 gene (A330023F24Rik) 
RIKEN cDNA A330076H08 gene (A330076H08Rik) 
RIKEN cDNA A430106G13 gene (A430106G13Rik) 
RIKEN cDNA B230325K18 gene (B230325K18Rik) 
RIKEN cDNA C230004F18 gene (C230004F18Rik) 
RIKEN cDNA D130062J21 gene (D130062J21Rik) 
ring finger protein 165 (Rnf165) 
scratch family zinc finger 2 (Scrt2) 
Sec24 related gene family, member A (S. cerevisiae) (Sec24a) 
selectin, lymphocyte (Sell) 
serine/arginine repetitive matrix 2 (Srrm2) 
serine/arginine repetitive matrix 4 (Srrm4) 
shisa family member 6 (Shisa6) 
SLIT-ROBO Rho GTPase activating protein 1 (Srgap1) 
small nucleolar RNA host gene 11 (Snhg11) 
solute carrier family 12, member 3 (Slc12a3) 
solute carrier family 22 (organic anion transporter), member 6 (Slc22a6) 
solute carrier family 22 (organic anion transporter), member 8 (Slc22a8) 
son of sevenless homolog 1 (Drosophila) (Sos1) 
SR-related CTD-associated factor 4 (Scaf4) 
synapsin I (Syn1) 
synaptojanin 1 (Synj1) 
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tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 
(Tanc2) 
TOX high mobility group box family member 2 (Tox2) 
transmembrane protein 119 (Tmem119) 
transmembrane protein 131 (Tmem131) 
transmembrane protein 88 (Tmem88) 
tubulin, beta 4A class IVA (Tubb4a) 
ubiquilin 2 (Ubqln2) 
vesicle-associated membrane protein 2 (Vamp2) 
visinin-like 1 (Vsnl1) 
WAS protein family, member 1 (Wasf1) 
WAS/WASL interacting protein family, member 3 (Wipf3) 
Wiskott-Aldrich syndrome-like (human) (Wasl) 
YLP motif containing 1 (Ylpm1) 
zinc finger and BTB domain containing 33 (Zbtb33) 
zinc finger homeobox 2 (Zfhx2) 
zinc finger homeodomain 4 (Zfhx4) 
zinc finger protein 703 (Zfp703) 
zinc finger protein 804A (Zfp804a) 
zinc finger, DBF-type containing 2 (Zdbf2) 
zinc finger, matrin type 1 (Zmat1) 
zinc finger, MIZ-type containing 2 (Zmiz2) 
  
273 
 
 
Table 17S. Systemic or local administration of vincristine elicits strong mechanical allodynia and 
gait disturbances. 
Systemic (0.5 mg/kg, i.p.) or local (10 µg, i.pl.) administration of vincristine elicits strong mechanical 
allodynia (PWT) and gait disturbances (% contralateral) in C57BL6 mice. Statistical significance was 
determined by repeated measures two-way ANOVA with Sidak’s multiple comparisons test and 
defined as p <0.05 compared to control. All data are shown as mean ± SEM; n = 6 for all groups. ∗p 
<0.05. n.d.: not determined. 
 
Control  
PBS  
(i.p.) 
PWT [g] 
Vincristine  
(0.5 mg/kg; 
i.p.)  
PWT [g] 
Vincristine  
(10 μg, i.pl) 
PWT [g] 
Control  
5% glucose 
(i.pl) 
% contralateral 
Vincristine  
(10 μg, i.pl) 
% contralateral 
Day 0 3.09 ± 0.07 3.37 ± 0.04 3.35 ± 0.08 118.43 ± 5.25 110.84 ± 4.89 
3 h 3.31 ± 0.08 3.01 ± 0.05 * 1.52 ± 0.07 n.d. n.d. 
24 h 3.16 ± 0.09 1.65 ± 0.13 * 1.36 ± 0.11 n.d. n.d. 
Day 2 3.10 ± 0.07 1.53 ± 0.14 * 2.43 ± 0.19 103.22 ± 11.15 84.58 ± 3.74 * 
Day 4 3.11 ± 0.08 1.31 ± 0.09 * 3.63 ± 0.16 94.44 ± 4.80  7.16 ± 1.60 * 
Day 7 3.08 ± 0.10 1.71 ± 0.12 * 4.67 ± 0.13 115.18 ± 6.48 7.09 ± 1.57 * 
Day 9 3.10 ± 0.10 1.84 ± 0.14 * n.d. n.d n.d. 
Day 11 3.13 ± 0.08 1.83 ± 0.11 * n.d. 105.43 ± 2.99 1.41 ± 0.76 * 
  
274 
 
 
Table 18S. Nlrp3-/- or animals co-treated with MCC950 are protected from development of 
mechanical allodynia.  
Nlrp3-/- or animals co-treated with MCC950 (20 mg/kg, i.p.) are protected from development of 
mechanical allodynia (PWT) following systemic (0.5 mg/kg, i.p.) or local (10 µg, i.pl.) administration 
of vincristine. Statistical significance was determined by repeated measures two-way ANOVA with 
Sidak’s multiple comparisons test and defined as p <0.05 compared to wt. All data are shown as mean 
± SEM; n = 6 for all groups. ∗p <0.05. n.d.: not determined. 
PWT 
[g] 
Wt 
(0.5 mg/kg; 
i.p.)  
PWT [g] 
Nlrp3 -/- 
vincristine  
(0.5 mg/kg; 
i.p.)  
PWT [g] 
MCC90 + 
vincristine  
(0.5 mg/kg; 
i.p.)  
PWT [g] 
Wt 
vincristine  
(10 μg, i.pl) 
PWT [g] 
Nlrp3 -/- 
vincristine  
(10 μg, i.pl) 
PWT [g] 
MCC90 +  
vincristine  
(10 μg, i.pl) 
PWT [g] 
Day 0 3.4 ± 0.07 3.41 ± 0.09  3.47 ± 0.20 3.19 ± 0.25 3.24 ± 0.19 3.67 ± 0.17 
3 h 2.96 ± 0.07 3.66 ± 0.09  3.00 ± 0.33 1.47 ± 0.40 2.03 ± 0.83 * 3.50 ± 0.09 * 
24 h 1.51 ± 0.17 3.33 ± 0.178 * 3.11 ± 0.31 * 1.56 ± 0.47 2.90 ± 0.46 * 3.18 ± 0.26 * 
Day 2 1.33 ± 0.05 3.19 ± 0.22 * 3.22 ± 0.16 * 2.63 ± 0.53 3.01 ± 0.37  2.82 ± 0.24  
Day 4 1.34 ± 0.12 3.01 ± 0.09 * 3.16 ± 0.28 * 3.64 ± 0.30 3.64 ± 0.59  4.25 ± 0.19 
Day 7 1.63 ± 0.23 3.32 ± 0.29 * 3.01 ± 0.21 * 4.96 ± 0.30 4.40 ± 0.64  4.67 ± 0.20 
Day 9 1.92 ± 0.21 - 2.17 ± 0.32 n.d. n.d. n.d. 
Day 11 1.79 ± 0.21 2.74 ± 0.19 2.33 ± 0.37 n.d. n.d. n.d. 
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Table 19S. Nlrp3-/- or animals co-treated with MCC950 are protected from development of gait 
disturbances. 
Nlrp3-/- or animals co-treated with MCC950 (20 mg/kg, i.p.) are protected from development of gait 
disturbances (% contralateral) following local (10 µg; i.pl.) administration of vincristine. Statistical 
significance was determined by repeated measures two-way ANOVA with Sidak’s multiple 
comparisons test and defined as p <0.05 compared to littermates (Nlrp3 -/-) or PBS + vincristine 
(MCC950). All data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05. 
 
Wt 
vincristine  
(10 μg, i.pl) 
% contralateral 
Nlrp3 -/- 
vincristine  
(10 μg, i.pl) 
% contralateral 
MCC90 +  
vincristine  
(10 μg, i.pl)  
% contralateral 
PBS + 
vincristine  
(10 μg, i.pl)  
% contralateral 
Day 0 93.30 ± 7.43 110.71 ± 4.01 116.94 ± 8.79 99.83 ± 5.46 
Day 2 68.87 ± 11.42 85.09 ± 7.81  74.22 ± 10.05 84.13 ± 8.28 
Day 4 5.65 ± 2.55 56.19 ± 12.19 * 82.58 ± 16.12 * 10.13 ± 2.74 
Day 7 10.17 ± 3.10 85.89 ± 11.40 * 65.01 ± 10.36 * 11.91 ±  2.89 
Day 9 1.18 ± 1.18 77.76 ± 11.58 * 64.99 ± 14.12 * 1.41 ± 1.43 
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Table 20S. Ice-/- and Gsdmd-/- animals, but not Casp11-/- animals, are protected from 
development of mechanical allodynia following systemic administration of vincristine. 
Ice-/- and Gsdmd-/- animals, but not Casp11-/- animals, are protected from development of mechanical 
allodynia (PWT) following systemic (0.5 mg/kg, i.p.) administration of vincristine. Cohort control 
for Ice-/- as in Table 18S. Statistical significance was determined by repeated measures two-way 
ANOVA with Sidak’s multiple comparisons test and defined as p <0.05 compared to cohort control. 
All data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05 n.d.: not determined. 
PWT [g] Ice -/- 
Casp11-/- cohort 
control 
Casp11-/-  
Gsdmd-/-
cohort control 
Gsdmd-/- 
Day 0 3.79 ± 0.09 3.19 ± 0.11 3.37 ± 0.12 3.36 ± 0.06 3.72 ± 0.11 
3 h 3.46 ± 0.21 n.d.  n.d. 2.91 ± 0.06 3.11 ± 0.28 
24 h 3.12 ± 0.19 * 1.43 ± 0.19 1.66 ± 0.19 1.47 ± 0.11 3.07 ± 0.28 * 
Day 2 2.41 ± 0.25 * 1.76 ± 0.13  1.17 ± 0.18  1.39 ± 0.16 2.61 ± 0.15 * 
Day 4 2.35 ± 0.21 * 1.46 ± 0.17  1.35 ± 0.19  1.36 ± 0.19 2.82 ± 0.25* 
Day 7 3.17 ± 0.33 * 1.52 ± 0.10 1.51 ± 0.14  1.44 ± 0.30 3.06 ± 0.33 
Day 11 2.11 ± 0.39 1.61 ± 0.24 1.19 ± 0.16  2.02 ± 0.23 2.12 ± 0.32 
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Table 21S. Ice-/- and Gsdmd-/- animals, but not Casp11-/- animals, are protected from development 
of mechanical allodynia following local administration of vincristine. 
Ice-/- and Gsdmd-/- animals, but not Casp11-/- animals, are protected from development of mechanical 
allodynia (PWT) following local (10 µg, i.pl.) administration of vincristine. Cohort control for Ice-/- 
as in Table 19S. Statistical significance was determined by repeated measures two-way ANOVA 
with Sidak’s multiple comparisons test and defined as p <0.05 compared to cohort control. All data 
are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05.  
PWT [g] Ice -/- 
Casp11-/- 
cohort control 
Casp11-/-  
Gsdmd-/-
cohort 
control 
Gsdmd-/- 
Day 0 3.79 ± 0.09 3.33 ± 0.14 3.54 ± 0.11  3.19 ± 0.10 3.26 ± 0.33 
3 h 3.46 ± 0.21 1.19 ± 0.10 1.27 ± 0.11  1.47 ± 0.16 2.66 ± 0.36 * 
24 h 3.12 ± 0.19 * 1.71 ± 0.13 1.79 ± 0.15  1.56 ± 0.19 2.44 ± 0.27 * 
Day 2 2.41 ± 0.25 1.39 ± 0.14 1.78 ± 0.18  2.63 ± 0.22 1.90 ± 0.12 
Day 4 2.35 ± 0.21 3.06 ± 0.27 2.56 ± 0.24  3.64 ± 0.12 3.38 ± 0.28 
Day 7 3.17 ± 0.33 4.64 ± 0.14 4.57 ± 0.08  4.96 ± 0.12 5.16 ± 0.07 
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Table 22S. Development of mechanical allodynia following systemic administration of vincristine 
in Il1b-/-, Il1r1-/- and NaV1.9
-/- animals. 
Development of mechanical allodynia (PWT) following systemic (0.5 mg/kg, i.p.) administration of 
vincristine in Il1b-/-, Il1r1-/- and NaV1.9
-/- animals. Statistical significance was determined by repeated 
measures two-way ANOVA with Sidak’s multiple comparisons test and defined as p <0.05 compared 
to cohort control. All data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05.  
PWT [g] Cohort control Il1b-/- Il1r1-/- NaV1.9
-/- 
Day 0 3.32 ± 0.04 3.30 ± 0.19 3.59 ± 0.08 3.29 ± 0.12 
24 h 1.23 ± 0.07 3.13 ± 0.18 * 3.46 g ± 0.12 * 3.15 ± 0.11 * 
Day 2 1.39 ± 0.10 3.11 ± 0.28 * 3.18 ± 0.12 * 3.03 ± 0.24 * 
Day 4 1.68 ± 0.19 3.10 g ± 0.18 * 2.82 ± 0.10 * 2.29 ± 0.37 
Day 7 1.69 ± 0.22 2.77 g ± 0.30 * 2.11 ± 0.21 2.29 ± 0.39 
Day 9 1.49 ± 0.33 2.76 ± 0.20 * 2.46 ± 0.35 2.12 ±  0.41 
Day 11 1.81 ± 0.17 2.76 ± 0.22 * 2.23 ± 0.28 2.41 ± 0.23 
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Table 23S. Development of mechanical allodynia following local administration of vincristine in 
Il1b-/-, Il1r1-/- and NaV1.9
-/- animals. 
Development of mechanical allodynia (PWT) following local (10 µg, i.pl.) administration of 
vincristine in Il1b-/-, Il1r1-/- and NaV1.9
-/- animals. Statistical significance was determined by repeated 
measures two-way ANOVA with Sidak’s multiple comparisons test and defined as p <0.05 compared 
to cohort control. All data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05. 
PWT [g] Cohort control Il1b-/- Il1r1-/- NaV1.9
-/- 
Day 0 3.18 ± 0.13 3.30 ± 0.19 3.59 ± 0.08 3.29 ± 0.12 
3 h 1.34 ± 0.22 3.38 ± 0.12 * 3.07 ± 0.19 * 3.25 ± 0.20 * 
24 h 1.13 ± 0.14 2.88 ± 0.25 * 3.00 ± 0.28 * 2.48 ± 0.42 * 
Day 2 2.39 ± 0.86 2.96 ± 0.28 3.22 ± 0.30 3.23 ± 0.12 
Day 4 4.47 ± 0.29 3.79 ± 0.05 3.68 ± 0.30 3.61 ± 0.23 
Day 7 4.57 ± 0.24 4.08 ± 0.29 4.72 ± 0.22  4.22 ± 0.21 
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Table 24S. Development of gait disturbances following local administration of vincristine in Ice-/- 
and Gsdmd-/- and Casp11-/- animals. 
Development of gait disturbances (% contralateral) following local (10 µg, i.pl.) administration of 
vincristine in Ice-/- and Gsdmd-/- and Casp11-/- animals. Statistical significance was determined by 
repeated measures two-way ANOVA with Sidak’s multiple comparisons test and defined as p <0.05 
compared to cohort control. All data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05. 
% 
contralateral 
Cohort control Ice -/- Casp11-/-  Gsdmd-/- 
Day 0 98.02 ± 7.03 90.88 ± 5.04 103.80 ± 9.04 109.09 ± 3.43 
Day 2 82.20 ± 7.91 81.26 ± 10.96 83.96 ± 5.12 87.09 ± 16.63 
Day 4 4.57 ± 2.82 45.27 ± 14.98 77.16 ± 9.67 * 100.40 ± 2.70 * 
Day 7 7.83 ± 2.62 54.58 ± 12.34 * 74.80 ± 3.23 * 71.13 ± 10.04 * 
Day 9 1.41 ± 1.41 71.68 ± 4.23 * 63.23 ± 14.79 88.81 ± 13.55 * 
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Table 25S. Development of gait disturbances following local administration of vincristine in Il1b-/-, 
Il1r1-/- and NaV1.9
-/- animals. 
Development of gait disturbances (% contralateral) following local (10 µg, i.pl.) administration of 
vincristine in Il1b-/-, Il1r1-/- and NaV1.9
-/- animals. Statistical significance was determined by repeated 
measures two-way ANOVA with Sidak’s multiple comparisons test and defined as p <0.05 compared 
to cohort control. All data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05.  
% 
contralateral 
Cohort control Il1b-/- Il1r1-/- NaV1.9
-/- 
Day 0 94.44 ± 5.89 93.43 ± 8.91 94.20 ± 8.81 95.10 ± 3.92 
Day 2 70.19 ± 5.00 94.43 ± 1.79 * 77.28 ± 4.69 71.52 ± 8.02 
Day 4 7.28 ± 3.49 94.91 ± 4.52 * 65.15 ± 11.92 * 51.14 ± 12.18 
Day 7 7.71 ± 2.55 66.11 ± 3.41 * 64.48 ± 9.60 * 35.12 ± 12.83 
Day 9 27.21 ± 10.12 63.01 ± 4.37 58.04 ± 5.93 27.08 ± 9.19 
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Table 26S. C57BL6 mice co-treated with anakinra and systemic or local administration of 
vincristine are protected from mechanical allodynia and gait disturbances. 
C57BL6 mice co-treated with anakinra (100 mg/kg, i.p.; 10 doses/12 days) and systemic (0.5 mg/kg, 
i.p.) or local (10 µg, i.pl.) administration of vincristine are protected from mechanical allodynia 
(PWT) and gait disturbances (% contralateral). Statistical significance was determined by repeated 
measures two-way ANOVA with Sidak’s multiple comparisons test and defined as p <0.05 compared 
to cohort control (VC+ PBS). All data are shown as mean ± SEM; n = 6 for all groups. ∗p <0.05. n.d.: 
not determined. 
 
Vincristine  
(0.5 mg/kg, 
i.p.) + PBS 
 PWT [g] 
Vincristine  
(0.5 mg/kg; 
i.p.) + 
anakinra 
PWT [g] 
Vincristine  
(10 μg, i.pl) 
+ PBS 
 PWT [g] 
Vincristine  
(10 μg, i.pl) 
+ anakinra 
PWT [g] 
Vincristine  
(10 μg, i.pl) 
 + PBS 
% contralateral 
Vincristine  
(10 μg, i.pl) 
+ anakinra 
% contralateral 
Day 0 3.41 ± 0.05 3.65 ± 0.06 3.49 ± 0.13 3.88 ± 0.12 89.52 ± 7.83 103.27 ± 7.11 
3 h 3.13 ± 0.09 3.57 ± 0.13 1.74 ± 0.19 3.55 ± 0.08 * n.d. n.d. 
24 h 1.72 ± 0.17 3.28 ± 0.14 * 1.14 ± 0.18 3.39 ± 0.22 * n.d. n.d. 
Day 2 1.38 ± 0.05 3.16 ± 0.24 * 1.60 ± 0.17 3.65 ± 0.13 * 59.85 ± 8.59 97.72 ± 3.56 * 
Day 4 1.49 ± 0.09 2.87 ± 0.18 * 3.95 ± 0.25 3.47 ± 0.21 4.57 ± 2.82 95.55 ± 7.43 * 
Day 7 1.48 ± 0.16 2.69 ± 0.20 * 4.94 ± 0.26 4.03 ± 0.27 9.95 ± 3.99 43.49 ± 7.36 * 
Day 9 1.70 ± 0.15 2.79 ± 0.17 * n.d. n.d. n.d. n.d. 
Day 11 1.74 ± 0.16 2.57 ± 0.30 * n.d. n.d. 0 ± 0 %) 29.45 ± 7.59 
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10. Appendix 4: supplementary documents 
10.1. Animal Ethics Approval Certificate PHARM/401/18, Treatment of vincristine-
induced neuropathy 
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10.2. Animal Ethics Approval Certificate PHARM/PACE/368/16, Mechanisms of 
cisplatin-and oxaliplatin-induced neuropathy 
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